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Preamble
It is important that the medical profession play a central role
in critically evaluating the use of diagnostic procedures and
therapies introduced and tested for detection, management, or
prevention of disease. Rigorous, expert analysis of the avail-
able data documenting absolute and relative benefits and risks
of these procedures and therapies can produce guidelines that
improve the effectiveness of care, optimize patient outcomes,
and favorably affect the cost of care by focusing resources on
the most effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of guidelines in the area of
cardiovascular disease since 1980. The American College of
Cardiology (ACC)/AHA Task Force on Practice Guidelines
is charged with developing, updating, and revising practice
guidelines for cardiovascular diseases and procedures and
directs this effort. Writing committees are charged with
assessing the evidence as an independent group of authors to
develop, update, or revise recommendations for clinical
practice.
Experts in the subject under consideration have been
selected from both organizations to examine subject-specific
data and write guidelines in partnership with representatives
from other medical practitioner and specialty groups. Writing
committees are specifically charged to perform a formal
literature review, weigh the strength of evidence for or
against particular treatments or procedures, and include
estimates of expected health outcomes where data exist.
Patient-specific modifiers, comorbidities, and issues of pa-
tient preference that might influence the choice of tests or
therapies are considered, as well as the frequency of
follow-up and cost-effectiveness. When available, informa-
tion from studies on cost is considered, but data on efficacy
and clinical outcomes constitute the primary basis for recom-
mendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid actual, potential, or perceived conflicts of
interest that might arise as a result of industry relationships or
personal interests among the writing committee. Specifically, all
members of the writing committee, as well as peer reviewers of
the document, are asked to disclose all such relationships that
might be perceived as real or potential conflicts of interest.
Writing committee members are also strongly encouraged to
declare previous relationships with industry that might be per-
ceived as relevant to guideline development. If a writing com-
mittee member develops a new relationship with industry during
their tenure, they are required to notify guideline staff in writing.
These statements are reviewed by the parent task force, reported
orally to all members at each meeting of the writing committee,
and updated and reviewed by the writing committee as changes
occur. Please refer to the methodology manual for ACC/AHA
guideline writing committees for further description of the
relationships with industry policy (1). See Appendix 1 for author
relationships with industry and Appendix 2 for peer reviewer
relationships with industry pertinent to this guideline.
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range of
generally acceptable approaches for diagnosis, management, and
prevention of specific diseases or conditions. Clinicians should
consider the quality and availability of expertise in the area
where care is provided. These guidelines attempt to define
practices that meet the needs of most patients in most circum-
stances. The recommendations reflect a consensus of expert
opinion after a thorough review of the available current scientific
evidence and are intended to improve patient care.
Patient adherence to prescribed and agreed upon medical
regimens and lifestyles is an important aspect of treatment.
Prescribed courses of treatment in accordance with these
recommendations are only effective if they are followed.
Because lack of patient understanding and adherence may
adversely affect outcomes, physicians and other healthcare
providers should make every effort to engage the patient’s
active participation in prescribed medical regimens and
lifestyles.
If these guidelines are used as the basis for regulatory or
payer decisions, the goal is quality of care and serving the
patient’s best interest. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and the patient in light of all of the circumstances
presented by that patient. There are circumstances in which
deviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
AHA Task Force on Practice Guidelines and considered
current unless they are updated, revised, or withdrawn from
distribution. The Executive Summary and Recommendations
are published in the December 2, 2008, issue of the Journal
of the American College of Cardiology and the December 2,
2008, issue of Circulation. The full-text guidelines are
e-published in the same issue of these journals and posted on
the ACC (www.acc.org) and AHA (http://my.americanheart.
org) World Wide Web sites.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
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1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are, whenever
possible, evidence-based. Unlike other ACC/AHA practice
guidelines, there is not a large body of peer-reviewed pub-
lished evidence to support most recommendations, which will
be clearly indicated in the text. An extensive literature survey
was conducted that led to the incorporation of 647 references.
Searches were limited to studies, reviews, and other evidence
conducted in human subjects and published in English. Key
search words included but were not limited to adult congen-
ital heart disease (ACHD), atrial septal defect, arterial switch
operation, bradycardia, cardiac catheterization, cardiac reop-
eration, coarctation, coronary artery abnormalities, cyanotic
congenital heart disease, Doppler-echocardiography,
d-transposition of the great arteries, Ebstein’s anomaly,
Eisenmenger physiology, familial, heart defect, medical ther-
apy, patent ductus arteriosus, physical activity, pregnancy,
psychosocial, pulmonary arterial hypertension, right heart
obstruction, supravalvular pulmonary stenosis, surgical ther-
apy, tachyarrhythmia, tachycardia, tetralogy of Fallot, trans-
plantation, tricuspid atresia, and Wolff-Parkinson-White. Ad-
ditionally, the writing committee reviewed documents related
to the subject matter previously published by the ACC and
AHA. References selected and published in this document are
representative and not all-inclusive.
The committee reviewed and ranked evidence supporting
current recommendations with the weight of evidence ranked
as Level A if the data were derived from multiple randomized
clinical trials involving a large number of individuals. The
committee ranked available evidence as Level B when data
were derived from a limited number of trials involving a
comparatively small number of patients or from well-
designed data analyses of nonrandomized studies or observa-
tional data registries. Evidence was ranked as Level C when
the consensus of experts was the primary source of the
recommendation. In the narrative portions of these guide-
lines, evidence is generally presented in chronological order
of development. Studies are identified as observational,
randomized, prospective, or retrospective. The committee
emphasizes that for certain conditions for which no other
therapy is available, the indications are based on expert
consensus and years of clinical experience and are thus
well supported, even though the evidence was ranked as
Level C. An analogous example is the use of penicillin in
pneumococcal pneumonia where there are no randomized
trials and only clinical experience. When indications at
Level C are supported by historical clinical data, appro-
priate references (eg, case reports and clinical reviews) are
cited if available. When Level C indications are based
strictly on committee consensus, no references are cited.
The final recommendations for indications for a diagnostic
procedure, a particular therapy, or an intervention in
ACHD patients summarize both clinical evidence and
expert opinion. The schema for classification of recom-
mendations and level of evidence is summarized in Table
1, which also illustrates how the grading system provides
an estimate of the size of treatment effect and an estimate
of the certainty of the treatment effect.
1.2. Organization of Committee and
Relationships With Industry
The ACC/AHA Task Force on Practice Guidelines was
formed to create clinical practice guidelines for select cardio-
vascular conditions with important implications for public
health. This guideline writing committee was assembled to
adjudicate the evidence and construct recommendations re-
garding the diagnosis and treatment of ACHD. Writing
committee members were selected with attention to ACHD
subspecialties, broad geographic representation, and involve-
ment in academic medicine and clinical practice. The writing
committee included representatives of the American Society
of Echocardiography, Canadian Cardiovascular Society,
Heart Rhythm Society, International Society for Adult Con-
genital Heart Disease, Society for Cardiovascular Angiogra-
phy and Interventions, and Society of Thoracic Surgeons.
All members of the writing committee were required to
disclose all relationships with industry relevant to the data
under consideration (1).
1.3. Document Review and Approval
This document was reviewed by 3 external reviewers nomi-
nated from both the ACC and the AHA, as well as from the
the American Society of Echocardiography, Canadian Car-
diovascular Society, Heart Rhythm Society, International
Society for Adult Congenital Cardiac Disease, Society for
Cardiovascular Angiography and Interventions, and Society
of Thoracic Surgeons, and 20 individual content reviewers,
which included reviewers from the ACC Congenital Heart
Disease and Pediatric Cardiology Committee and the AHA
Congenital Cardiac Defects Committee. All reviewer rela-
tionships with industry information were collected and dis-
tributed to the writing committee and are published in this
document (see Appendix 2 for details). The committee thanks
all reviewers for their comments. Many of their suggestions
were incorporated into the final document.
This document was approved for publication by the gov-
erning bodies of the ACCF and the AHA and endorsed by the
American Society of Echocardiography, Heart Rhythm Soci-
ety, International Society for Adult Congenital Heart Disease,
Society for Cardiovascular Angiography and Interventions,
and Society of Thoracic Surgeons.
1.4. Epidemiology and Scope of the Problem
Remarkable improvement in survival of patients with con-
genital heart disease (CHD) has occurred over the past half
century since reparative surgery has become commonplace.
Since the advent of neonatal repair of complex lesions in the
1970s, an estimated 85% of patients survive into adult life.
The 32nd Bethesda Conference report in 2000 estimated that
there were approximately 800 000 adults with CHD in the
United States (2,3). Given modern surgical mortality rates of
less than 5%, one would expect that in the next decade,
almost 1 in 150 young adults will have some form of CHD.
In particular, there are a substantial number of young adults
with single-ventricle physiology, systemic right ventricles, or
1895JACC Vol. 52, No. 23, 2008 Warnes et al.
December 2, 2008:1890–947 ACC/AHA 2008 Guidelines for Adults With CHD
complex intracardiac baffles who are now entering adult life
and starting families. Young adults have many psychological,
social, and financial issues that present barriers to proactive
health management. The infrastructure that is provided to
most pediatric cardiology centers, namely, case management
by advanced practice nurses and social workers, is largely
lacking within the adult healthcare system. Recognizing the
compound effects of a complex and unfamiliar disease with
an unprepared patient and healthcare system, the ACC/AHA
ACHD Guideline Writing Committee has determined that the
most immediate step it can take to support the practicing
cardiologist in the care of ACHD patients is to provide a
consensus document that outlines the most important diag-
nostic and management strategies and indicates when referral
to a highly specialized center is appropriate. To provide ease
of use, the writing committee constructed this document by
lesion type and in each section included recommendations on
topics common to all lesions (eg, infective endocarditis [IE]
prophylaxis, pregnancy, physical activity, and medical
therapy).
1.5. Recommendations for Delivery of Care
and Ensuring Access
CLASS I
1. The focus of current healthcare access goals for ACHD pa-
tients should include the following:
a. Strengthening organization of and access to transition clinics
for adolescents and young adults with CHD, including funding
of allied healthcare providers to provide infrastructure compa-
Table 1. Applying Classification of Recommendations and Level of Evidence
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior
myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak.
Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may
be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline
recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from
the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will
increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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rable to that provided for children with CHD. (Level of Evi-
dence: C)
b. Organization of outreach and education programs for pa-
tients, their families, and caregivers to recapture patients
leaving pediatric supervisory care or who are lost to follow-
up. Such programs can determine when and where further
intervention is required. (Level of Evidence: C)
c. Enhanced education of adult cardiovascular special-
ists and pediatric cardiologists in the pathophysiology
and management of ACHD patients. (Level of Evi-
dence: C)
d. A liaison with regulatory agencies at the local, regional,
state, and federal levels to create programs commensurate
with the needs of this large cardiovascular population.
(Level of Evidence: C)
2. Health care for ACHD patients should be coordinated by
regional ACHD centers of excellence that would serve as a
resource for the surrounding medical community, affected
individuals, and their families. (Table 2)
a. Every academic adult cardiology/cardiac surgery center
should have access to a regional ACHD center for consul-
tation and referral. (Level of Evidence: C)
b. Each pediatric cardiology program should identify the ACHD
center to which the transfer of patients can be made. (Level
of Evidence: C)
c. All emergency care facilities should have an affiliation with
a regional ACHD center. (Level of Evidence: C)
3. ACHD patients should carry a complete medical “passport”
that outlines specifics of their past and current medical his-
tory, as well as contact information for immediate access to
data and counsel from local and regional centers of excellence.
(Level of Evidence: C)
4. Care of some ACHD patients is complicated by additional
special needs, including but not restricted to intellectual
incapacities or psychosocial limitations, and designated
healthcare guardians should be included in all medical decision
making. (Level of Evidence: C)
5. Every ACHD patient should have a primary care physician. To
ensure and improve communication, current clinical records
should be on file with the primary care physician and local
cardiovascular specialist, as well as at a regional ACHD center;
patients should also have copies of relevant records. (Level of
Evidence: C)
6. Every cardiovascular family caregiver should have a referral
relationship with a regional ACHD center so that all patients
have geographically accessible care. (Level of Evidence: C)
The need for delivery of appropriate health care to ACHD
patients largely remains unmet. The 32nd Bethesda Confer-
ence report in 2000 recommended organizing ACHD care
within a regional and national system of specialized ACHD
centers of excellence that would disseminate care, provide
education, orchestrate research and innovation, and serve as a
general resource for the region within this model (3) (Table
2). Such a system has been demonstrated to improve care for
adults with similar chronic severe illness such as severe heart
failure, for which measures of improvement surrounding
uniformity of care within a guidelines framework, medical
and surgical outcomes, decreased visits, improved patient
quality of life, cost containment, data collection and knowl-
edge dissemination, trials of new therapeutics, and enhanced
insurability have been achieved.
The pediatric cardiology team should be paired with adult
cardiologists to facilitate transition of care for affected
individuals. It is recommended that all ACHD patients have a
provider who constitutes the medical “home,” as well as at
least 1 overreaching visit with a cardiologist with advanced
training and experience in caring for ACHD patients (4).
These models of care delivery for ACHD patients fall
directly into concordance with the overarching goals of the
guidelines currently established by this ACC/AHA Guideline
Table 2. Personnel and Services Recommended for Regional
ACHD Centers
Type of Service Personnel/Resources
Cardiologist specializing in ACHD One or several 24/7
Congenital cardiac surgeon Two or several 24/7
Nurse/physician assistant/nurse
practitioner
One or several
Cardiac anesthesiologist Several 24/7
Echocardiography* Two or several 24/7
• Includes TEE, intraoperative TEE
Diagnostic catheterization* Yes, 24/7
Noncoronary interventional catheterization* Yes, 24/7
Electrophysiology/pacing/AICD
implantation*
One or several
Exercise testing • Echocardiography
• Radionuclide
• Cardiopulmonary
• Metabolic
Cardiac imaging/radiology* • Cardiac MRI
• CT scanning
• Nuclear medicine
Multidisciplinary teams • High-risk obstetrics
• Pulmonary hypertension
• Heart failure/transplant
• Genetics
• Neurology
• Nephrology
• Cardiac pathology
• Rehabilitation services
• Social services
• Vocational services
• Financial counselors
Information technology • Data collection
• Database support
• Quality assessment
review/protocols
*These modalities must be supervised/performed and interpreted by physi-
cians with expertise and training in CHD.
ACHD indicates adult congenital heart disease; 24/7, availability 24 hours
per day, 7 days per week; TEE, transesophageal echocardiography; AICD,
automatic implantable cardioverter defibrillator; MRI, magnetic resonance
imaging; and CT, computed tomography.
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Committee. A national ACHD database has been proposed to
facilitate the establishment of medical and surgical outcomes
and quality-of-life measures.
1.5.1. Recommendations for Access to Care
CLASS I
1. An individual primary caregiver or cardiologist without specific
training and expertise in ACHD should manage the care of
adults with complex and moderate CHD (Tables 3 and 4) only
in collaboration with level 2 or 3 ACHD specialists (4). (Level of
Evidence: C)
2. For ACHD patients in the lowest-risk group (simple CHD; Table
5), cardiac follow-up at a regional ACHD center is recom-
mended at least once to formulate future needs for follow-up.
(Level of Evidence: C)
3. Frequent follow-up (generally every 12 to 24 months) at a
regional ACHD center is recommended for the larger group of
adults with complex and moderate CHD. A smaller group of
adults with very complex CHD will require follow-up at a
regional ACHD center at a minimum of every 6 to 12 months.
(Level of Evidence: C)
4. Stabilized adult patients with CHD who require admission for
urgent or acute care should be transferred to a regional ACHD
center, except in some circumstances after consultation with
the patient’s primary level 2 or level 3 ACHD specialist (4).
(Level of Evidence: C)
5. Diagnostic and interventional procedures including imaging
(ie, echocardiography, magnetic resonance imaging [MRI], or
computed tomography [CT]), advanced cardiac catheteriza-
tion, and electrophysiology procedures for adults with complex
and moderate CHD should be performed in a regional ACHD
center with appropriate experience in CHD and in a labora-
tory with appropriate personnel and equipment. Personnel
performing such procedures should work as part of a team
with expertise in the surgical and transcatheter manage-
ment of patients with CHD. (Level of Evidence: C)
6. Surgical procedures that require general anesthesia or con-
scious sedation in adults with moderate or complex CHD
should be performed in a regional ACHD center with an anes-
thesiologist familiar with ACHD patients. (Level of Evidence: C)
7. ACHD patients should be transferred to an ACHD center for
urgent or acute care of cardiac problems. (Level of Evidence: C)
8. Adult patients with complex or high-risk CHD should be trans-
ferred to an ACHD center for urgent or acute noncardiac
problems. (Level of Evidence: C)
9. An ACHD specialist should be notified or consulted when a
patient with simple or low-risk CHD is admitted to a non-ACHD
center. (Level of Evidence: C)
The features of an ACHD center, outlined in Table 2,
describe a team that includes level 2 and 3 ACHD specialists.
The 32nd Bethesda Conference described 3 levels of training
of adult cardiovascular specialists in terms of experience in
ACHD (6). Task Force 9 covered training in the care of adult
patients with CHD and differentiated 3 levels of training and
expected expertise. Level 1 training consists of basic expo-
sure to CHD patients and organized educational material on
CHD. To enable proper recognition of the problems of adults
with CHD and to be cognizant of when specialized referral is
needed, all medical cardiology fellows should achieve level 1
training in CHD. Level 1 trainees should be instructed by a
Table 4. Diagnoses in Adult Patients With Congenital Heart
Disease of Moderate Complexity*
Aorto–left ventricular fistulas
Anomalous pulmonary venous drainage, partial or total
Atrioventricular septal defects (partial or complete)
Coarctation of the aorta
Ebstein’s anomaly
Infundibular right ventricular outflow obstruction of significance
Ostium primum atrial septal defect
Patent ductus arteriosus (not closed)
Pulmonary valve regurgitation (moderate to severe)
Pulmonary valve stenosis (moderate to severe)
Sinus of Valsalva fistula/aneurysm
Sinus venosus atrial septal defect
Subvalvular AS or SupraAS (except HOCM)
Tetralogy of Fallot
Ventricular septal defect with:
Absent valve or valves
Aortic regurgitation
Coarctation of the aorta
Mitral disease
Right ventricular outflow tract obstruction
Straddling tricuspid/mitral valve
Subaortic stenosis
*These patients should be seen periodically at regional adult congenital heart
disease centers.
Modified from Warnes CA, Liberthson R, Danielson GK, et al. Task force 1:
the changing profile of congenital heart disease in adult life. J Am Coll Cardiol.
2001;37:1170–5 (3).
AS indicates aortic stenosis; HOCM, hypertrophic obstructive cardiomyopa-
thy; and SupraAS, supravalvular aortic stenosis.
Table 3. Types of Adult Congenital Heart Disease of Great
Complexity*
Conduits, valved or nonvalved
Cyanotic congenital heart (all forms)
Double-outlet ventricle
Eisenmenger syndrome
Fontan procedure
Mitral atresia
Single ventricle (also called double inlet or outlet, common, or primitive)
Pulmonary atresia (all forms)
Pulmonary vascular obstructive disease
Transposition of the great arteries
Tricuspid atresia
Truncus arteriosus/hemitruncus
Other abnormalities of atrioventricular or ventriculoarterial connection not
included above (ie, crisscross heart, isomerism, heterotaxy syndromes,
ventricular inversion)
*These patients should be seen regularly at adult congenital heart disease centers.
Modified from Warnes CA, Liberthson R, Danielson GK, et al. Task force 1:
the changing profile of congenital heart disease in adult life. J Am Coll Cardiol.
2001;37:1170–5 (3).
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faculty member with level 2 or 3 training or its equivalent. A
pediatric cardiologist should also be involved in these train-
ing programs.
Level 2 training represents additional training for fellows
who plan to care for adult patients with CHD so that they may
acquire expertise in the clinical evaluation and management
of such patients. Level 2 training generally requires 1 year of
training in ACHD: either a 1-year formal program at a
regional or tertiary care ACHD center or cumulative experi-
ence of 12 months through repetitive rotations or electives as
a cardiology fellow with experienced ACHD cardiologists.
This training should prepare the individual to be well
equipped for the routine care of even moderate to complex
ACHD and to recognize when more advanced consultation or
referral is advisable.
Level 3 training represents the level of knowledge needed
by those graduates who wish to make a clinical and academic/
research commitment to this field and not only become
competent in the care of the entire spectrum of adult patients
with CHD but also participate in the teaching and research of
ACHD. Level 3 trainees generally require 2 years of training.
These 24 months may either be consecutive or cumulative
experience, and some recognition can be given to overall
experience in CHD, be it pediatric, adolescent, or adult (eg,
prior pediatric cardiology training or rotations). Such level 3
training would be sufficient to clinically manage the most
complex ACHD patient in a regional or tertiary care center, to
pursue an academic career, to train others in the field, or to
direct an ACHD center program (7).
1.5.2. Recommendations for Psychosocial Issues
CLASS I
1. Individual and family psychosocial screening (including knowl-
edge assessment of cardiac disease and management; percep-
tions about health and the impact of CHD; social functioning
with family, friends, and significant others; employment and
insurability status; and screening for cognitive, mood, and
psychiatric disorders) should be part of the care of ACHD
patients. Advanced practice nurses, physician assistants, psy-
chologists, and social workers should play an integral role in
assessing and providing for the psychosocial needs of ACHD
patients. (Level of Evidence: C)
2. Informational tools should be developed before transfer from
adolescent to adult care and used for patient/family education
regarding CHD, including the following elements, to be pro-
vided in electronic format:
a. Demographic data, including physician contact. (Level of
Evidence: C)
b. Description of CHD, surgeries, interventional procedures,
and most recent diagnostic studies. (Level of Evidence: C)
c. Medications. (Level of Evidence: C)
3. Additional health maintenance screening and information
should be offered to ACHD patients as indicated during each
visit to their ACHD healthcare provider, including the following:
a. Endocarditis prophylaxis measures (refer to Section 1.6,
Recommendations for Infective Endocarditis). (Level of
Evidence: C)
b. Exercise prescription, guidelines for exercise, and athletic
participation for patients with CHD should reflect the pub-
lished recommendations of the 36th Bethesda Conference
report (5). (Level of Evidence: C)
c. Contraception and pregnancy information, including educa-
tion regarding risk of CHD in offspring (for men and women).
(Level of Evidence: C)
d. General medical/dental preventive care (eg, smoking ces-
sation, weight loss/maintenance, hypertension/lipid
screening, oral care, and substance abuse counseling).
(Level of Evidence: A)
e. Recommended follow-up with cardiology. (Level of Evi-
dence: C)
4. Vocational referral and health insurance information should be
offered to ACHD patients during the transition period and
refreshed at the time of their initial consultation in a tertiary
referral center and intermittently as indicated by their social
situation. (Level of Evidence: C)
5. A formal transition process should be used to provide optimal
transfer of patients into ACHD care. This process should begin
by 12 years of age and should be individualized on the basis of
the patient’s maturity level, with the goal being to transition
and ultimately transfer the patient into adult care settings
depending on the stability of the disease and psychosocial
status. (Level of Evidence: C)
6. A psychological evaluation should be obtained if an adult’s mental
competency is in question and no appointed adult surrogate is
available. (Level of Evidence: C)
7. All ACHD patients should be encouraged to complete an
advance directive, ideally at a time during which they are not
extremely ill or hospitalized, so that they can express their
wishes thoughtfully in a less stressful setting and communi-
cate these wishes to their families and caregivers. (Level of
Evidence: C)
New information is emerging about cognitive functioning
in adolescents who underwent surgical repair in infancy with
cardiopulmonary bypass that indicates some deficits in plan-
ning and self-management (8–12). Long-term behavioral
outcome studies after the neonatal arterial switch operation
(ASO) for transposition of the great arteries (TGA) have
Table 5. Diagnoses in Adult Patients With Simple Congenital
Heart Disease*
Native disease
Isolated congenital aortic valve disease
Isolated congenital mitral valve disease (eg, except parachute valve, cleft
leaflet)
Small atrial septal defect
Isolated small ventricular septal defect (no associated lesions)
Mild pulmonary stenosis
Small patent ductus arteriosus
Repaired conditions
Previously ligated or occluded ductus arteriosus
Repaired secundum or sinus venosus atrial septal defect without residua
Repaired ventricular septal defect without residua
*These patients can usually be cared for in the general medical community.
Modified from Warnes CA, Liberthson R, Danielson GK, et al. Task force 1:
the changing profile of congenital heart disease in adult life. J Am Coll Cardiol.
2001;37:1170–5 (3).
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demonstrated highly specific disabilities that might impact
the quality of self-care (13). Longer survival and decreasing
morbidity among ACHD patients have made quality-of-life
issues much more central to the understanding and manage-
ment of this population (14–24). Some quality-of life-issues
pertinent to ACHD patients, regardless of severity of disease,
include independent living arrangements, education, employ-
ment, sports, health and life insurance acquisition, contracep-
tion, genetic counseling, and pregnancy concerns (25).
Circumstantial depression and anxiety are understandable
in older adolescents and young adults with chronic health
problems. One pilot study suggests that up to one third of
ACHD patients may have a psychiatric disorder, with depres-
sion and anxiety being most prominent (26), whereas only
20% of the general population are afflicted with psychiatric
illness (27). Accordingly, a careful assessment of depressive
symptoms and their possible overlap with symptoms of
medical illness or side effects of medications must be part of
the clinical evaluation of ACHD patients (17,28).
1.5.3. Transition of Care
Physical and emotional maturity is the primary requirement
for transfer of adolescent or young adult patients into adult
care environments. The age at which this occurs varies and
may range from the mid-teens to the mid-20s, depending on
the patient. However, the process of transitioning, that is,
preparing young patients for successful transfer to an adult
healthcare provider at a later time, should begin by the age of
12 years (29). Strategies for transfer of patients with CHD
into adult care settings are well described (30,31) and use a
stepwise approach to establishing autonomy and understand-
ing one’s cardiac problem and lifestyle issues important to
long-term stability of CHD.
Pertinent medical records, including diagrams of cardiac
defects and operations, operative and procedural reports,
recent physical examination, electrocardiograms (ECGs), and
echocardiograms, should be provided to all cardiologists
involved in the care of a patient with CHD. In addition, once
patients are properly educated and aware of basic terminol-
ogy pertaining to their own cardiac status, they should be
offered copies of their medical reports, which implies and
imparts responsibility and autonomy regarding their
condition.
1.6. Recommendations for Infective
Endocarditis
CLASS I
1. ACHD patients must be informed of their potential risk for IE
and should be provided with the AHA information card with
instructions for prophylaxis. (Level of Evidence: B)
2. When patients with ACHD present with an unexplained febrile
illness and potential IE, blood cultures should be drawn before
antibiotic treatment is initiated to avoid delay in diagnosis due
to “culture-negative” IE. (Level of Evidence: B)
3. Transthoracic echocardiography (TTE) should be performed
when the diagnosis of native-valve IE is suspected. (Level of
Evidence: B)
4. Transesophageal echocardiography (TEE) is indicated if TTE
windows are inadequate or equivocal, in the presence of a
prosthetic valve or material or surgically constructed shunt, in
the presence of complex congenital cardiovascular anatomy,
or to define possible complications of endocarditis (eg, sepsis,
abscess, valvular destruction or dehiscence, embolism, or
hemodynamic instability) (32). (Level of Evidence: B)
5. ACHD patients with evidence of IE should have early consulta-
tion with a surgeon with experience in ACHD because of the
potential for rapid deterioration and concern about possible
infection of prosthetic material. (Level of Evidence: B)
CLASS IIa
1. Antibiotic prophylaxis before dental procedures that involve
manipulation of gingival tissue or the periapical region of teeth
or perforation of the oral mucosa is reasonable in patients with
CHD with the highest risk for adverse outcome from IE,
including those with the following indications:
a. Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair. (Level of Evidence: B)
b. Previous IE. (Level of Evidence: B)
c. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: B)
d. Completely repaired CHD with prosthetic materials,
whether placed by surgery or by catheter intervention,
during the first 6 months after the procedure. (Level of
Evidence: B)
e. Repaired CHD with residual defects at the site or adjacent
to the site of a prosthetic patch or prosthetic device that
inhibit endothelialization. (Level of Evidence: B)
2. It is reasonable to consider antibiotic prophylaxis against IE
before vaginal delivery at the time of membrane rupture in
select patients with the highest risk of adverse outcomes. This
includes patients with the following indications:
a. Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair. (Level of Evidence: C)
b. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: C)
CLASS III
1. Prophylaxis against IE is not recommended for nondental
procedures (such as esophagogastroduodenoscopy or colonos-
copy) in the absence of active infection. (Level of Evidence: C)
The clinical setting and presentation of endocarditis have
changed over the last 50 years, in part owing to technical
advances (eg, cardiac surgery, hemodialysis), the use of
prosthetic devices and indwelling lines, the increasing prev-
alence of intravenous drug abuse, the emergence of resistant
organisms, and the continued development of increasingly
potent antibiotics (33–38). True surgical cures of congenital
cardiovascular disorders are infrequent, and almost all pa-
tients who have undergone surgery are left with some form of
residua or sequelae, many of which predispose to IE
(33,34,37–42).
A delay in diagnosis of IE carries the risk of significant
morbidity and mortality. A high index of suspicion for IE in
any patient with operated or unoperated CHD is a key to early
diagnosis (34,38,39,41,43–46). Cardiac lesions and their
relative risks of developing IE are listed in Table 6.
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The 2007 AHA guidelines for the prevention of endocar-
ditis have substantially changed the recommendations for
antibiotic prophylaxis on the basis of a consensus of expert
opinions (32). The new, simplified recommendations are
based on the proposition that most bacteremia occurs during
activities of daily living, that IE is more likely to result from
long-term cumulative exposure to these daily random bacte-
remias than from procedural bacteremias, and that proof is
lacking that prophylaxis prevents any (or at most a very small
number) cases of IE. They posit that the risks of antibiotic
adverse events in the patient (allergic reactions) and the
emergence of resistant organisms exceed any proven benefit
of antibiotic prophylaxis against IE.
The new AHA guidelines appropriately emphasize main-
tenance of oral health and hygiene to reduce daily bacteremia
and underscore that this is more important than any dental
antibiotic prophylaxis. Accordingly, the 2007 writing com-
mittee for the updated guidelines on prevention of endocar-
ditis concluded that antibiotic prophylaxis for dental proce-
dures likely to induce procedural bacteremia (those that
involve manipulation of gingival tissue or the periapical
region of the teeth or perforation of the gingival mucosa)
should be confined to cardiac conditions associated with the
most significant adverse outcomes should IE develop (32).
They included in this group those with previous IE, those
with prosthetic cardiac valves or surgically constructed con-
duits or shunts, those with unrepaired cyanotic CHD or CHD
repaired with prosthetic material or devices (until 6 months
after the procedure), those with repaired CHD with residual
defects at or adjacent to the site of a prosthetic patch or
device, and cardiac transplant patients who develop valvu-
lopathy. They specifically recommend no IE prophylaxis
before gastrointestinal or genitourinary procedures, a major
departure from previous guidelines. The present ACHD Guide-
line Committee understands that there may be reluctance to
deviate from prior recommendations for patients with some
forms of CHD. Accordingly, this committee recommends that
healthcare providers discuss the rationale for these new changes
with their patients, including the lack of scientific evidence
demonstrating proven benefit for IE prophylaxis. In those
settings, the clinician should determine that the risks associated
with antibiotics are low before continuing a prophylaxis
regimen.
The present writing committee proposes that the “high-
risk” group in whom it is reasonable to give antibiotic
prophylaxis before dental procedures would include the
following: 1) those with a prosthetic cardiac valve; 2) those
with prior IE; 3) those with unrepaired and palliated cyanotic
CHD, including surgically constructed palliative shunts and
conduits; 4) those with repaired CHD with prosthetic material
or device, whether placed by surgery or by catheter interven-
tion, during the first 6 months after the procedure; and 5)
those with repaired CHD with residual defects at the site or
adjacent to the site of a prosthetic patch or prosthetic device
that inhibit endothelialization.
We emphasize that nonchemotherapeutic methods are partic-
ularly important in the adolescent or young adult patient with
CHD, among whom nail biting, acne, and problems with dental
health are common. Oral prevention starts with meticulous oral
care and routine preventive care by a dentist or oral hygienist. A
patient with cyanotic heart disease often has spongy, friable
gums, and a soft-bristle toothbrush must be used.
Female contraception should be planned with the risks and
benefits of intrauterine devices kept in mind.
1.7. Recommendations for Noncardiac Surgery
CLASS I
1. Basic preoperative assessment for ACHD patients should in-
clude systemic arterial oximetry, an ECG, chest x-ray, TTE, and
blood tests for full blood count and coagulation screen. (Level
of Evidence: C)
2. It is recommended that when possible, the preoperative eval-
uation and surgery for ACHD patients be performed in a
regional center specializing in congenital cardiology, with
experienced surgeons and cardiac anesthesiologists. (Level of
Evidence: C)
3. Certain high-risk patient populations should be managed at
centers for the care of ACHD patients under all circumstances,
unless the operative intervention is an absolute emergency.
High-risk categories include patients with the following:
a. Prior Fontan procedure. (Level of Evidence: C)
b. Severe pulmonary arterial hypertension (PAH). (Level of
Evidence: C)
c. Cyanotic CHD. (Level of Evidence: C)
d. Complex CHD with residua such as heart failure, valve dis-
ease, or the need for anticoagulation. (Level of Evidence: C)
e. Patients with CHD and malignant arrhythmias. (Level of
Evidence: C)
Table 6. Cardiac Conditions Associated With the Highest Risk
of Adverse Outcome From Endocarditis for Which Prophylaxis
With Dental Procedures Is Reasonable
Condition Congenital Specific Condition*
• Previous infective
endocarditis
• Unrepaired cyanotic CHD, including
palliative shunts and conduits
• Prosthetic cardiac valve
or prosthetic material
used for cardiac valve
repair
• Completely repaired congenital
heart defect with prosthetic
material or device, whether placed
by surgery or by catheter
intervention, during the first 6
months after the procedure†
• Repaired CHD with residual defects
at the site or adjacent to the site of
a prosthetic patch or prosthetic
device that inhibit endothelialization
• Cardiac transplant recipients who
develop cardiac valvulopathy
*Except for the conditions listed above, antibiotic prophylaxis is no longer
recommended for any other form of CHD.
†Prophylaxis is reasonable because endothelialization of prosthetic material
occurs within 6 months after the procedure.
Modified with permission to include footnotes from Wilson et al. Prevention
of infective endocarditis: guidelines from the American Heart Association: a
guideline from the American Heart Association Rheumatic Fever, Endocarditis,
and Kawasaki Disease Committee, Council on Cardiovascular Disease in the
Young, and the Council on Clinical Cardiology, Council on Cardiovascular
Surgery and Anesthesia, and the Quality of Care and Outcomes Research
Interdisciplinary Working Group. Circulation. 2007;116:1736–54 (32).
CHD indicates congenital heart disease.
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4. Consultation with ACHD experts regarding the assessment of risk
is recommended for patients with CHD who will undergo noncar-
diac surgery. (Level of Evidence: C)
5. Consultation with a cardiac anesthesiologist is recommended
for moderate- and high-risk patients. (Level of Evidence: C)
Performance of any surgical procedure in ACHD patients
carries a greater risk than in the normal population. Certain
surgical procedures are frequently required in cyanotic pa-
tients, such as intervention for gallstones, scoliosis, and, less
commonly, cerebral abscess. The risk for noncardiac surgery
depends on the nature of the underlying CHD, the extent of
the procedure, and the urgency of intervention. Table 7 lists
lesions at moderate and high risk for noncardiac surgery.
A thorough evaluation of the patient with CHD should be
undertaken before anticipated noncardiac surgery. Basic pre-
operative assessment includes an ECG, chest x-ray, TTE, and
blood tests for full blood count and coagulation screen. It is
recommended, when possible, that the preoperative evalua-
tion and surgery be performed in an ACHD center with
experienced surgeons and cardiac anesthesiologists. This
allows close perioperative follow-up by an ACHD specialist.
Select high-risk patient populations should be managed at
centers for the care of ACHD patients under all circum-
stances, unless the operative intervention is an absolute
emergency. These patients include those with prior Fontan
procedure, severe PAH, cyanotic CHD, or complex CHD
with residua such as heart failure, valve disease, or the need
for anticoagulation. Patients with cyanotic CHD, especially
when associated with PAH, are at highest risk from noncar-
diac surgery (47).
Postoperatively, patients with CHD may need intensive
care unit monitoring facilities even for relatively minor
procedures. Nursing staff should be informed about the
specific issues related to the CHD.
1.8. Recommendations for Pregnancy
and Contraception
CLASS I
1. Patients with CHD should have consultation with an ACHD
expert before they plan to become pregnant to develop a plan
for management of labor and the postpartum period that
includes consideration of the appropriate response to potential
complications. This care plan should be made available to all
providers. (Level of Evidence: C)
2. Patients with intracardiac right-to-left shunting should have
fastidious care taken of intravenous lines to avoid paradoxical
air embolus. (Level of Evidence: C)
3. Prepregnancy counseling is recommended for women receiving
chronic anticoagulation with warfarin to enable them to make
an informed decision about maternal and fetal risks (48–50).
(Level of Evidence: B)
CLASS IIa
1. Meticulous prophylaxis for deep venous thrombosis, including
early ambulation and compression stockings, can be useful for
all patients with an intracardiac right-to-left shunt. Subcutane-
ous heparin or low-molecular-weight heparin is reasonable for
prolonged bed rest. Full anticoagulation can be useful for the
high-risk patient. (Level of Evidence: C)
CLASS III
1. The estrogen-containing oral contraceptive pill is not recom-
mended in ACHD patients at risk of thromboembolism, such as
those with cyanosis related to an intracardiac shunt, severe
PAH, or Fontan repair. (Level of Evidence: C)
Congenital malformations now represent the most common
cause of maternal morbidity and mortality from heart disease
in North America. Both men and women with ACHD should
have a thorough understanding of the risks of transmitting
CHD to their offspring. Counseling by an ACHD expert
before pregnancy is important and should include genetic
evaluation and, specifically for women, assessment of poten-
tial fetal risk, risk of prematurity or low birth weight in the
offspring, review of medications that may be deleterious to
the fetus, appropriate management of anticoagulation, and
discussion of potential maternal complications (51). If preg-
nancy occurs, fetal echocardiography should be obtained and
its consequences discussed (51).
The outcome of pregnancy is favorable in most women
with CHD provided that functional class and systemic ven-
tricular function are good. PAH presents a serious risk during
pregnancy, particularly when the pulmonary pressure exceeds
70% of systemic pressure, irrespective of functional class.
Events often occur after delivery (52). The need for full
anticoagulation during pregnancy, although not a contraindi-
cation, poses an increased risk to both mother and fetus (53).
The relative risks and benefits of the different anticoagulant
approaches need to be discussed fully with the prospective
mother. There is a small group of patients with complex CHD
or high-risk disorders in whom pregnancy is either dangerous
or contraindicated because of risk to mother or fetus. If
pregnancy occurs and continues with any of these disorders,
these high-risk patients should be managed and delivered in
specialized centers with multidisciplinary expertise and ex-
perience in CHD, obstetrics, anesthesiology, and neonatol-
ogy. In patients in whom pregnancy termination is consid-
ered, the risks of termination versus continuation of
pregnancy should be evaluated and discussed.
Although endocarditis is a recognized risk for maternal
morbidity and mortality, endocarditis prophylaxis around the
Table 7. Congenital Cardiac Lesions and Perioperative Risk
for Noncardiac Surgery
High risk
Pulmonary hypertension, primary or secondary
Cyanotic congenital heart disease
New York Heart Association class III or IV
Severe systemic ventricular dysfunction (ejection fraction less than 35%)
Severe left-sided heart obstructive lesions
Moderate risk
Prosthetic valve or conduit
Intracardiac shunt
Moderate left-sided heart obstruction
Moderate systemic ventricular dysfunction
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time of delivery is not universally recommended for patients
with structural heart disease, because some believe that the
risk of bacteremia is low. Others routinely administer antibi-
otics because it is not known in advance whether or not
instrumentation will be required. Thus, there is no consensus
on this point (54). Antibiotics should be considered for those
at highest risk of an adverse outcome and, when appropriate,
given as the membranes rupture. Intravenous amoxicillin and
gentamicin should be considered for women with high-risk
anatomy or previous history of endocarditis (see Section 1.6,
Recommendations for Infective Endocarditis).
1.8.1. Contraception
There are limited data on the safety of various contraceptive
techniques in ACHD patients. The estrogen-containing oral
contraceptive pill is generally not recommended in ACHD
patients at risk of thromboembolism, such as those with
cyanosis, prior Fontan procedure, atrial fibrillation, or PAH.
In addition, this form of contraceptive therapy may upset
anticoagulation control. However, medroxyprogesterone, the
progesterone-only pills, and levonorgestrel may also cause
fluid retention and should be used with caution in patients
with heart failure. Depression and breakthrough bleeding may
prevent the use of the progesterone-only pills, and there is a
higher failure rate than with combined oral contraceptives.
Levonorgestrel, barrier methods, and tubal ligation are the
recommended contraceptive methods for women with cya-
notic CHD and PAH. The potential complications of the
“morning after pill” (levonorgestrel “plan B”) should be
explained to those at risk of acute fluid retention. Tubal
ligation, although the most secure method of contraception,
can be a high-risk procedure in patients with complex CHD
or those with PAH. Hysteroscopic sterilization (Essure) may
be reasonable for high-risk patients (55). Sterilization of a
male partner of a woman with CHD should only occur after
full explanation of the prognosis to the patient. The specialist
in the ACHD clinic needs to interact with both the general
practitioner and the gynecologist to provide optimal advice
regarding contraception. The risk of endocarditis with intra-
uterine devices in women with CHD is controversial, and
recommendations should be individualized on the basis of
discussions between the cardiologist and gynecologist.
Breast feeding is safe in women with CHD. Women
requiring cardiovascular medications should be aware that
many of the medications will cross into breast milk and
should clarify the potential effect of medications on the infant
with a pediatrician.
1.9. Recommendations for Arrhythmia
Diagnosis and Management
CLASS I
1. Complete and appropriate noninvasive testing, as well as clear
knowledge of the specific anatomy and review of all surgical
and procedural records, is recommended before electrophysio-
logical testing or device placement is attempted in ACHD
patients. (Level of Evidence: C)
2. Decisions regarding tachycardia management in ACHD pa-
tients should take into account the broad cardiovascular
picture, particularly repairable hemodynamic issues that might
favor a surgical or catheter-based approach to treatment.
(Level of Evidence: B)
3. Catheter ablation procedures for ACHD patients should be
performed at centers where the staff is experienced with the
complex anatomy and distinctive arrhythmia substrates en-
countered in congenital heart defects. (Level of Evidence: B)
4. Pacemaker and device lead placement (or replacement) in
ACHD patients should be performed at centers where the staff
is familiar with the unusual anatomy of congenital heart
defects and their surgical repair. (Level of Evidence: B)
5. Epicardial pacemaker and device lead placement should be
performed in all cyanotic patients with intracardiac shunts who
require devices. (Level of Evidence: B)
CLASS IIa
1. It is reasonable to recommend the use of an implantable
cardioverter defibrillator for any patient who has had a cardiac
arrest or experienced an episode of hemodynamically sig-
nificant or sustained ventricular tachycardia. (Level of Evi-
dence: C)
2. Pacemaker implantation can be beneficial in ACHD patients
with bradyarrhythmias and may be helpful in overdrive pacing in
patients with difficult-to-control tachyarrhythmias (see ACC/
AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac
Rhythm Abnormalities) (56). (Level of Evidence: B)
CLASS IIb
1. Pacemaker implantation may be beneficial for asymptomatic
adult patients with resting heart rates of less than 40 beats per
minute or abrupt pauses in excess of 3 seconds. (Level of
Evidence: C)
Cardiac arrhythmias are a major source of morbidity and
mortality for ACHD patients (Table 8). Although rhythm
disorders can often be observed in adults with unrepaired or
palliated defects, the most difficult cases usually involve
patients who have undergone prior intracardiac repairs, espe-
cially when this reparative surgery was performed relatively
late in life (57,58). In this setting, the electrical pathology
stems from the unique and complex myocardial substrates
created by septal patches and suture lines in combination with
cyanosis and abnormal pressure/volume status of variable
duration. Virtually the entire spectrum of rhythm disturbances
is manifested in these patients, including some disorders that
are specific to the anatomic defect or the surgical technique
used for repair.
1.10. Cyanotic Congenital Heart Disease
Right-to-left intracardiac or extracardiac shunts result in
hypoxemia, erythrocytosis, and cyanosis.
1.10.1. Recommendations for Hematologic Problems
CLASS I
1. Indications for therapeutic phlebotomy are hemoglobin greater
than 20 g per dL and hematocrit greater than 65%, associated
with headache, increasing fatigue, or other symptoms of hyper-
viscosity in the absence of dehydration or anemia. (Level of
Evidence: C)
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CLASS III
1. Repeated routine phlebotomies are not recommended because
of the risk of iron depletion, decreased oxygen-carrying capac-
ity, and stroke. (Level of Evidence: C)
Cyanosis in patients with CHD has profound hematologic
consequences that may affect many organ systems and need to
be recognized and managed appropriately. The hematologic
complications of chronic hypoxemia are erythrocytosis, iron
deficiency, and bleeding diathesis (59). The increase in red
blood cell mass that accompanies cyanosis is a compensatory
response to improve oxygen transport. The white blood cell
count is usually normal, and the platelet count may be normal or
reduced.
The increased red blood cell mass may result in an increase in
blood viscosity. However, the most likely cause of complica-
tions in adults with cyanotic CHD is aggressive phlebotomy or
blood loss (60). Most cyanotic patients have compensated
erythrocytosis with stable hemoglobin that requires no
intervention.
The treatment for iron deficiency in a patient with desta-
bilized erythropoiesis is challenging. Oral administration of
iron frequently results in a rapid and dramatic increase in red
cell mass; therefore, caution should be exercised and hemo-
globin monitored. Once the serum ferritin and/or transferrin
saturation is within the normal range, iron supplementation
may be discontinued.
1.10.1.1. Hemostasis
Hemostatic abnormalities have been documented in up to 20%
of cyanotic patients. Platelet dysfunction and clotting factor
deficiencies combine to produce a bleeding tendency in these
patients. Epistaxis, gingival bleeding, menorrhagia, and pulmo-
nary hemorrhage are the most common causes of bleeding. The
use of anticoagulants and antiplatelet agents, therefore, is con-
troversial and confined to well-defined indications with careful
monitoring of the degree of anticoagulation.
1.10.1.2. Renal Function
In chronic cyanosis, the renal glomeruli are abnormal, fre-
quently hypercellular, and congested and eventually become
sclerotic (61). This results in a reduction of the glomerular
filtration rate, increased creatinine levels, and proteinuria.
This may cause problems with radiopaque contrast material
and dehydration, leading to uremia, oliguria, and even anuria.
Thus, patients should be hydrated before procedures that
involve contrast media.
1.10.1.3. Gallstones
The increased breakdown of red blood cells in chronic
cyanosis results in an increased risk of calcium bilirubinate
gallstones.
1.10.1.4. Orthopedic and Rheumatologic Complications
Hypertrophic osteoarthropathy with thickened, irregular peri-
osteum occurs in the setting of cyanotic CHD. Scoliosis
occurs in a high percentage of patients with cyanotic CHD
and is occasionally severe enough to compromise pulmonary
function and require surgical intervention. Preoperative eval-
uation by an ACHD cardiologist and cardiac anesthesiologist
is recommended before the operation for scoliosis is under-
taken because of the recognized increased risk of surgery in
cyanotic patients, especially those with PAH, for whom this
procedure may be contraindicated.
1.10.1.5. Neurological Complications
Neurological complications include an increased risk for
paradoxical cerebral emboli. Brain abscess in cyanotic pa-
tients and thromboembolic events in patients with atrial
tachycardia or atrial stasis associated with transvenous pacing
leads can result in new neurological symptoms. These com-
plications should be suspected in a cyanotic patient with
headache, fever, and new neurological symptoms. Substantial
cognitive and psychosocial issues are prevalent in this pop-
ulation, as discussed in Section 1.5.2, Recommendations for
Psychosocial Issues.
1.11. Recommendations for General Health
Issues for Cyanotic Patients
CLASS I
1. Cyanotic patients should drink nonalcoholic and noncaffein-
ated fluids frequently on long-distance flights to avoid dehydra-
tion. (Level of Evidence: C)
Table 8. Rhythm Disturbances in Adults With Congenital Heart
Disease
Rhythm Disturbance Associated Lesions
Tachycardias
Wolff-Parkinson-White
syndrome
Ebstein’s anomaly
Congenitally corrected transposition
Intra-atrial reentrant
tachycardia (atrial flutter)
Postoperative Mustard
Postoperative Senning
Postoperative Fontan
Tetralogy of Fallot
Other
Atrial fibrillation Mitral valve disease
Aortic stenosis
Tetralogy of Fallot
Palliated single ventricle
Ventricular tachycardia Tetralogy of Fallot
Aortic stenosis
Other
Bradycardias
Sinus node dysfunction Postoperative Mustard
Postoperative Senning
Postoperative Fontan
Sinus venosus ASD
Heterotaxy syndrome
Spontaneous AV block AV septal defects
Congenitally corrected transposition
Surgically induced AV block VSD closure
Subaortic stenosis relief
AV valve replacement
AV indicates atrioventricular; ASD, atrial septal defect; and VSD, ventricular
septal defect.
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CLASS IIb
1. Supplemental oxygenation may be considered for cyanotic
patients during long-distance flights. (Level of Evidence: C)
Cyanotic patients should use only pressurized commercial
airplanes. Oxygen therapy, although often unnecessary, may
be suggested for prolonged travel. Similarly, residence at
high altitude is detrimental for patients with cyanosis. Dehy-
dration should be avoided by frequent fluid intake on long
flights and during sports activities.
Competitive sports should be avoided in cyanotic patients
(62). Cyanosis is a recognized handicap to fetal growth and
development, and pregnancy outcome is impacted, with an
increased risk of congestive heart failure, preterm delivery,
intrauterine growth retardation, and miscarriage. Increased
maternal and fetal mortality are also noted and correlate with
the degree of cyanosis, ventricular dysfunction, and pulmo-
nary pressures (54).
1.11.1. Hospitalization and Operation
Cyanotic patients are at high risk during any hospitalization
or operation. Management strategies that should be applied
include those likely to reduce the risk of paradoxical emboli
related to air in the intravenous lines. Medication adjustment
may be needed, with cyanosis taken into account.
1.12. Recommendations for Heart
and Heart/Lung Transplantation
CLASS I
1. Patients with CHD and heart failure who may require heart
transplantation should be evaluated and managed in tertiary
care centers with medical and surgical personnel with experi-
ence and expertise in the management of both CHD and heart
transplantation. (Level of Evidence: C)
2. Patients with CHD and heart or respiratory failure whomay require
lung or heart/lung transplantation should be evaluated and man-
aged in tertiary care centers with medical and surgical personnel
with experience and expertise in the management of CHD and
lung or heart/lung transplantation. (Level of Evidence: C)
The pretransplantation evaluation involves a multidisci-
plinary approach that addresses assessment of cardiopulmo-
nary, renal, neurological, hepatic, infectious disease, socio-
economic, and psychological issues. In addition to history
and physical examination, diagnostic studies include ECG,
echocardiography, chest x-ray, and Holter monitoring. Car-
diac catheterization is required to assess pulmonary vascular
resistance (PVR) and transpulmonary gradient (63). In addi-
tion to cardiac catheterization, MRI or CT angiography is
often performed to delineate the anatomy in patients with
complex CHD (eg, patients with malpositioning of the great
arteries and/or substernal position of an extracardiac con-
duit, abnormalities of systemic venous return, and situs
abnormalities).
Many patients with long-standing heart failure may have
elevated PVR. Consequently, donor right-sided heart failure
may result when the heart is abruptly placed proximal to such
a high-resistance pulmonary vascular bed.
Heart/lung transplantation is usually reserved for patients
with uncorrectable or previously repaired or palliated CHD
associated with significant pulmonary vascular obstructive
disease, such as single-ventricle physiology with pulmonary
vascular disease or left ventricular (LV) dysfunction with
associated pulmonary vascular disease. When a simple car-
diac defect is present, such as atrial septal defect (ASD),
ventricular septal defect (VSD), or patent ductus arteriosus
(PDA), the cardiac defect can often be repaired at lung
transplantation (64). In the presence of more complex intra-
cardiac abnormalities, combined heart/lung transplantation is
usually most appropriate.
2. Atrial Septal Defect
One of the most common adult congenital heart defects, an
ASD is a persistent communication between the atria. There
are several different types of ASD: the secundum ASD in the
region of the fossa ovalis; the primum ASD, positioned
inferiorly near the crux of the heart; the sinus venosus ASD,
located superiorly near the superior vena caval entry or
inferiorly near the inferior vena caval entry; and the uncom-
mon coronary sinus septal defect, which causes shunting
through the ostium of the coronary sinus.
2.1. Unrepaired Atrial Septal Defect
The consequence of a left-to-right shunt across an ASD is
right ventricular (RV) volume overload and pulmonary over-
circulation. Large atrial shunts lead to symptoms from excess
pulmonary blood flow and right-sided heart failure, including
frequent pulmonary infections, fatigue, exercise intolerance,
and palpitations. Atrial arrhythmias—atrial flutter, atrial fi-
brillation, and sick sinus syndrome—are a common result of
long-standing right-sided heart volume and pressure over-
load. Flow-related PAH accompanies large left-to-right
shunts, and pulmonary vascular obstructive disease may
develop in adult years but occurs much later with ASD than
with high-pressure left-to-right shunts such as VSD or PDA.
2.2. Recommendations for Evaluation of the
Unoperated Patient
CLASS I
1. ASD should be diagnosed by imaging techniques with demon-
stration of shunting across the defect and evidence of RV
volume overload and any associated anomalies. (Level of
Evidence: C)
2. Patients with unexplained RV volume overload should be
referred to an ACHD center for further diagnostic studies to rule
out obscure ASD, partial anomalous venous connection, or
coronary sinoseptal defect. (Level of Evidence: C)
CLASS IIa
1. Maximal exercise testing can be useful to document exercise
capacity in patients with symptoms that are discrepant with
clinical findings or to document changes in oxygen saturation
in patients with mild or moderate PAH. (Level of Evidence: C)
2. Cardiac catheterization can be useful to rule out concomitant
coronary artery disease in patients at risk because of age or
other factors. (Level of Evidence: B)
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CLASS III
1. In younger patients with uncomplicated ASD for whom nonin-
vasive imaging results are adequate, diagnostic cardiac cath-
eterization is not indicated. (Level of Evidence: B)
2. Maximal exercise testing is not recommended in ASD with
severe PAH. (Level of Evidence: B)
The diagnostic workup for a patient with a suspected ASD
is directed at defining the presence, size, and location of the
ASD; the functional effect of the shunt on the right and left
ventricles and the pulmonary circulation; and any associated
lesions.
2.3. Management Strategies
2.3.1. Recommendations for Medical Therapy
CLASS I
1. Cardioversion after appropriate anticoagulation is recom-
mended to attempt restoration of the sinus rhythm if atrial
fibrillation occurs. (Level of Evidence: A)
2. Rate control and anticoagulation are recommended if sinus
rhythm cannot be maintained by medical or interventional
means. (Level of Evidence: A)
Patients with small shunts and normal RV size are gener-
ally asymptomatic and require no medical therapy. Routine
follow-up of the patient with a small ASD without evidence
of RV enlargement or PAH should include assessment of
symptoms, especially arrhythmias and possible paradoxical
embolic events. A repeat echocardiogram should be obtained
every 2 to 3 years to assess RV size and function and
pulmonary pressure. Reductions in LV compliance related to
hypertension, coronary artery disease, or acquired valvular
disease increase the degree of left-to-right shunt across an
existing ASD.
Atrial arrhythmias should be treated to restore and main-
tain sinus rhythm if possible (65). If atrial fibrillation occurs,
both antiarrhythmic therapy and anticoagulation should be
recommended.
2.3.2. Recommendations for Interventional
and Surgical Therapy
CLASS I
1. Closure of an ASD either percutaneously or surgically is indi-
cated for right atrial and RV enlargement with or without
symptoms. (Level of Evidence: B)
2. A sinus venosus, coronary sinus, or primum ASD should be
repaired surgically rather than by percutaneous closure. (Level
of Evidence: B)
3. Surgeons with training and expertise in CHD should perform
operations for various ASD closures. (Level of Evidence: C)
CLASS IIa
1. Surgical closure of secundum ASD is reasonable when concom-
itant surgical repair/replacement of a tricuspid valve is con-
sidered or when the anatomy of the defect precludes the use of
a percutaneous device. (Level of Evidence: C)
2. Closure of an ASD, either percutaneously or surgically, is
reasonable in the presence of:
a. Paradoxical embolism. (Level of Evidence: C)
b. Documented orthodeoxia-platypnea. (Level of Evidence: B)
CLASS IIb
1. Closure of an ASD, either percutaneously or surgically, may be
considered in the presence of net left-to-right shunting, pulmonary
artery pressure less than two thirds systemic levels, PVR less
than two thirds systemic vascular resistance, or when responsive
to either pulmonary vasodilator therapy or test occlusion of the
defect (patients should be treated in conjunction with providers
who have expertise in the management of pulmonary hyperten-
sive syndromes). (Level of Evidence: C)
2. Concomitant Maze procedure may be considered for intermit-
tent or chronic atrial tachyarrhythmias in adults with ASDs.
(Level of Evidence: C)
CLASS III
1. Patients with severe irreversible PAH and no evidence of a
left-to-right shunt should not undergo ASD closure. (Level of
Evidence: B)
2.3.3. Indications for Closure of Atrial Septal Defect
Small ASDs with a diameter of less than 5 mm and no
evidence of RV volume overload do not impact the natural
history of the individual and thus may not require closure
unless associated with paradoxical embolism. Larger defects
with evidence of RV volume overload on echocardiography
usually only cause symptoms in the third decade of life, and
closure is usually indicated to prevent long-term complica-
tions such as atrial arrhythmias, reduced exercise tolerance,
hemodynamically significant tricuspid regurgitation (TR),
right-to-left shunting and embolism during pregnancy, overt
congestive cardiac failure, or pulmonary vascular disease that
may develop in up to 5% to 10% of affected (mainly female)
individuals.
The majority of secundum ASDs can be closed with a
percutaneous catheter technique. When this is not feasible or
is not appropriate, surgical closure is recommended.
Sinus venosus, coronary sinus, and primum defects are not
amenable to device closure. An ASD with a large septal
aneurysm or a multifenestrated atrial septum requires careful
evaluation by and consultation with interventional cardiolo-
gists before device closure is selected as the method of repair.
2.4. Recommendations for
Postintervention Follow-Up
CLASS I
1. Early postoperative symptoms of undue fever, fatigue, vomit-
ing, chest pain, or abdominal pain may represent postpericar-
diotomy syndrome with tamponade and should prompt imme-
diate evaluation with echocardiography. (Level of Evidence: C)
2. Annual clinical follow-up is recommended for patients postop-
eratively if their ASD was repaired as an adult and the following
conditions persist or develop:
a. PAH. (Level of Evidence: C)
b. Atrial arrhythmias. (Level of Evidence: C)
c. RV or LV dysfunction. (Level of Evidence: C)
d. Coexisting valvular or other cardiac lesions. (Level of Evi-
dence: C)
3. Evaluation for possible device migration, erosion, or other
complications is recommended for patients 3 months to 1 year
after device closure and periodically thereafter. (Level of
Evidence: C)
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4. Device erosion, which may present with chest pain or syncope,
should warrant urgent evaluation. (Level of Evidence: C)
Follow-up for patients after device closure requires clinical
assessment of symptoms of arrhythmia, chest pain, or embolic
events and echocardiographic surveillance for device position,
residual shunting, and complications such as thrombus forma-
tion or pericardial effusion. Pericardial effusions and cardiac
tamponade may occur up to several weeks after surgical repair of
ASDs and should be evaluated by clinical examination and
echocardiography before hospital discharge and at the early
postoperative visits. Assessment of pulmonary pressure, RV
function, and residual atrial shunting should also be made during
follow-up echocardiography. Clinical and ECG surveillance for
recurrent or new-onset arrhythmia is an important feature of
postoperative evaluation.
2.4.1. Recommendation for Reproduction
CLASS III
1. Pregnancy in patients with ASD and severe PAH (Eisenmenger
syndrome) is not recommended owing to excessive maternal
and fetal mortality and should be strongly discouraged. (Level
of Evidence: A)
Women with large shunts and PAH may experience ar-
rhythmias, ventricular dysfunction, and progression of PAH.
Pregnancy in patients with ASD and severe PAH (Eisen-
menger syndrome) is contraindicated owing to excessive
maternal and fetal mortality and should be strongly discour-
aged (66,67). Paradoxical embolism may occasionally be
encountered in small and large ASDs (53,68).
3. Ventricular Septal Defect
VSD is the most common congenital heart defect at birth (69)
and presents in approximately 3.0 to 3.5 infants per 1000 live
births. Although VSD is most often an isolated lesion, it is a
common component of complex abnormalities such as
conotruncal defects (eg, tetralogy of Fallot and TGA). VSD
can also be associated with left-sided obstructive lesions such
as subaortic stenosis (SubAS) and coarctation of the aorta. A
subpulmonary (supracristal) VSD is often associated with
progressive aortic valve regurgitation caused by prolapse of
the aortic cusp (usually right) through the defect.
It is unlikely for an adult with an isolated VSD to present
with no prior workup/diagnosis. Possible scenarios include
the following:
● An asymptomatic patient with a systolic murmur previ-
ously thought to be an innocent murmur
● Fever and bacteremia secondary to IE
● A new diastolic murmur of aortic regurgitation (AR)
secondary to aortic valve prolapse
● Cyanosis and exercise intolerance secondary to the pro-
gressive development of pulmonary vascular disease.
3.1. Recommendations for Cardiac
Catheterization
CLASS I
1. Cardiac catheterization to assess the operability of adults with
VSD and PAH should be performed in an ACHD regional center
in collaboration with experts. (Level of Evidence: C)
CLASS IIa
1. Cardiac catheterization can be useful for adults with VSD in
whom noninvasive data are inconclusive and further informa-
tion is needed for management. Data to be obtained include
the following:
a. Quantification of shunting. (Level of Evidence: B)
b. Assessment of pulmonary pressure and resistance in pa-
tients with suspected PAH. Reversibility of PAH should be
tested with various vasodilators. (Level of Evidence: B)
c. Evaluation of other lesions such as AR and double-
chambered right ventricle. (Level of Evidence: C)
d. Determination of whether multiple VSDs are present before
surgery. (Level of Evidence: C)
e. Performance of coronary arteriography is indicated in pa-
tients at risk for coronary artery disease. (Level of Evidence: C)
f. VSD anatomy, especially if device closure is contemplated.
(Level of Evidence: C)
3.2. Management Strategies
3.2.1. Recommendation for Medical Therapy
CLASS IIb
1. Pulmonary vasodilator therapy may be considered for adults with
VSDs with progressive/severe pulmonary vascular disease (refer
to Section 9, Pulmonary Hypertension/Eisenmenger Physiology).
(Level of Evidence: B)
3.2.2. Recommendations for Surgical Ventricular
Septal Defect Closure
CLASS I
1. Surgeons with training and expertise in CHD should perform VSD
closure operations. (Level of Evidence: C)
2. Closure of a VSD is indicated when there is a Qp/Qs (pulmo-
nary–to–systemic blood flow ratio) of 2.0 or more and clinical
evidence of LV volume overload. (Level of Evidence: B)
3. Closure of a VSD is indicated when the patient has a history of
IE. (Level of Evidence: C)
CLASS IIa
1. Closure of a VSD is reasonable when net left-to-right shunting
is present at a Qp/Qs greater than 1.5 with pulmonary artery
pressure less than two thirds of systemic pressure and PVR
less than two thirds of systemic vascular resistance. (Level of
Evidence: B)
2. Closure of a VSD is reasonable when net left-to-right shunting
is present at a Qp/Qs greater than 1.5 in the presence of LV
systolic or diastolic failure. (Level of Evidence: B)
CLASS III
1. VSD closure is not recommended in patients with severe
irreversible PAH. (Level of Evidence: B)
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3.2.3. Recommendation for Interventional
Catheterization
CLASS IIb
1. Device closure of a muscular VSD may be considered, espe-
cially if the VSD is remote from the tricuspid valve and the
aorta, if the VSD is associated with severe left-sided heart
chamber enlargement, or if there is PAH. (Level of Evidence: C)
Indications for catheter device closure of VSD include
residual defects after prior attempts at surgical closure,
restrictive VSDs with a significant left-to-right shunt, trauma,
or iatrogenic artifacts after surgical replacement of the aortic
valve. Indications for closure of restrictive VSDs in the adult
population include a history of bacterial endocarditis or a
hemodynamically significant left-to-right shunt (Qp/Qs
greater than 1.5:1).
3.3. Key Issues to Evaluate and Follow-Up
3.3.1. Recommendations for Surgical and Catheter
Intervention Follow-Up
CLASS I
1. Adults with VSD with residual heart failure, shunts, PAH, AR, or
RV outflow tract (RVOT) or LV outflow tract (LVOT) obstruction
should be seen at least annually at an ACHD regional center.
(Level of Evidence: C)
2. Adults with a small residual VSD and no other lesions should be
seen every 3 to 5 years at an ACHD regional center. (Level of
Evidence: C)
3. Adults with device closure of a VSD should be followed up every
1 to 2 years at an ACHD center depending on the location of
the VSD and other factors. (Level of Evidence: C)
Adults with no residual VSD, no associated lesions, and
normal pulmonary artery pressure do not require continued
follow-up at a regional ACHD center except on referral from
the patient’s cardiologist or physician. Patients who develop
bifascicular block or transient trifascicular block after VSD
closure are at risk in later years for the development of
complete heart block and should be followed up yearly by
history and ECG and have periodic ambulatory monitoring
and/or exercise testing.
3.3.2. Recommendation for Reproduction
CLASS III
1. Pregnancy in patients with VSD and severe PAH (Eisenmenger
syndrome) is not recommended owing to excessive maternal
and fetal mortality and should be strongly discouraged. (Level
of Evidence: A)
Women with small VSDs, no PAH, and no associated
lesions have no increased cardiovascular risk for pregnancy.
Women with PAH should be counseled against pregnancy
(refer to Section 9, Pulmonary Hypertension/Eisenmenger
Physiology).
Pregnancy is generally well tolerated, with no maternal
mortality and no significant maternal or fetal morbidity.
Although the left-to-right shunt may increase with the in-
crease in cardiac output during pregnancy, this is counterbal-
anced by the decrease in peripheral resistance. Women with
large shunts and PAH may experience arrhythmias, ventric-
ular dysfunction, and progression of PAH.
4. Atrioventricular Septal Defect
The terms atrioventricular septal defect (AVSD), atrioven-
tricular (AV) canal defect, and endocardial cushion defect can
be used interchangeably to describe this group of defects.
Tetralogy of Fallot and other conotruncal anomalies and
heterotaxy syndromes also occur in association with AVSD.
4.1. Recommendation for Heart
Catheterization
CLASS IIa
1. Cardiac catheterization is reasonable to assess PAH and test
vasoreactivity in patients with repaired or unrepaired AVSD.
(Level of Evidence: B)
Heart catheterization has a limited role in the assessment of
these patients unless noninvasive findings are equivocal.
Evaluation of PAH and coronary anatomy may be needed
when reoperation is being considered. Hemodynamic data
may also be needed when noninvasive studies have not been
able to provide this information.
4.2. Recommendations for Surgical Therapy
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations for AVSD. (Level of Evidence: C)
2. Surgical reoperation is recommended in adults with previously re-
paired AVSD with the following indications:
a. Left AV valve repair or replacement for regurgitation or
stenosis that causes symptoms, atrial or ventricular ar-
rhythmias, a progressive increase in LV dimensions, or
deterioration of LV function. (Level of Evidence: B)
b. LVOT obstruction with a mean gradient greater than 50
mm Hg or peak instantaneous gradient greater than 70
mmHg, or a gradient less than 50 mmHg in association with
significant mitral regurgitation or AR. (Level of Evidence: B)
c. Residual/recurrent ASD or VSD with significant left-to-
right shunting (refer to Section 2.0, Atrial Septal Defect,
and Section 3.0, Ventricular Septal Defect). (Level of Evi-
dence: B)
Primary operation is rarely recommended for complete
AVSD in adults because of pulmonary vascular obstructive
disease. Unoperated partial or transitional AVSD, also known
as partial or transitional AV canal, may not be identified until
adulthood. Primary repair is generally recommended pro-
vided there is no fixed PAH.
4.3. Recommendations for
Endocarditis Prophylaxis
CLASS IIa
1. Antibiotic prophylaxis before dental procedures that involve
manipulation of gingival tissue or the periapical region of teeth
1908 Warnes et al. JACC Vol. 52, No. 23, 2008
ACC/AHA 2008 Guidelines for Adults With CHD December 2, 2008:1890–947
or perforation of the oral mucosa is reasonable in patients with
CHD with the highest risk for adverse outcome from IE,
including those with the following indications:
a. Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair. (Level of Evidence: B)
b. Previous IE. (Level of Evidence: B)
c. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: B)
d. Completely repaired CHD with prosthetic materials,
whether placed by surgery or by catheter intervention,
during the first 6 months after the procedure. (Level of
Evidence: B)
e. Repaired CHD with residual defects at the site or adjacent
to the site of a prosthetic patch or prosthetic device that
inhibit endothelialization. (Level of Evidence: B)
2. It is reasonable to consider antibiotic prophylaxis against IE
before vaginal delivery at the time of membrane rupture in
select patients with the highest risk of adverse outcomes. This
includes patients with the following indications:
a. Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair. (Level of Evidence: C)
b. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: C)
CLASS III
1. Prophylaxis against IE is not recommended for nondental
procedures (such as esophagogastroduodenoscopy or colonos-
copy) in the absence of active infection. (Level of Evidence: C)
4.4. Recommendations for Pregnancy
CLASS I
1. All women with a history of AVSD should be evaluated before
conception to ensure that there are no significant residual hemo-
dynamic lesions that might complicate the management of preg-
nancy. (Level of Evidence: C)
2. The issue of pregnancy risk and preventive measures should be
discussed with women with Down syndrome and their caregiv-
ers. (Level of Evidence: C)
Pregnancy is usually well tolerated by women who have
had repair and who have no major residua, as well as by
women with a primum defect who are functionally well.
Pregnancy is not advised for women with severe PAH.
5. Patent Ductus Arteriosus
5.1. Recommendations for Evaluation of the
Unoperated Patient
CLASS I
1. Definitive diagnosis of PDA should be based on visualization by
imaging techniques and demonstrations of the shunting across
the defect (with or without evidence of clinically significant LV
volume overload). (Level of Evidence: C)
CLASS III
1. Diagnostic cardiac catheterization is not indicated for uncom-
plicated PDA with adequate noninvasive imaging. (Level of
Evidence: B)
2. Maximal exercise testing is not recommended in PDA with
significant PAH. (Level of Evidence: B)
The diagnostic workup for a patient with a suspected PDA
is directed at defining the presence and size of the PDA, the
functional effect of the shunt on the left atrium and left
ventricle, the pulmonary circulation, and any associated
lesions.
5.2. Management Strategies
5.2.1. Recommendations for Medical Therapy
CLASS I
1. Routine follow-up is recommended for patients with a small
PDA without evidence of left-sided heart volume overload.
Follow-up is recommended every 3 to 5 years for patients with
a small PDA without evidence of left-heart volume overload.
(Level of Evidence: C)
CLASS III
1. Endocarditis prophylaxis is not recommended for those with a
repaired PDA without residual shunt. (Level of Evidence: C)
5.2.2. Recommendations for Closure of Patent
Ductus Arteriosus
CLASS I
1. Closure of a PDA either percutaneously or surgically is indi-
cated for the following:
a. Left atrial and/or LV enlargement or if PAH is present, or in
the presence of net left-to-right shunting. (Level of Evi-
dence: C)
b. Prior endarteritis. (Level of Evidence: C)
2. Careful evaluation and consultation with ACHD interventional
cardiologists is recommended before surgical closure is se-
lected as the method of repair for patients with a calcified PDA.
(Level of Evidence: C)
3. Surgical repair, by a surgeon experienced in CHD surgery, is
recommended when:
a. The PDA is too large for device closure. (Level of Evidence: C)
b. Distorted ductal anatomy precludes device closure (eg, aneu-
rysm or endarteritis) (42). (Level of Evidence: B)
CLASS IIa
1. It is reasonable to close an asymptomatic small PDA by
catheter device. (Level of Evidence: C)
2. PDA closure is reasonable for patients with PAH with a net
left-to-right shunt. (Level of Evidence: C)
CLASS III
1. PDA closure is not indicated for patients with PAH and net
right-to-left shunt. (Level of Evidence: C)
5.2.3. Surgical/Interventional Therapy
Surgical closure of PDA in the adult may pose some
problems due to the friability and/or calcification of the
ductus, atherosclerosis, and aneurysm formation, as well as
the presence of other unrelated comorbid conditions, such as
coronary atherosclerosis or renal disease, that may adversely
affect the perioperative risk. Adults with PDA are better
suited for percutaneous closure with either the occlusion
device or coils because of its high success and few compli-
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cations (70). If the PDA is associated with other conditions
that require surgical correction, the ductus may be closed
during the same operation, although percutaneous closure of
the PDA before other cardiac surgery may decrease the risk of
cardiopulmonary bypass.
5.3. Key Issues to Evaluate and Follow-Up
Adults with large PDAs are likely to have Eisenmenger
physiology. Such patients require frequent follow-up to
monitor their progress/deterioration. Problems associated
with Eisenmenger physiology are discussed in Section 9,
Pulmonary Hypertension/Eisenmenger Physiology.
Patients who have undergone surgical/PDA closure can be
discharged safely from follow-up once complete closure of
the ductus is documented by TTE. Antibiotic prophylaxis is
discontinued 6 months after PDA closure. Follow-up approx-
imately every 5 years for patients who received a device is
recommended because of the lack of long-term data on device
closure with the occlusion device.
6. Left-Sided Heart Obstructive Lesions:
Aortic Valve Disease, Subvalvular and
Supravalvular Aortic Stenosis,
Associated Disorders of the Ascending
Aorta, and Coarctation
LVOT obstruction syndromes include SubAS, valvular AS,
SupraAS, and aortic coarctation (71). Obstruction can occur
singly or at multiple levels, as an isolated lesion, or in
combination with septal defects or conotruncal anomalies.
Bicuspid aortic valve (BAV) is one of the most common
congenital cardiovascular malformations, with an estimated
incidence of 1% to 2% of the population.
6.1. Associated Lesions
Abnormalities associated with BAV disease include SubAS,
parachute mitral valve, VSD, PDA, or coarctation of the aorta
with varying degrees of arch hypoplasia. A left-dominant
coronary artery system is more frequent with BAV (72).
Turner syndrome may be associated with AS in addition to
aortic coarctation. The presence of multiple levels of left-
sided heart obstructions (eg, SubAS, BAV, AS, coarctation,
parachute mitral valve, or supramitral ring) is termed Shones
syndrome. Patients presenting in childhood with LVOT
obstruction generally have more complex or severe disease
than those found to have BAV in adult life. BAV disease can
be associated with progressive dilation of the aortic root,
aortic aneurysm, and even rupture or dissection; intrinsic
abnormalities of aortic wall elastin may result in ascending
aortic dilation even with a normally functioning aortic valve.
6.2. Recommendations for Evaluation of the
Unoperated Patient
Recommendations and guidelines concerning AS, BAV, and
AR in the adult patient are also discussed in the 2006 valvular
heart disease guidelines (73).
CLASS I
1. Primary imaging and hemodynamic assessment of AS and
aortic valve disease are recommended by echocardiography-
Doppler to evaluate the presence and severity of AS or AR; LV
size, function, and mass; and dimensions and anatomy of the
ascending aorta and associated lesions. (Level of Evidence: B)
2. Echocardiography is recommended for reevaluation of patients
with AS who experience a change in signs or symptoms and for
assessment of changes in AS hemodynamics during preg-
nancy. (Level of Evidence: B)
3. In asymptomatic adolescents and young adults, echocardiog-
raphy-Doppler is recommended yearly for AS with a mean
Doppler gradient greater than 30 mm Hg or peak instantaneous
gradient greater than 50 mm Hg and every 2 years for patients
with lesser gradients. (Level of Evidence: C)
4. Cardiac catheterization is recommended when noninvasive
measurements are inconclusive or discordant with clinical
signs. (Level of Evidence: C)
5. Coronary angiography is recommended before aortic valve
surgery for coronary angiography in adults at risk for coronary
artery disease. (Level of Evidence: B)
6. Coronary angiography is recommended before a Ross proce-
dure if noninvasive imaging of the coronary arteries is inade-
quate. (Level of Evidence: C)
7. A yearly ECG is recommended in young adults less than 30
years of age with mean Doppler gradients greater than
30 mm Hg or peak Doppler gradients greater than 50 mm Hg.
(Level of Evidence: C)
8. An ECG is recommended every other year in young adults less
than 30 years of age with mean Doppler gradients less than
30 mm Hg or peak Doppler gradients less than 50 mm Hg.
(Level of Evidence: C)
CLASS IIa
1. In asymptomatic young adults less than 30 years of age,
exercise stress testing is reasonable to determine exercise
capability, symptoms, and blood pressure response. (Level of
Evidence: C)
2. Exercise stress testing is reasonable for patients with a mean
Doppler gradient greater than 30 mm Hg or peak Doppler
gradient greater than 50 mm Hg if the patient is interested in
athletic participation or if clinical findings differ from noninva-
sive measurements. (Level of Evidence: C)
3. Exercise stress testing is reasonable for the evaluation of an
asymptomatic young adult with a mean Doppler gradient
greater than 40 mm Hg or a peak Doppler gradient greater than
64 mm Hg or when the patient anticipates athletic participa-
tion or pregnancy. (Level of Evidence: C)
4. Dobutamine stress testing can be beneficial in the evaluation
of a mild aortic valve gradient in the face of low LV ejection
fraction and reduced cardiac output. (Level of Evidence: B)
5. MRI/CT can be beneficial to add important information about
the anatomy of the thoracic aorta. (Level of Evidence: C)
6. Exercise stress testing can be useful to evaluate blood pressure
response or elicit exercise-induced symptoms in asymptomatic
older adults with AS. (Level of Evidence: B)
CLASS IIb
1. Magnetic resonance angiography may be beneficial in quanti-
fying AR when other data are ambiguous or borderline. (Level of
Evidence: C)
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CLASS III
1. Exercise stress testing should not be performed in symptom-
atic patients with AS or those with repolarization abnormality
on ECG or systolic dysfunction on echocardiography. (Level of
Evidence: C)
6.3. Problems and Pitfalls
Problems and pitfalls regarding BAV stenosis include the
following:
● The click murmur of a BAV may be misdiagnosed as mitral
valve prolapse.
● A systolic murmur may be thought to be “benign” because
an ejection click is not recognized.
● To quantify the severity of valvular AS by echocardiogra-
phy-Doppler, mean gradient and aortic valve area should
be used rather than relying only on peak systolic gradient,
which may overestimate the severity of stenosis. The aortic
valve area should be indexed to body surface area to correct
for different body sizes and habitus.
● Progressive aortic dilatation may occur in patients with
BAV even in the absence of significant AS or AR.
● In the presence of increased LV dimensions and normal
wall thickness, an increased LV mass is present. LV mass
calculations are needed and should be indexed to body
surface area (74).
6.4. Management Strategies for Left
Ventricular Outflow Tract Obstruction and
Associated Lesions
6.4.1. Recommendations for Medical Therapy
CLASS IIa
1. It is reasonable to treat systemic hypertension in patients with
AS while monitoring diastolic blood pressure to avoid reducing
coronary perfusion. (Level of Evidence: C)
2. It is reasonable to administer beta blockers in patientswith BAV and
aortic root dilatation. (Level of Evidence: C)
3. It is reasonable to use long-term vasodilator therapy in patients
with AR and systemic hypertension while carefully monitoring
diastolic blood pressure to avoid reducing coronary perfusion.
(Level of Evidence: C)
CLASS IIb
1. It may be reasonable to treat patients with BAV and risk factors
for atherosclerosis with statins with the aim of ‘‘slowing down
degenerative changes in the aortic valve and preventing athero-
sclerosis. (Level of Evidence: C)
CLASS III
1. Vasodilator therapy is not indicated for long-term therapy in AR
for the following:
a. The asymptomatic patient with only mild to moderate AR and
normal LV function. (Level of Evidence: B)
b. The asymptomatic patient with LV systolic dysfunction who
is otherwise a candidate for aortic valve replacement
(AVR). (Level of Evidence: B)
c. The asymptomatic patient with either LV systolic function
or mild to moderate LV diastolic dysfunction who is other-
wise a candidate for AVR. (Level of Evidence: C)
There are currently no established medical treatments
proven to alter the natural history or halt the progression of
stenosis in BAV disease (refer to Section 1.6, Recommenda-
tions for Infective Endocarditis, for additional information).
Beta-blockers may be administered to delay or prevent aortic
root dilatation or progression, but benefit has only been
validated in patients with Marfan syndrome or acute aortic
dissections. Judicious afterload reduction in patients with
hypertension to reduce systolic blood pressure and lower LV
wall tension may delay onset of LV dilatation or dysfunction
but should be balanced against the risk of reducing diastolic
coronary perfusion. There is no clear evidence that afterload
reduction decreases the volume of AR or reduces the need for
AVR (75). Multimodality molecular imaging has identified
proteolytic and osteogenic activity in early aortic valve
disease, a precursor to atherosclerotic and calcific degenera-
tive AS (76). Thus, statins may slow the progression of
acquired or calcific degenerative AS and probably have a role
in the treatment of BAV disease, early in the process, before
significant calcification and AS or AR have developed (77).
Although no clinical trials have confirmed the benefits of
statins in BAV disease, it appears reasonable to treat those
patients who have risk factors for atherosclerosis.
6.4.2. Catheter and Surgical Intervention
6.4.2.1. Recommendations for Catheter Interventions for
Adults With Valvular Aortic Stenosis
CLASS I
1. In young adults and others without significantly calcified aortic
valves and no AR, aortic balloon valvotomy is indicated in the
following patients:
a. Those with symptoms of angina, syncope, dyspnea on exer-
tion, and peak-to-peak gradients at catheterization greater
than 50 mmHg. (Level of Evidence: C)
b. Asymptomatic adolescents or young adults who demon-
strate ST or T-wave abnormalities in the left precordial leads
on ECG at rest or with exercise and a peak-to-peak catheter
gradient greater than 60 mm Hg. (Level of Evidence: C)
CLASS IIa
1. Aortic balloon valvotomy is reasonable in the asymptomatic
adolescent or young adult with AS and a peak-to-peak gradient
on catheterization greater than 50 mm Hg when the patient is
interested in playing competitive sports or becoming pregnant.
(Level of Evidence: C)
CLASS IIb
1. Aortic balloon valvotomy may be considered as a bridge to
surgery in hemodynamically unstable adults with AS, adults at
high risk for AVR, or when AVR cannot be performed secondary
to significant comorbidities. (Level of Evidence: C)
CLASS III
1. In older adults, aortic balloon valvotomy is not recommended
as an alternative to AVR, although certain younger patients
may be an exception and should be referred to a center with
experience in aortic balloon valvuloplasties. (Level of Evidence: B)
2. In asymptomatic adolescents and young adults, aortic balloon
valvotomy should not be performed with a peak-to-peak gradi-
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ent less than 40 mm Hg without symptoms or ECG changes.
(Level of Evidence: B)
6.4.2.2. Recommendations for Aortic Valve
Repair/Replacement and Aortic Root Replacement
CLASS I
1. Aortic valvuloplasty, AVR, or Ross repair is indicated in pa-
tients with severe AS or chronic severe AR while they undergo
coronary artery bypass grafting surgery on the aorta, or surgery
on other heart valves. (Level of Evidence: C)
2. AVR is indicated for patients with severe AS and LV dysfunction
(LV ejection fraction less than 50%). (Level of Evidence: C)
3. AVR is indicated in adolescents or young adults with severe AR
who have:
a. Development of symptoms. (Level of Evidence: C)
b. Development of persistent LV dysfunction (LV ejection
fraction less than 50%) or progressive LV dilatation (LV
end-diastolic diameter 4 standard deviations above normal).
(Level of Evidence: C)
4. Surgery to repair or replace the ascending aorta in a patient
with a BAV is recommended when the ascending aorta diame-
ter is 5.0 cm or more or when there is progressive dilation at a
rate greater than or equal to 5 mm per year (73). (Level of
Evidence: B)
CLASS IIa
1. AVR is reasonable for asymptomatic patients with severe AR
and normal systolic function (ejection fraction greater than
50%) but with severe LV dilatation (LV end-diastolic diameter
greater than 75 mm or end-systolic dimension greater than
55 mm*). (Level of Evidence: B)
2. Surgical aortic valve repair or replacement is reasonable in
patients with moderate AS undergoing coronary artery bypass
grafting or other cardiac or aortic root surgery. (Level of
Evidence: B)
CLASS IIb
1. AVR may be considered for asymptomatic patients with any of
the following indications:
a. Severe AS and abnormal response to exercise. (Level of
Evidence: C)
b. Evidence of rapid progression of AS or AR. (Level of Evi-
dence: C)
c. Mild AS while undergoing coronary artery bypass grafting or
other cardiac surgery and evidence of a calcific aortic valve.
(Level of Evidence: C)
d. Extremely severe AS (aortic valve area less than 0.6 cm
and/or mean Doppler systolic AV gradient greater than
60 mm Hg) in an otherwise good operative candidate.
(Level of Evidence: C)
e. Moderate AR undergoing coronary artery bypass grafting
or other cardiac surgery. (Level of Evidence: C)
f. Severe AR with rapidly progressive LV dilation, when the
degree of LV dilation exceeds an end-diastolic dimension of
70 mm or end-systolic dimension of 50 mm, with declining
exercise tolerance, or with abnormal hemodynamic re-
sponse to exercise. (Level of Evidence: C)
2. Surgical repair may be considered in adults with AS or AR and
concomitant ascending aortic dilatation (ascending aorta di-
ameter greater than 4.5 cm) coexisting with AS or AR. (Level
of Evidence: B)
3. Early surgical repair may be considered in adults with the
following indications:
a. AS and a progressive increase in ascending aortic size.
(Level of Evidence: C)
b. Mild AR if valve-sparing aortic root replacement is being
considered. (Level of Evidence: C)
CLASS III
1. AVR is not useful for prevention of sudden death in asymptom-
atic adults with AS who have none of the findings listed under
the Class IIa/IIb indications. (Level of Evidence: B)
2. AVR is not indicated in asymptomatic patients with AR who
have normal LV size and function. (Level of Evidence: B)
When valvular AS is secondary to bicuspid commissural
fusion, especially in young adults, the potential exists for
successful balloon dilation with gradient reduction and ex-
tended freedom from reintervention (78). Increasing calcifi-
cation, with concomitantly increasing transvalvular gradient
with increasing patient age, limits results in older adults, in
whom AVR is the intervention of choice (78). Criteria for
intervention vary, with typical indications including a valve
area less than or equal to 0.45 cm2 per m2 (if not indexed, 0.8
cm2 for an average-sized adult with a height of 1.7 m2),
especially in the setting of the symptoms of dyspnea, angina,
or syncope or with worsening ventricular function. Balloon
valvuloplasty may be considered in younger patients in whom
there is a need to have augmented cardiac output, such as those
with a desire to become pregnant or to participate in vigorous
sports. When balloon valvuloplasty is indicated, patients should
be referred to a center experienced in the procedure.
In BAV disease, there is no consensus regarding the
specific diameter of the ascending aorta for which replacement is
indicated, but greater than or equal to 5.0 cm has been suggested
by some (73). Whether aortic root replacement or wrapping is
optimal in such patients is a matter of debate; results of AVR in
CHD have an acceptable medium-term result (79).
6.5. Recommendations for Key Issues to
Evaluate and Follow-Up
CLASS I
1. Lifelong cardiology follow-up is recommended for all patients
with aortic valve disease (AS or AR) (operated or unoperated;
refer to Section 6.2, Recommendations for Evaluation of the
Unoperated Patient). (Level of Evidence: A)
2. Serial imaging assessment of aortic root anatomy is recom-
mended for all patients with BAV, regardless of severity. The
frequency of imaging would depend on the size of the aorta at
initial assessment: if less than 40 mm, it should be reimaged
approximately every 2 years; if greater than or equal to 40 mm,
it should be reimaged yearly or more often as progression of
root dilation warrants or whenever there is a change in clinical
symptoms or findings. (Level of Evidence: B)
3. Prepregnancy counseling is recommended for women with AS
who are contemplating pregnancy. (Level of Evidence: B)
4. Patient referral to a pediatric cardiologist experienced in fetal
echocardiography is indicated in the second trimester of preg-
*Consider lower threshold values for patients of small stature of either
gender.
1912 Warnes et al. JACC Vol. 52, No. 23, 2008
ACC/AHA 2008 Guidelines for Adults With CHD December 2, 2008:1890–947
nancy to search for cardiac defects in the fetus. (Level of
Evidence: C)
5. Women with BAV and ascending aorta diameter greater than
4.5 cm should be counseled about the high risks of pregnancy.
(Level of Evidence: C)
6. Patients with moderate to severe AS should be counseled
against competitive athletics and strenuous isometric exer-
cise. (Level of Evidence: B)
7. Echocardiographic screening for the presence of BAV is rec-
ommended for first-degree relatives of patients with BAV.
(Level of Evidence: B)
Progressive or recurrent AS, AR, or aortic enlargement
may occur in the presence of a BAV. Patients with or without
intervention should be followed up at least yearly for symp-
toms and findings of progressive AS/AR ventricular dysfunc-
tion and arrhythmia. This includes resting and stress ECGs to
look for ischemic changes or arrhythmia; echocardiography-
Doppler to monitor LV size/volume and systolic and diastolic
function, aortic valve function, and aortic root size and
anatomy; and 24-hour ambulatory ECG monitoring.
6.6. Isolated Subaortic Stenosis
SubAS refers to a discrete fibrous ring or fibromuscular
narrowing and is distinct from genetic hypertrophic cardio-
myopathy with dynamic LVOT obstruction. SubAS may
occur as an associated defect with VSDs, AVSD, or
conotruncal anomalies and may develop after patch closure of
a perimembranous or misaligned VSD or AVSD (80).
6.6.1. Clinical Course With/Without Previous
Intervention
The course of SubAS is often progressive. The unrepaired
history includes progressive aortic valve damage, ventricular
dysfunction, IE, and sudden cardiac death. The dominant
feature may be obstruction or AR (81–83). AR occurs in
more than 50% of those with SubAS. Once the peak Doppler
gradient across the SubAS is more than 30 mm Hg, and if the
membrane is immediately adjacent to the aortic valve or there
is extension of the membrane onto the mitral valve, LVOT
obstruction is likely to be progressive (82). Once the peak
instantaneous Doppler LVOT gradient reaches 50 mm Hg or
more, there is increased risk for moderate or severe AR (82).
Patients are at risk for endocarditis, which will contribute to
worsening AR (84).
6.7. Recommendations for Surgical
Intervention
CLASS I
1. Surgical intervention is recommended for patients with SubAS
and a peak instantaneous gradient of 50 mmHg or a mean
gradient of 30 mmHg on echocardiography-Doppler. (Level of
Evidence: C)
2. Surgical intervention is recommended for SubAS with less than
a 50 mm Hg peak or less than a 30 mm Hg mean gradient and
progressive AR and an LV dimension at end-systolic diameter of
50 mm or LV ejection fraction less than 55%. (Level of
Evidence: C)
CLASS IIb
1. Surgical resection may be considered in patients with a mean
gradient of 30 mm Hg, but careful follow-up is required to
detect progression of stenosis or AR. (Level of Evidence: C)
2. Surgical resection may be considered for patients with less
than a 50 mm Hg peak gradient or less than a 30 mm Hg mean
gradient in the following situations:
a. When LV hypertrophy is present. (Level of Evidence: C)
b. When pregnancy is being planned. (Level of Evidence: C)
c. When the patient plans to engage in strenuous/competitive
sports. (Level of Evidence: C)
CLASS III
1. Surgical intervention is not recommended to prevent AR for
patients with SubAS if the patient has trivial LVOT obstruction
or trivial to mild AR. (Level of Evidence: C)
Surgical intervention should be recommended for patients
with SubAS when the peak instantaneous echocardiographic
gradient is greater than 50 mm Hg, the mean gradient is
greater than 30 mm Hg, or catheter measurement of the
resting peak-to-peak gradient is greater than 50 mm Hg.
Patients with lesser degrees of obstruction may be considered
for surgery in the presence of LV systolic dysfunction or
significant aortic valve regurgitation, or if the patient desires
to become pregnant or to participate in active sports.
Postoperative complications may include damage to the
aortic or mitral valve, heart block, iatrogenic VSD, and IE.
SubAS may recur after surgical repair; repair of SubAS in
children does not necessarily prevent AR development in
adults (81,85). However, data exist to suggest that surgical
resection of fixed SubAS before the development of a more
than 40 mm Hg LVOT gradient may prevent reoperation and
secondary progressive aortic valve disease (86). Although
catheter palliation has been performed in some centers on an
experimental basis, its efficacy has not been demonstrated (87).
6.8. Recommendations for Key Issues to
Evaluate and Follow-Up
CLASS I
1. Lifelong cardiology follow-up, including evaluation by and/or
consultation with a cardiologist with expertise in ACHD, is
recommended for all patients with SubAS, repaired or not.
(Level of Evidence: C)
2. The unoperated asymptomatic adult with stable LVOT obstruc-
tion due to SubAS and a mean gradient less than 30 mm Hg
without LV hypertrophy or significant AR should be monitored
at yearly intervals for increasing obstruction, the development
or progression of AR, and the evaluation of systolic and
diastolic LV function. (Level of Evidence: B)
CLASS IIa
1. Stress testing to determine exercise capability, symptoms,
ECG changes or arrhythmias, or increase in LVOT gradient is
reasonable in the presence of otherwise equivocal indications
for intervention. (Level of Evidence: C)
Progressive and/or recurrent obstruction and progressive
AR may occur in patients with or without intervention.
Recurrent obstruction is frequent after resection of SubAS
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and occurs at a rate of approximately 20% over 10 years. In
addition, AR may occur despite resection of the subaortic
membrane.
6.9. Supravalvular Aortic Stenosis
Supravalvular aortic stenosis (SupraAS) is a fixed obstruction
that arises from just above the sinus of Valsalva and extends
a variable distance along the aorta. The origin of the coronary
arteries is usually proximal to the obstruction, which subjects
them to high systolic pressure and limited diastolic flow.
There may be partial or complete ostial obstruction of the
coronary arteries, ectasia, or aneurysm of the coronary
arteries (88).
SupraAS is commonly seen in Williams syndrome and can
be associated with hypoplasia of the entire aorta, renal artery
stenosis, stenoses of other major aortic branches, and long-
segment peripheral pulmonary artery stenosis. Williams syn-
drome, an autosomal dominant disorder due to an elastin gene
mutation, is associated with abnormal (elfin) facies, cognitive
and behavioral disorders, and joint abnormalities. Familial
non-Williams SubAS is also associated with branch pulmo-
nary artery stenosis and hypoplasia, as well as hypoplastic
descending aorta and renal artery stenosis.
6.9.1. Clinical Course (Unrepaired)
Most patients with SubAS will be followed up from child-
hood and may present in adult life with symptoms due to
significant outflow obstruction, systemic hypertension, or
ischemia. Clinical presentation with ischemic symptomatol-
ogy referable to insufficient coronary artery flow has been
reported due to either anatomic obstruction or myocardial
hypertrophy that limits nonepicardial coronary flow (89).
6.10. Recommendations for Evaluation of the
Unoperated Patient
CLASS I
1. TTE and/or TEE with Doppler and either MRI or CT should be
performed to assess the anatomy of the LVOT, the ascending
aorta, coronary artery anatomy and flow, and main and branch
pulmonary artery anatomy and flow. (Level of Evidence: C)
2. Assessment of anatomy and flow in the proximal renal
arteries is recommended in ACHD patients with SupraAS.
(Level of Evidence: C)
3. Assessment of systolic and diastolic ventricular function is
recommended in ACHD patients with SupraAS. (Level of Evi-
dence: C)
4. Assessment of aortic and mitral valve anatomy and function
is recommended in ACHD patients with SupraAS. (Level of
Evidence: C)
5. Adults with a history or presence of SupraAS should be
screened periodically for myocardial ischemia. (Level of Evi-
dence: C)
CLASS IIa
1. Exercise testing, dobutamine stress testing, positron emission
tomography, or stress sestamibi with adenosine studies can be
useful to evaluate the adequacy of myocardial perfusion. (Level
of Evidence: C)
6.10.1. Imaging
TTE and TEE demonstrate the diameter and anatomy of the
aortic sinus, sinotubular ridge, and proximal ascending aorta;
the origins of the coronary arteries; the systolic gradient
across the SupraAS obstruction; and the degree of left
ventricle hypertrophy. MRI/CT is required to more precisely
define the anatomy of the aorta and branches, as well as the
pulmonary arteries. As with any long-segment obstruction,
assessment of the gradient can be challenging and may
require cardiac catheterization for complete assessment of
hemodynamic severity of the stenosis. Patients with Williams
syndrome should have imaging of the entire aorta, including
the renal arteries, because of the association with arterial
stenosis at any level.
6.10.2. Myocardial Perfusion Imaging
Patients with an inability to perform maximal stress testing
secondary to limited cognitive function or physical capacity
may undergo perfusion imaging with pharmacologic stress
(adenosine or dobutamine) nuclear imaging with positron
emission tomography, single photon emission computed to-
mography, or MRI.
6.10.3. Cardiac Catheterization
Diagnostic catheterization may help to delineate anatomy and
accurately measure gradients. Selective coronary angiogra-
phy should be approached with caution after thorough non-
invasive and angiographic examination of the aortic root,
because coronary ostial stenosis is a frequent occurrence in
this population. Intravascular ultrasonography may provide
definition of coronary artery anatomy and define the nature
and extent of the diseased vessel before consideration of
repair.
6.11. Management Strategies for
Supravalvular Left Ventricular Outflow Tract
6.11.1. Recommendations for Interventional and
Surgical Therapy
CLASS I
1. Operative intervention should be performed for patients with
supravalvular LVOT obstruction (discrete or diffuse) with symp-
toms (ie, angina, dyspnea, or syncope) and/or mean gradient
greater than 50 mm Hg or peak instantaneous gradient by
Doppler echocardiography greater than 70 mmHg. (Level of
Evidence: B)
2. Surgical repair is recommended for adults with lesser degrees
of supravalvular LVOT obstruction and the following
indications:
a. Symptoms (ie, angina, dyspnea, or syncope). (Level of
Evidence: B)
b. LV hypertrophy. (Level of Evidence: C)
c. Desire for greater degrees of exercise or a planned preg-
nancy. (Level of Evidence: C)
d. LV systolic dysfunction. (Level of Evidence: C)
3. Interventions for coronary artery obstruction in patients with
SupraAS should be performed in ACHD centers with demon-
strated expertise in the interventional management of such
patients. (Level of Evidence: C)
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Surgical relief of SupraAS is accomplished with the use of
complex patching of the aorta, with reconstruction of the
coronary ostia or bypass grafting, depending on the anatomy
of the lesion. Surgical results with reconstruction of the
coronary ostium or bypass grafting, depending on anatomy of
the lesions noted, have been described without long-term
follow-up (90). Branch pulmonary artery stenosis may be
addressed during the same surgical procedure. There are no
long-term follow-up data on adults after surgery for SupraAS.
Catheter-based techniques have not been described for this
lesion.
6.11.2. Recommendations for Key Issues to Evaluate
and Follow-Up
CLASS I
1. Both operated and unoperated patients with SupraAS should
be followed up annually at a regional ACHD center. (Level of
Evidence: C)
2. Long-term psychosocial assessment and oversight, including
the need for legal guardianship, are recommended for patients
with Williams syndrome. (Level of Evidence: C)
Repair of SupraAS results in low early and late mortality
and a low incidence of recurrent obstruction. The durability
of patch material requires long-term observation for assess-
ment of aneurysm formation. Both operated and unoperated
patients with SupraAS require lifelong annual follow-up to
evaluate the degree of obstruction and LV compensation, the
development of coronary insufficiency or systemic hyperten-
sion, and the development of mitral regurgitation.
Patients with Williams syndrome require long-term psy-
chosocial follow-up to assess competency for self-care and
recommend appropriate measures. This is particularly impor-
tant because these patients have verbal and social skills that
result in an overestimation of their executive functioning.
6.11.3. Recommendations for Reproduction
CLASS I
1. SupraAS, whether associated with Williams syndrome or non-
syndromic, has a strong likelihood of being an inherited disor-
der. Undetected family members may be at risk for hyperten-
sion, coronary disease, or stroke; therefore, all available
relatives should be screened. (Level of Evidence: C)
2. Patients with SupraAS and significant obstruction, coronary
involvement, or aortic disease should be counseled against
pregnancy. (Level of Evidence: C)
6.12. Aortic Coarctation
Discrete coarctation of the aorta consists of short-segment
narrowing in the region of the ligamentum arteriosum adja-
cent to the origin of the left subclavian artery. In some cases,
there is also narrowing of the aortic arch or isthmus. Exten-
sive collateral vessels may arise proximal to the obstruction,
masking the severity of obstruction. An associated intrinsic
abnormality in the aortic wall predisposes to dissection or
rupture in the ascending aorta or the area of the coarctation.
Associated lesions include BAV, SubAS, mitral valve abnor-
malities such as parachute mitral stenosis, VSD, and circle of
Willis cerebral artery aneurysm.
6.12.1. Recommendations for Clinical Evaluation
and Follow-Up
CLASS I
1. Every patient with systemic arterial hypertension should have
the brachial and femoral pulses palpated simultaneously to
assess timing and amplitude evaluation to search for the
“brachial-femoral delay” of significant aortic coarctation. Su-
pine bilateral arm (brachial artery) blood pressures and prone
right or left supine leg (popliteal artery) blood pressures should
be measured to search for differential pressure. (Level of
Evidence: C)
2. Initial imaging and hemodynamic evaluation by TTE, including
suprasternal notch acoustic windows, is useful in suspected
aortic coarctation. (Level of Evidence: B)
3. Every patient with coarctation (repaired or not) should have at
least 1 cardiovascular MRI or CT scan for complete evaluation
of the thoracic aorta and intracranial vessels. (Level of Evi-
dence: B)
Aortic coarctation may be recognized in the adult, usually
because of systemic arterial hypertension and discrepant
upper- and lower-extremity pulses. Patients may complain of
exertional headaches, leg fatigue, or claudication. Occasion-
ally, the patient may come to medical attention because of a
murmur due to BAV or VSD.
6.13. Management Strategies for Coarctation
of the Aorta
6.13.1. Medical Therapy
Hypertension should be controlled by beta blockers, ACE
inhibitors, or angiotensin-receptor blockers as first-line med-
ications. The choice of beta blockers or vasodilators may be
influenced in part by the aortic root size, the presence of AR,
or both.
6.13.2. Recommendations for Interventional and
Surgical Treatment of Coarctation of the Aorta
in Adults
CLASS I
1. Intervention for coarctation is recommended in the following
circumstances:
a. Peak-to-peak coarctation gradient greater than or equal to
20 mm Hg. (Level of Evidence: C)
b. Peak-to-peak coarctation gradient less than 20 mm Hg in
the presence of anatomic imaging evidence of significant
coarctation with radiological evidence of significant collat-
eral flow. (Level of Evidence: C)
2. Choice of percutaneous catheter intervention versus surgical
repair of native discrete coarctation should be determined by
consultation with a team of ACHD cardiologists, intervention-
alists, and surgeons at an ACHD center. (Level of Evidence: C)
3. Percutaneous catheter intervention is indicated for recurrent,
discrete coarctation and a peak-to-peak gradient of at least
20 mm Hg. (Level of Evidence: B)
4. Surgeons with training and expertise in CHD should perform
operations for previously repaired coarctation and the following
indications:
a. Long recoarctation segment. (Level of Evidence: B)
b. Concomitant hypoplasia of the aortic arch. (Level of Evidence: B)
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CLASS IIb
1. Stent placement for long-segment coarctation may be consid-
ered, but the usefulness is not well established, and the
long-term efficacy and safety are unknown. (Level of Evidence: C)
The appropriate type of treatment for native coarctation of
the aorta in adults remains somewhat controversial. In par-
ticular, for women who are or will be of childbearing age
after repair, there is a concern about the tissue integrity of the
paracoarctation region, particularly during pregnancy. As
such, one may select direct surgical repair with excision of
the paracoarctation tissue for those individuals. For recurrent
aortic coarctation (coarctation after surgical repair), the pre-
vailing opinion now is that catheter-based intervention (bal-
loon or stent) is generally safe and the preferred alternative to
surgery in the absence of confounding features (eg, aneurysm
or pseudoaneurysm formation, or significant coarctation that
affects the adjoining arch arterial branches). For localized
discrete narrowing, balloon angioplasty is an acceptable
alternative to surgical repair as a primary intervention but is
still considered less suitable for long-segment or tortuous
forms of coarctation.
In the majority of circumstances, discrete recoarctation is
managed with balloon dilation with or without stent place-
ment. In many ACHD centers, surgery is reserved for patients
who are unsuitable for percutaneous treatment or who have
undergone unsuccessful percutaneous treatment.
The use of partial or full cardiopulmonary bypass may be
required to prevent paralytic complications. Rebound hyper-
tension can occur early after repair and may be prevented or
blunted by preoperative administration of a beta blocker.
Morbidity in adults with reoperation for coarctation can be
considerable and may include significant early postoperative
bleeding, pleural effusion, lung contusion, recurrent laryngeal
nerve palsy, or phrenic nerve injury (with hemidiaphragmatic
paresis or paralysis). Other postoperative complications in-
clude recoarctation and hypertension. Aneurysm formation at
the repair site can occur after patch aortoplasty (particularly
with the use of a Dacron patch) or resection of the coarctation
shelf. False aneurysms may also occur at the repair site. Late
dissection proximal or distal to the repair site can occur.
Paraplegia secondary to spinal cord ischemia is rare but is
more common with poor collateral circulation. Arm claudi-
cation or subclavian steal syndrome is rare but in particular
may occur after use of the subclavian flap technique.
6.13.3. Recommendations for Key Issues to Evaluate
and Follow-Up
CLASS I
1. Lifelong cardiology follow-up is recommended for all patients
with aortic coarctation (repaired or not), including an evalua-
tion by or consultation with a cardiologist with expertise in
ACHD. (Level of Evidence: C)
2. Patients who have had surgical repair of coarctation at the
aorta or percutaneous intervention for coarctation of the aorta
should have at least yearly follow-up. (Level of Evidence: C)
3. Even if the coarctation repair appears to be satisfactory, late
postoperative thoracic aortic imaging should be performed to
assess for aortic dilatation or aneurysm formation. (Level of
Evidence: B)
4. Patients should be observed closely for the appearance or
reappearance of resting or exercise-induced systemic arterial
hypertension, which should be treated aggressively after reco-
arctation is excluded. (Level of Evidence: B)
5. Evaluation of the coarctation repair site by MRI/CT should be
performed at intervals of 5 years or less, depending on the
specific anatomic findings before and after repair. (Level of
Evidence: C)
CLASS IIb
1. Routine exercise testing may be performed at intervals deter-
mined by consultation with the regional ACHD center. (Level of
Evidence: C)
All patients with either interventional catheterization or
surgical repair of coarctation of the aorta should have close
follow-up and aggressive management of blood pressure and
other risk factors for cardiovascular disease. This should
include at least yearly cardiology evaluations. Consultation
with a cardiologist with special expertise in ACHD should be
obtained on initial contact to determine risk factors specific
for the patient’s anatomy and the presence of associated
lesions. Evaluation of the repair site by MRI/CT should be
repeated at intervals of 5 years or less, depending on the
specific anatomic findings before and after repair.
7. Right Ventricular Outflow
Tract Obstruction
Obstruction to the RVOT in the adult patient can be either
congenital or acquired. Congenital obstruction can be at the
pulmonary valve, below the pulmonary valve, or above the
pulmonary valve. Below the pulmonary valve, obstruction
can be either at the infundibular or the subinfundibular level.
Infundibular stenosis is a crucial component of tetralogy of
Fallot.
7.1. Valvular Pulmonary Stenosis
Valvular PS is usually an isolated lesion. In long-standing,
severe PS, there may be an element of infundibular hyper-
trophy and potential obstruction.
7.1.1. Recommendations for Evaluation of the
Unoperated Patient
CLASS I
1. Two-dimensional echocardiography-Doppler, chest x-ray, and
ECG are recommended for the initial evaluation of patients with
valvular PS. (Level of Evidence: C)
2. A follow-up physical examination, echocardiography-Doppler,
and ECG are recommended at 5-year intervals in the asymp-
tomatic patient with a peak instantaneous valvular gradient by
Doppler less than 30 mm Hg. (Level of Evidence: C)
3. A follow-up echocardiography-Doppler is recommended every 2
to 5 years in the asymptomatic patient with a peak instanta-
neous valvular gradient by Doppler greater than 30 mm Hg.
(Level of Evidence: C)
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CLASS III
1. Cardiac catheterization is unnecessary for diagnosis of valvular
PS and should be used only when percutaneous catheter
intervention is contemplated. (Level of Evidence: C)
There is little progression in PS severity when the gradient
is less than 30 mm Hg; such patients can be followed up at
least every 5 years with a clinical examination and Doppler-
echocardiography. Those with more significant stenosis
should be followed up on an annual basis. Most patients with
PS who reach adulthood are asymptomatic and require no
specific therapy.
Patients with valvular PS do not require cardiac catheter-
ization for diagnosis, and the relationship between the peak-
to-peak invasive hemodynamic gradient and the Doppler
peak instantaneous gradient becomes relevant in deciding
appropriateness for invasive evaluation and intervention.
There are recent data that suggest the peak-to-peak gradient
by cardiac catheterization correlates best with the mean
Doppler (and not peak instantaneous Doppler) gradient in this
situation (91) and that the peak instantaneous gradient sys-
tematically overestimates the peak-to-peak cardiac catheter-
ization gradient by slightly more than 20 mm Hg. Correlation
of the echocardiography-Doppler gradient with other clinical
findings is important.
7.1.2. Management Strategies
7.1.2.1. Recommendations for Intervention in Patients With
Valvular Pulmonary Stenosis
CLASS I
1. Balloon valvotomy is recommended for asymptomatic patients
with a domed pulmonary valve and a peak instantaneous Doppler
gradient greater than 60 mmHg or a mean Doppler gradient
greater than 40 mmHg (in association with less than moderate
pulmonary valve regurgitation). (Level of Evidence: B)
2. Balloon valvotomy is recommended for symptomatic patients
with a domed pulmonary valve and a peak instantaneous
Doppler gradient greater than 50 mm Hg or a mean Doppler
gradient greater than 30 mm Hg (in association with less than
moderate pulmonary regurgitation). (Level of Evidence: C)
3. Surgical therapy is recommended for patients with severe PS
and an associated hypoplastic pulmonary annulus, severe
pulmonary regurgitation, subvalvular PS, or supravalvular PS.
Surgery is also preferred for most dysplastic pulmonary valves
and when there is associated severe TR or the need for a
surgical Maze procedure. (Level of Evidence: C)
4. Surgeons with training and expertise in CHD should perform
operations for the RVOT and pulmonary valve. (Level of Evi-
dence: B)
CLASS IIb
1. Balloon valvotomy may be reasonable in asymptomatic pa-
tients with a dysplastic pulmonary valve and a peak instanta-
neous gradient by Doppler greater than 60 mm Hg or a mean
Doppler gradient greater than 40 mm Hg. (Level of Evidence: C)
2. Balloon valvotomy may be reasonable in selected symptomatic
patients with a dysplastic pulmonary valve and peak instanta-
neous gradient by Doppler greater than 50 mm Hg or a mean
Doppler gradient greater than 30 mm Hg. (Level of Evidence: C)
CLASS III
1. Balloon valvotomy is not recommended for asymptomatic pa-
tients with a peak instantaneous gradient by Doppler less than
50 mm Hg in the presence of normal cardiac output. (Level of
Evidence: C)
2. Balloon valvotomy is not recommended for symptomatic pa-
tients with PS and severe pulmonary regurgitation. (Level of
Evidence: C)
3. Balloon valvotomy is not recommended for symptomatic pa-
tients with a peak instantaneous gradient by Doppler less than
30 mm Hg. (Level of Evidence: C)
Since the initial successful report of percutaneous balloon
valvotomy for pulmonary valve stenosis in 1982 (92), the
procedure has evolved to be the treatment of choice for
patients with classic domed valvular PS. Balloon valvotomy
produces relief of the gradient by commissural splitting. As
might be expected from the morphology, results in patients
with a dysplastic pulmonary valve are less impressive.
Because of the elasticity of the pulmonary annulus, it has
been found that oversizing the balloons up to 1.4 times the
measured pulmonary annulus is more effective in achieving a
successful result (usually defined by a final valvular gradient
of less than 20 mm Hg). To accomplish this oversizing in
adults, a double-balloon procedure is frequently used. In
general, acute complications from the procedure have been
minimal. During the acute performance of the valvotomy,
vagal symptoms predominate, along with catheter-induced
ventricular ectopy and occasionally right bundle-branch
block.
Other complications include pulmonary valve regurgita-
tion, pulmonary edema (presumably from increasing pulmo-
nary blood flow to previously underperfused lungs), cardiac
perforation and tamponade, high-grade AV nodal block, and
transient RVOT obstruction. The latter is sometimes referred
to as a “suicidal right ventricle” and is due to abrupt
infundibular obstruction once the pulmonary valve obstruc-
tion has been relieved (93). This may be alleviated by volume
expansion and beta blockade. This postprocedural infundib-
ular obstruction tends to regress over time.
In patients with PS and significant valvular regurgitation,
valve replacement may be required. Mechanical valve re-
placement (94) is rarely used because of concerns regarding
thrombosis. Bioprosthetic valves (95) can be effectively
implanted with good durability in patients of all ages,
although valvular degeneration eventually ensues in all.
7.1.3. Recommendation for Clinical Evaluation and
Follow-Up After Intervention
CLASS I
1. Periodic clinical follow-up is recommended for all patients after
surgical or balloon pulmonary valvotomy, with specific atten-
tion given to the degree of pulmonary regurgitation; RV pres-
sure, size, and function; and TR. The frequency of follow-up
should be determined by the severity of hemodynamic abnor-
malities but should be at least every 5 years. (Level of
Evidence: C)
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Long-term follow-up after balloon valvuloplasty in pa-
tients without valve dysplasia suggests a low (0% to 4.8%)
incidence of restenosis (96,97) and a moderate (39%) inci-
dence of pulmonary regurgitation. In adult patients without
valve dysplasia, excellent results were also observed, with a
residual gradient primarily found only in those patients who
had an inadequate initial result (98). In the Valvuloplasty and
Angioplasty of Congenital Anomalies (VACA) registry (99),
follow-up data were available on 533 patients a mean of 8.7
years after valvotomy. A suboptimal result (defined as
gradient greater than 35 mm Hg at the end of the procedure)
was present in 23%. Valve morphology and annulus size were
the most significant predictors of long-term results. Pulmo-
nary regurgitation was more commonly seen when the
balloon-to-annulus ratio exceeded 1.4, which suggests an
optimal ratio of 1.2 to 1.4. When restenosis does occur after
percutaneous balloon pulmonary valvotomy, it appears that a
repeat procedure is effective in patients without dysplastic
pulmonary valves (100).
Percutaneous balloon valvotomy thus appears to be an
excellent alternative to surgical valvuloplasty or valve re-
placement in most patients with classic, doming, valvular PS.
Its use in patients with a dysplastic valve is much less
established. After surgical valvotomy, pulmonary regurgita-
tion is common, and after 3 to 4 decades, RV dysfunction and
secondary TR may ensue, necessitating pulmonary valve
replacement in some patients. This should be undertaken
before there is severe RV enlargement and any more than
mild RV dysfunction. Deteriorating exercise capacity or the
onset of atrial or ventricular arrhythmias is also a sign of
the need for pulmonary valve replacement. This emphasizes
the need for lifelong follow-up in such patients (101).
7.2. Right-Sided Obstruction Due to
Supravalvular, Branch, and Peripheral
Pulmonary Artery Stenosis
The pulmonary arterial segments distal to patent stenotic
lesions often exhibit poststenotic dilation. Central and periph-
eral pulmonary artery stenosis may be a major cardiovascular
feature in the Alagille and Keutel syndromes (102–106).
Pulmonary artery stenoses are also sequelae of the congenital
Rubella syndrome, Williams syndrome, or scarring at the site
of a previous pulmonary artery band or aorticopulmonary
shunt.
7.2.1. Clinical Course
Peripheral pulmonary artery stenoses tend to occur in multi-
ple tertiary branches of the pulmonary tree and are progres-
sive, and by the time patients are seen as adults, there may be
considerable loss of lung parenchyma due to totally occluded
segmental pulmonary arteries. With PAH, pulmonary valve
regurgitation may be expected.
7.2.2. Recommendations for Evaluation of Patients
With Supravalvular, Branch, and Peripheral
Pulmonary Stenosis
CLASS I
1. Patients with suspected supravalvular, branch, or peripheral
PS should have baseline imaging with echocardiography-
Doppler plus 1 of the following: MRI angiography, CT angiog-
raphy, or contrast angiography. (Level of Evidence: C)
2. Once the diagnosis is established, follow-up echocardiography-
Doppler to assess RV systolic pressure should be performed
periodically, depending on severity. (Level of Evidence: C)
TTE-Doppler helps confirm the presence of RV systolic
hypertension and any pulmonary valve regurgitation. Echo-
cardiography may also be able to define proximal pulmonary
branch stenosis. It is of much less value in the identification
of peripheral PS. TEE is likewise useful only when there are
proximal pulmonary artery lesions. Radionuclide studies
reveal the severity of peripheral PS in different lung seg-
ments. Cardiac MRI with pulmonary angiography and CT are
much superior to echocardiography-Doppler for imaging
these lesions, and both can help confirm the diagnosis.
7.2.3. Recommendations for Interventional Therapy
in the Management of Branch and Peripheral
Pulmonary Stenosis
CLASS I
1. Percutaneous interventional therapy is recommended as the
treatment of choice in the management of appropriate focal
branch and/or peripheral pulmonary artery stenosis with
greater than 50% diameter narrowing, an elevated RV systolic
pressure greater than 50 mmHg, and/or symptoms. (Level of
Evidence: B)
2. In patients with the above indications for intervention, sur-
geons with training and expertise in CHD should perform
operations for management of branch pulmonary artery steno-
sis not anatomically amenable to percutaneous interventional
therapy. (Level of Evidence: B)
Branch pulmonary artery stenosis and/or hypoplasia may
be associated with a variety of cardiac malformations or may
be a residual from prior surgical intervention, such as an
anastomotic lesion at the distal site of a prior Blalock-Taussig
or Potts shunt procedure. Surgical exposure to these areas is
often difficult, which favors attempts at percutaneous
approaches.
The highly elastic pulmonary arteries have proven to be
resilient to balloon procedures, and angioplasty methods have
generally given way to stent procedures in which there
appears to be a higher initial success rate and a lower
intermediate-term incidence of restenosis (107). Stenting of
branch PS has also been used in the operating room as
adjunctive therapy. The use of balloon angioplasty and
stenting may also be applied to more distal peripheral PS,
although the results have generally been less impressive than
with branch stenosis (108).
7.2.4. Recommendations for Evaluation and
Follow-Up
CLASS I
1. Patients with peripheral PS should be followed up every 1 to 2
years, on the basis of severity, with a clinical evaluation and
echocardiography-Doppler to evaluate RV systolic pressure and
RV function. (Level of Evidence: C)
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2. Discussion with a cardiac surgeon with expertise in CHD
should take place before percutaneous peripheral pulmonary
artery interventions are undertaken. (Level of Evidence: C)
The lesions in peripheral PS may be progressive, so
patients should be followed up every 1 to 2 years with
echocardiography-Doppler to assess RV peak systolic pres-
sure and function. Restenosis of these lesions is common, and
repeat percutaneous angioplasty, stenting, and/or surgical
intervention may be required when this occurs.
7.3. Right-Sided Heart Obstruction Due to
Stenotic Right Ventricular–Pulmonary Artery
Conduits or Bioprosthetic Valves
Some gradient is to be expected across any RV–pulmonary
artery conduit or any bioprosthetic valve placed in the RVOT,
depending on the valve size and flow across the valve.
7.3.1. Recommendation for Evaluation and
Follow-Up After Right Ventricular–Pulmonary
Artery Conduit or Prosthetic Valve
CLASS I
1. After surgical relief of RVOT obstruction with a conduit or
prosthetic valve, patients should be followed up on a 1- to
2-year basis with echocardiography-Doppler assessment of RV
systolic pressure and function, as well as a measurement of
the gradient across the RVOT. (Level of Evidence: C)
7.3.2. Echocardiography
TTE and Doppler are particularly helpful in delineating
hemodynamics and facilitate measurement of RV pressure,
RV size and function, and gradient across the conduit and
prosthetic valve. However, tubular narrowing in a conduit is
often associated with underestimation of the gradient.
7.3.3. Magnetic Resonance Imaging/
Computed Tomography
CT and MRI can be used to help define lesion severity and
may demonstrate conduit adherence to the sternum, some-
thing of interest to the surgeon if a reoperation is
contemplated.
7.3.4. Cardiac Catheterization
Because distal conduit stenosis is frequent, MRI and CT, as
well as cardiac catheterization and angiography, can define
the level and severity of stenosis.
7.3.5. Recommendations for Reintervention in
Patients With Right Ventricular–Pulmonary Artery
Conduit or Bioprosthetic Pulmonary Valve Stenosis
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations for patients with severe pulmonary prosthetic valve
stenosis (peak gradient greater than 50 mm Hg) or conduit
regurgitation and any of the following:
a. Decreased exercise capacity. (Level of Evidence: C)
b. Depressed RV function. (Level of Evidence: C)
c. At least moderately enlarged RV end-diastolic size. (Level of
Evidence: C)
d. At least moderate TR. (Level of Evidence: C)
CLASS IIa
1. Either surgical or percutaneous therapy can be useful in
symptomatic patients with discrete RV–pulmonary artery con-
duit obstructive lesions with greater than 50% diameter nar-
rowing or when a bioprosthetic pulmonary valve has a peak
gradient by Doppler greater than 50 mm Hg or a mean gradient
greater than 30 mm Hg. (Level of Evidence: C)
2. Either surgical or percutaneous therapy can be useful in
asymptomatic patients when a pulmonary bioprosthetic valve
has a peak Doppler gradient greater than 50 mm Hg. (Level of
Evidence: C)
CLASS IIb
1. Surgical intervention may be considered preferable to percuta-
neous catheter intervention when an associated Maze proce-
dure is being considered for the treatment of atrial arrhythmia.
(Level of Evidence: C)
Both angioplasty and stenting have been applied to ob-
struction in an RV–to–pulmonary artery conduit. Such cases
can present difficult issues, and the decision to proceed with
a percutaneous intervention should be made in association
with an ACHD surgeon or an ACHD interventionalist.
Surgical intervention is generally required once there is
evidence of important RV enlargement or the development of
significant TR.
7.3.6. Key Issues to Evaluate and Follow-Up
Most patients are not limited physically unless the gradient
across the conduits or prosthetic valves is greater than
50 mm Hg.
7.4. Double-Chambered Right Ventricle
In patients with a double-chambered right ventricle, the right
ventricle is divided into a high-pressure proximal and lower-
pressure distal chamber by anomalous myocardial muscle
bundles.
7.4.1. Recommendations for Intervention in Patients
With Double-Chambered Right Ventricle
CLASS I
1. Surgery is recommended for patients with a peak midventricular
gradient by Doppler greater than 60 mmHg or a mean Doppler
gradient greater than 40 mmHg, regardless of symptoms. (Level
of Evidence: B)
CLASS IIb
1. Symptomatic patients with a peak midventricular gradient by
Doppler greater than 50 mm Hg or a mean Doppler gradient
greater than 30 mm Hg may be considered for surgical resec-
tion if no other cause of symptoms can be discerned. (Level of
Evidence: C)
Peak RV systolic pressure, as estimated by echocardiography-
Doppler via the TR jet, may be the result of more than 1 level
of obstruction, and it is important to investigate this possibil-
ity thoroughly before surgical intervention is considered. This
is particularly important in the adult, in whom prior surgical
procedures and other causes of PAH may complicate the
clinical picture.
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In patients with a double-chambered right ventricle, resec-
tion and outflow-enlarging procedures have been very effec-
tive, with excellent long-term results (109). Many such
patients also require repair of an associated VSD.
8. Coronary Artery Abnormalities
8.1. General Recommendations for Evaluation
and Surgical Intervention
CLASS I
1. Any patient with CHD who has had coronary artery manipula-
tion should be evaluated for coronary artery patency, function,
and anatomic integrity at least once in adulthood. (Level of
Evidence: C)
2. Surgeons with training and expertise in CHD should perform
operations for the treatment of coronary artery anomalies.
(Level of Evidence: C)
Because there is no long-term follow-up information about
the sequelae of manipulation of the coronary arteries in the
various forms of CHD, it is prudent to evaluate these patients
at least once during adult life for late development of
coronary artery disease.
8.2. Recommendations for Coronary
Anomalies Associated With Supravalvular
Aortic Stenosis
CLASS I
1. Adults with a history or presence of SupraAS should be
screened every 1 or 2 years for myocardial ischemia. (Level of
Evidence: C)
2. Interventions for coronary artery obstruction in patients with
SupraAS should be performed in ACHD centers with demon-
strated expertise in the interventional management of these
patients. (Level of Evidence: C)
SupraAS may be associated with coronary obstruction
from partial to complete ostial obliteration, and these patients
are also at risk for ectasia and aneurysm of the coronary
arteries (88). Pathological specimens with diffuse or focal
intimal and medial fibrosis, hyperplasia, dysplasia, adventitial
fibroelastosis, and occasional intramedial dissection have
been reported in children and more commonly in adults
(110–112).
8.3. Recommendation for Coronary Anomalies
Associated With Tetralogy of Fallot
CLASS I
1. Coronary artery anatomy should be determined before any
intervention for RV outflow. (Level of Evidence: C)
The most common and important abnormality is the left
anterior descending coronary artery arising from the right
coronary artery and crossing the RV outflow, which occurs in
approximately 3% to 7% of persons with tetralogy of Fallot.
The occurrence is more common when the aortic root is more
anterior, rightward, or lateral (113).
8.3.1. Preintervention Evaluation
Coronary artery origin and course should be delineated before
any surgical or interventional procedure, because the poten-
tial exists for damage to anomalous coronary arteries to occur
during cardiac exposure, surgery on the RVOT, and stenting
of RV outflow.
8.4. Recommendation for Coronary Anomalies
Associated With Dextro-Transposition of the
Great Arteries After Arterial Switch Operation
CLASS I
1. Adult survivors with dextro-TGA (d-TGA) after arterial switch
operation (ASO) should have noninvasive ischemia testing every 3
to 5 years. (Level of Evidence: C)
The coronary artery course plays an important role in the
surgical repair of d-TGA. The most common anatomic
arrangement occurs in nearly two thirds of patients, with the
left coronary artery arising from the anterior facing sinus and
the right coronary artery from the posterior facing sinus.
Sixteen percent of patients with d-TGA have a circumflex
that arises from the right coronary artery, and the remaining
patients have inverted coronary artery variants, single coro-
nary arteries, or intramural coronary arteries (114). Damage
to the sinus node coronary artery, whether during surgery or
during balloon septostomy, has been implicated in the occur-
rence of atrial arrhythmias and sinus node dysfunction after
repair.
8.4.1. Clinical Course
After great artery translocation and transfer of coronary
arteries, early and late postoperative loss of coronary perfu-
sion may occur due to causes such as anatomic torsion,
extrinsic compression, focal or diffuse fibrocellular intimal
thickening, and small-caliber distal coronary arteries with
functional decrease in coronary flow reserve (115–117).
Survival free of coronary events has been reported as 93%
and 88% at 1 and 15 years, respectively, with many reports
associating coronary events with increased mortality (117).
8.4.2. Clinical Features and Evaluation After Arterial
Switch Operation
No single ischemia provocation test has been shown to be
both sufficiently sensitive and specific to screen for coronary
flow abnormalities after a switch repair of d-TGA. Combi-
nations of testing, including echocardiography, nuclear scin-
tigraphy, and exercise testing, have been suggested to im-
prove sensitivity and specificity (117).
Given the emergence of an adult population of survivors
with d-TGA after ASO, with undefined future course and
morbidity, the present writing committee recommends epi-
sodic noninvasive ischemia provocation testing every 3 to 5
years. Positive results should be pursued by invasive cathe-
terization with measurement of coronary flow reserve and
intravascular ultrasound when appropriate.
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8.5. Recommendations for Congenital
Coronary Anomalies of Ectopic Arterial Origin
CLASS I
1. The evaluation of individuals who have survived unexplained
aborted sudden cardiac death or with unexplained life-
threatening arrhythmia, coronary ischemic symptoms, or LV
dysfunction should include assessment of coronary artery
origins and course. (Level of Evidence: B)
2. CT or magnetic resonance angiography is useful as the initial
screening method in centers with expertise in such imaging.
(Level of Evidence: B)
3. Surgical coronary revascularization should be performed in
patients with any of the following:
a. Anomalous left main coronary artery coursing between the
aorta and pulmonary artery. (Level of Evidence: B)
b. Documented coronary ischemia due to coronary compression
(when coursing between the great arteries or in intramural
fashion). (Level of Evidence: B)
c. Anomalous origin of the right coronary artery between aorta
and pulmonary artery with evidence of ischemia. (Level of
Evidence: B)
CLASS IIa
1. Surgical coronary revascularization can be beneficial in the
setting of documented vascular wall hypoplasia, coronary
compression, or documented obstruction to coronary flow,
regardless of inability to document coronary ischemia. (Level of
Evidence: C)
2. Delineation of potential mechanisms of flow restriction via
intravascular ultrasound can be beneficial in patients with
documented anomalous coronary artery origin from the oppo-
site sinus. (Level of Evidence: C)
CLASS IIb
1. Surgical coronary revascularization may be reasonable in pa-
tients with anomalous left anterior descending coronary artery
coursing between the aorta and pulmonary artery. (Level of
Evidence: C)
8.5.1. Definition, Associated Lesions, and Clinical
Course
Congenital anomalous origin of the coronary arteries may
occur in 1% to 1.2% of all coronary angiograms performed,
with 0.5% of them having the highest-risk lesions of the left
main or left anterior descending branch artery arising from
the opposite sinus of Valsalva (118). Coronary anomalies
account for approximately 15% of sudden cardiac deaths in
athletes (potentially due to torsion or slitlike compression of
the proximal coronary artery, exercise-induced compression,
vasospasm, or ischemic or scar-induced ventricular arrhyth-
mia) (119,120). In 80% of autopsies in athletes with sudden
cardiac death and anomalous coronary artery origins, the
affected coronary artery coursed between the aorta and the
pulmonary artery (120,121).
8.6. Recommendations for Anomalous Left
Coronary Artery From the Pulmonary Artery
CLASS I
1. In patients with an anomalous left coronary artery from the
pulmonary artery (ALCAPA), reconstruction of a dual coronary
artery supply should be performed. The surgery should be
performed by surgeons with training and expertise in CHD at
centers with expertise in the management of anomalous coro-
nary artery origins. (Level of Evidence: C)
2. For adult survivors of ALCAPA repair, clinical evaluation with
echocardiography and noninvasive stress testing is indicated
every 3 to 5 years. (Level of Evidence: C)
ALCAPA is relatively rare, occurring in 1 in 300 000 live
births.
8.7. Management Strategies
8.7.1. Surgical Intervention
If patients present in adulthood with decreased systolic
function and previously unrecognized ALCAPA, the present
writing committee suggests surgical myocardial revascular-
ization to achieve a dual coronary supply, regardless of
myocardial viability testing, given the lack of current data to
correlate such testing with outcomes. Given the increasing
awareness of residual coronary artery, myocardial, and val-
vular abnormalities, the present writing committee suggests
surveillance with echocardiography and noninvasive ische-
mia provocation testing every 3 to 5 years for patients after
repair of ALCAPA.
8.7.2. Surgical and Catheterization-Based
Intervention
Surgical repair by either arterial bypass or, more commonly,
reimplantation of the anomalous coronary into the aorta is
indicated because of the risk of sudden cardiac death
(122,123). If ischemia is demonstrated in patients after repair
of ALCAPA with either concomitant symptomatology or
echocardiographic changes, the present writing committee
recommends invasive catheterization with planned interven-
tion determined by clinical findings.
8.8. Recommendations for Coronary
Arteriovenous Fistula
CLASS I
1. If a continuous murmur is present, its origin should be defined
either by echocardiography, MRI, CT angiography, or cardiac
catheterization. (Level of Evidence: C)
2. A large coronary arteriovenous fistula (CAVF), regardless of
symptomatology, should be closed via either a transcatheter or
surgical route after delineation of its course and its potential to
fully obliterate the fistula. (Level of Evidence: C)
3. A small to moderate CAVF in the presence of documented
myocardial ischemia, arrhythmia, otherwise unexplained ven-
tricular systolic or diastolic dysfunction or enlargement, or
endarteritis should be closed via either a transcatheter or
surgical approach after delineation of its course and its poten-
tial to fully obliterate the fistula. (Level of Evidence: C)
CLASS IIa
1. Clinical follow-up with echocardiography every 3 to 5 years can
be useful for patients with small, asymptomatic CAVF to
exclude development of symptoms or arrhythmias or progres-
sion of size or chamber enlargement that might alter manage-
ment. (Level of Evidence: C)
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CLASS III
1. Patients with small, asymptomatic CAVF should not undergo
closure of CAVF. (Level of Evidence: C)
Fistulas arise from either or both coronary arteries, with
drainage more typically to the right atrium, right ventricle, or
right atrium–superior vena cava junction, and occasionally to
the coronary sinus or left side of the heart. Although the
potential for associated myocardial ischemia and infarction,
endarteritis, dissection, and rupture has been documented,
there are few data associating occurrence, shunt properties,
anatomic features, and outcomes. Small fistulas may slowly
increase in size with advancing age and changes in systemic
blood pressure and aortic compliance. Periodic clinical eval-
uation with imaging such as echocardiography to assess both
the size of the fistula and ventricular function is reasonable.
Sometimes small fistulas are detected as an incidental finding
on echocardiography.
8.9. Recommendations for Management
Strategies
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations for management of patients with CAVF. (Level of
Evidence: C)
2. Transcatheter closure of CAVF should be performed only in
centers with expertise in such procedures. (Level of Evidence: C)
3. Transcatheter delineation of CAVF course and access to distal
drainage should be performed in all patients with audible
continuous murmur and recognition of CAVF. (Level of Evi-
dence: C)
Surgical closure of audible CAVF with appropriate anato-
my is recommended in all large CAVFs and in small to
moderate CAVFs in the presence of symptoms of myocardial
ischemia, threatening arrhythmia, unexplained ventricular
dysfunction, or left atrial hypertension. Numerous reports of
transcatheter closure with coils or detachable devices de-
scribe near or complete CAVF occlusion in attempted closure
procedures (124). Criteria for transcatheter closure of CAVF
are similar to those used for surgical closure of CAVF.
Transcatheter closure of CAVF should be performed only in
centers with particular expertise in such intervention.
8.9.1. Preintervention Evaluation After Surgical or
Catheterization-Based Repair
Patients with CAVF, even after repair, may still have large,
patulous epicardial conduits. Intermediate- and longer-term
follow-up of these thin-walled, ectatic coronary arteries after
either surgical or transcatheter repair appears mandated.
9. Pulmonary Hypertension/Eisenmenger
Physiology
PAH, a progressive increase in PVR, can lead to subpulmo-
nary ventricular failure and death. PAH can frequently be
related to pulmonary venous hypertension (most commonly
due to left AV valve disorders, volume excess, or SV
end-diastolic pressure elevation) and can be classified as
World Health Organization PAH class II (due to “left heart
disease”) with therapies guided toward improving these
causes. Within this section, however, the present writing
committee will primarily focus on disorders in which PAH is
due to other abnormalities and is generally hemodynamically
defined as a mean pulmonary artery pressure greater than
25 mm Hg at rest or greater than 30 mm Hg with exercise,
pulmonary capillary wedge pressure less than or equal to
15 mm Hg, and PVR greater than 3 mm Hg per L per min
per m2. Particular CHD-related PAH (CHD-PAH) occurs in a
number of different scenarios, including the following:
a. “Dynamic” PAH related to high shunt flow that responds
to reduction of the shunt
b. Immediate postoperative or “reactive” PAH
c. Late, postoperative PAH
d. Secondary to lesions that cause pulmonary venous
hypertension
e. Shunt reversal (eg, Eisenmenger physiology).
These guidelines will largely focus on management of
dynamic PAH and Eisenmenger physiology. Recently, CHD-
PAH has been recognized to have potentially differing
pathogenetic mechanisms, therapeutic goals, treatment plans,
and outcomes than idiopathic PAH.
9.1. Clinical Course
9.1.1. Dynamic Congenital Heart Disease–Pulmonary
Arterial Hypertension
The development of CHD-PAH associated with systemic–to–
pulmonary artery shunts is dependent on both the type and
size of the underlying anatomic defect, as well as the
magnitude of shunt flow (shear stress and structural changes
lead to intravascular and matrix-dependent inflammatory
mediator release and changes).
9.2. Recommendations for Evaluation of the
Patient With Congenital Heart Disease–
Pulmonary Arterial Hypertension
CLASS I
1. Care of adult patients with CHD-related PAH should be performed
in centers that have shared expertise and training in both ACHD
and PAH. (Level of Evidence: C)
2. The evaluation of all ACHD patients with suspected PAH should
include noninvasive assessment of cardiovascular anatomy
and potential shunting, as detailed below:
a. Pulse oximetry, with and without administration of supple-
mental oxygen, as appropriate. (Level of Evidence: C)
b. Chest x-ray. (Level of Evidence: C)
c. ECG. (Level of Evidence: C)
d. Diagnostic cardiovascular imaging via TTE, TEE, MRI, or CT
as appropriate. (Level of Evidence: C)
e. Complete blood count and nuclear lung scintigraphy. (Level
of Evidence: C)
3. If PAH is identified but its causes are not fully recognized,
additional testing should include the following:
a. Pulmonary function tests with volumes and diffusion capac-
ity (diffusing capacity of the lung for carbon monoxide).
(Level of Evidence: C)
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b. Pulmonary embolism–protocol CT with parenchymal lung
windows. (Level of Evidence: C)
c. Additional testing as appropriate to rule out contributing
causes of PAH. (Level of Evidence: C)
d. Cardiac catheterization at least once, with potential for
vasodilator testing or anatomic intervention, at a center
with expertise in catheterization, PAH, and management of
CHD-PAH. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to include a 6-minute walk test or similar
nonmaximal cardiopulmonary exercise test as part of the
functional assessment of patients with CHD-PAH. (Level of
Evidence: C)
9.2.1. Dynamic Congenital Heart Disease–Pulmonary
Arterial Hypertension
Surgical experience has suggested that the changes that occur
with shunt-mediated PAH are reversible, provided the sur-
gery is performed before pulmonary vascular changes are
“fixed.” Catheterization-based calculations of pulmonary
blood flow (Qp) with isolation of all sources of Qp, individ-
ualized measurements of resistance in isolated lung segments,
and direct measurement of pulmonary venous pressure are
typically used to assess PAH reversibility and the likelihood
of surgical success. Acute administration of inhaled (nitric
oxide) or intravenously administered (prostacyclin) pulmo-
nary vascular agents is frequently used in such investigations
to assess for acute reactivity.
9.2.2. Eisenmenger Physiology
Diagnosis and evaluation of Eisenmenger physiology require a
detailed history to look for all possible PAH triggers and a
thorough understanding of current and past anatomy, as well as
knowledge of all past surgical and medical interventions. Doc-
umentation of the size and direction of intracardiac or intravas-
cular shunts present at the atrial, ventricular, or great arterial
level is required, as is a precise documentation of pulmonary
arteriolar resistance. A suggested basic evaluation of adults with
presumed Eisenmenger physiology includes assessment of anat-
omy, degree of PAH, ventricular function, and both the presence
and magnitude of secondary complications.
9.3. Management Strategies
9.3.1. Recommendations for Medical Therapy of
Eisenmenger Physiology
CLASS I
1. It is recommended that patients with Eisenmenger syndrome
avoid the following activities or exposures, which carry in-
creased risks:
a. Pregnancy. (Level of Evidence: B)
b. Dehydration. (Level of Evidence: C)
c. Moderate and severe strenuous exercise, particularly iso-
metric exercise. (Level of Evidence: C)
d. Acute exposure to excessive heat (eg, hot tub or sauna).
(Level of Evidence: C)
e. Chronic high-altitude exposure, because this causes further
reduction in oxygen saturation and increased risk of
altitude-related cardiopulmonary complications (particu-
larly at an elevation greater than 5000 feet above sea
level). (Level of Evidence: C)
f. Iron deficiency. (Level of Evidence: B)
2. Patients with Eisenmenger syndrome should seek prompt
therapy for arrhythmias and infections. (Level of Evidence: C)
3. Patients with Eisenmenger syndrome should have hemoglobin,
platelet count, iron stores, creatinine, and uric acid assessed
at least yearly. (Level of Evidence: C)
4. Patients with Eisenmenger syndrome should have assessment
of digital oximetry, both with and without supplemental oxygen
therapy, at least yearly. The presence of oxygen-responsive
hypoxemia should be investigated further. (Level of Evidence: C)
5. Exclusion of air bubbles in intravenous tubing is recommended
as essential during treatment of adults with Eisenmenger
syndrome. (Level of Evidence: C)
6. Patients with Eisenmenger syndrome should undergo noncar-
diac surgery and cardiac catheterization only in centers with
expertise in the care of such patients. In emergent or urgent
situations in which transportation is not feasible, consultation
with designated caregivers in centers with expertise in the
care of patients with Eisenmenger syndrome should be per-
formed and sustained throughout care. (Level of Evidence: C)
CLASS IIa
1. All medications given to patients with Eisenmenger physiology
should undergo rigorous review for the potential to change
systemic blood pressure, loading conditions, intravascular
shunting, and renal or hepatic flow or function. (Level of
Evidence: C)
2. Pulmonary vasodilator therapy can be beneficial for patients
with Eisenmenger physiology because of the potential for
improved quality of life. (Level of Evidence: C)
An emphasis on patient education and avoidance of desta-
bilizing situations and volume shifts that result in alteration of
catecholamines, extreme fatigue, high-altitude exposure, con-
tact with cigarette smoke, changes in renal or hepatic func-
tion, or use of medications that may modulate flow to or
function of these organs is advocated. Avoidance of preg-
nancy and iron deficiency and prompt therapy for arrhythmia
or infection are recommended. A concept of team planning
for all procedures is mandated because of the potential for
morbid and mortal outcomes of even the simplest of inter-
ventions for any ailment. The optimal type and mode of
anesthetic administration should be individualized by experts
in the care of persons with Eisenmenger physiology. Risk of
right-to-left embolization warrants avoidance of bubbles, and
consideration of the use of air filters on all venous catheters
still tends to be advocated, although controversy exists
regarding the relative benefit obtained compared with metic-
ulous guarding of all intravenous administration systems.
Therapies for adults with CHD-PAH have been limited and
have included oxygen, warfarin, diuretics, calcium channel
blockers, long-term continuous intravenous epoprostenol,
oral prostacyclin analogues, oral endothelin antagonists, oral
phosphodiesterase inhibition, and lung or lung/heart trans-
plantation. The benefit of supplemental oxygen administration is
a matter of debate, given the conflict between recognized
concomitant oxygen-responsive and -unresponsive components
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to hypoxemia in many patients and the lack of sufficient trial
data to assess benefit (125,126).
In adults with Eisenmenger physiology, recognition of in vivo
pulmonary thrombus (127) contrasted with reports of in vitro
abnormalities of coagulation in persons with cyanosis (128) has
led to debate over the potential benefit of oral anticoagulant
therapy, particularly with the concomitant bleeding diathesis
inherent in the condition. In patients with active or chronic
hemoptysis, anticoagulation is contraindicated.
The theoretical possibility of worsening of right-to-left shunt-
ing raises questions about the safety of using pulmonary artery
modulating therapies that also have systemic vasodilator poten-
tial. Nevertheless, some of these agents (eg, intravenous
prostacyclin and oral sildenafil) have yielded improvements
in hemodynamics, exercise tolerance, and/or systemic arterial
oxygen saturation in limited case studies (128–134). The
potential for significant adverse reaction due to these agents
has been recognized.
9.4. Key Issues to Evaluate and Follow-Up
9.4.1. Recommendations for Reproduction
CLASS I
1. Women with severe CHD-PAH, especially those with Eisen-
menger physiology, and their partners should be counseled
about the absolute avoidance of pregnancy in view of the high
risk of maternal death, and they should be educated regarding
safe and appropriate methods of contraception. (Level of
Evidence: B)
2. Women with CHD-PAH who become pregnant should:
a. Receive individualized counseling from cardiovascular and
obstetric caregivers collaborating in care and with exper-
tise in management of CHD-PAH. (Level of Evidence: C)
b. Undergo the earliest possible pregnancy termination after
such counseling. (Level of Evidence: C)
3. Surgical sterilization carries some operative risk for women with
CHD-PAH but is a safer option than pregnancy. In view of
advances in minimally invasive techniques, the risks and benefits
of sterilization modalities should be discussed with an obstetri-
cian experienced in management of high-risk patients, as well as
with a cardiac anesthesiologist. (Level of Evidence: C)
CLASS IIb
1. Pregnancy termination in the last 2 trimesters of pregnancy
poses a high risk to the mother. It may be reasonable, however,
after the risks of termination are balanced against the risks of
continuation of the pregnancy. (Level of Evidence: C)
CLASS III
1. Pregnancy in women with CHD-PAH, especially those with
Eisenmenger physiology, is not recommended and should be
absolutely avoided in view of the high risk of maternal mortal-
ity. (Level of Evidence: B)
2. The use of single-barrier contraception alone in women with
CHD-PAH is not recommended owing to the frequency of
failure. (Level of Evidence: C)
3. Estrogen-containing contraceptives should be avoided. (Level
of Evidence: C)
Pregnancy carries particular risks for individual with CHD-
PAH, especially those with Eisenmenger physiology, with
mostly older case series suggesting maternal mortality in the
latter group of up to 50% and similarly high levels of fetal
loss. Even after a successful pregnancy, maternal mortality
may be particularly increased in the first several days after
delivery (135). Termination of pregnancy, particularly in its
mid and later phases, with its concomitant volume and
hormonal fluctuations, also carries a high maternal risk.
Termination in the first trimester is the safer option. Coun-
seled contraception is strongly advised, although the partic-
ular method of such is a matter of debate. Maternal steriliza-
tion carries a defined operative risk of mortality, and
endoscopic sterilization may be the safer option. Hormonal
therapies increase the preexisting potential for thrombosis,
although progesterone-only preparations may be considered.
Barrier methods have an increased rate of failure, and
intrauterine device implantation carries anecdotally increased
infection risk, although the highest risk is for local infection
in multipartner couples. There is no consensus on compara-
tive contraceptive risks; therefore, the patient should discuss
the options with a high-risk obstetrician (maternal fetal
medicine specialist).
9.4.2. Recommendations for Follow-Up
CLASS I
1. Patients with CHD-related PAH should:
a. Have coordinated care under the supervision of a trained CHD
and PAH provider and be seen by such individuals at least
yearly. (Level of Evidence: C)
b. Have yearly comprehensive evaluation of functional capac-
ity and assessment of secondary complications. (Level of
Evidence: C)
c. Discuss all medication changes or planned interventions
with their CHD-related PAH caregiver. (Level of Evidence: C)
CLASS III
1. Endocardial pacing is not recommended in patients with CHD-
PAH with persistent intravascular shunting, and alternative
access for pacing leads should be sought (the risks should be
individualized) (136). (Level of Evidence: B)
10. Tetralogy of Fallot
Tetralogy of Fallot has 4 components: subpulmonary infun-
dibular stenosis, a VSD, an aorta that overrides the VSD by
less than 50% of its diameter, and RV hypertrophy. The
single and large VSD is usually in the subaortic position. The
pulmonary valve is often small and stenotic. Pulmonary
artery anomalies are frequent and include hypoplasia and
stenosis. Pulmonary artery hypoplasia may involve the pul-
monary trunk or the branch pulmonary arteries. Pulmonary
artery stenosis at any of these levels is common.
10.1. Clinical Course (Unrepaired)
10.1.1. Presentation as an Unoperated Patient
An occasional patient is seen with relatively mild pulmonary
obstruction and mild cyanosis (the so-called pink tetralogy),
in which the diagnosis may not be made until adult life.
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10.2. Recommendations for Evaluation and
Follow-Up of the Repaired Patient
CLASS I
1. Patients with repaired tetralogy of Fallot should have at least
annual follow-up with a cardiologist who has expertise in
ACHD. (Level of Evidence: C)
2. Patients with tetralogy of Fallot should have echocardiographic
examinations and/or MRIs performed by staff with expertise in
ACHD. (Level of Evidence: C)
3. Screening for heritable causes of their condition (eg, 22q11
deletion) should be offered to all patients with tetralogy of
Fallot. (Level of Evidence: C)
4. Before pregnancy or if a genetic syndrome is identified, con-
sultation with a geneticist should be arranged for patients with
tetralogy of Fallot. (Level of Evidence: B)
5. Patients with unrepaired or palliated forms of tetralogy should
have a formal evaluation at an ACHD center regarding suitabil-
ity for repair. (Level of Evidence: B)
All patients should have regular follow-up with a cardiol-
ogist who has expertise in ACHD (3,4,29,42,137–139). The
frequency, although typically annual, may be determined by
the extent and degree of residual abnormalities. Key postop-
erative issues are summarized below:
● Residual pulmonary regurgitation
● RV dilation and dysfunction due to pulmonary regurgita-
tion, possibly with associated TR
● Residual RVOT obstruction
● Branch pulmonary artery stenosis or hypoplasia
● Sustained ventricular tachycardia
● Sudden cardiac death
● AV block, atrial flutter, and/or atrial fibrillation
● Progressive AR
● Syndromal associations.
The most common problem encountered in the adult
patient after repair is that of pulmonary regurgitation.
10.2.1. Recommendation for Imaging
CLASS 1
1. Comprehensive echocardiographic imaging should be per-
formed in a regional ACHD center to evaluate the anatomy and
hemodynamics in patients with repaired tetralogy of Fallot.
(Level of Evidence: B)
Echocardiography is usually very helpful in assessing a
patient after repair of tetralogy. The presence and severity of
residual RVOT obstruction and pulmonary regurgitation can
usually be assessed along with the presence or absence of TR.
The tricuspid regurgitant velocity facilitates measurement of
the RV pressure. A residual VSD may be seen. RV volume
and wall motion are not reliably quantified by standard
techniques, although size and function can be determined
qualitatively. Doppler measurement of the RV myocardial
performance index may be a useful adjunct to serial assess-
ment of RV systolic function. Atrial size can be assessed.
Aortic root dilation and AR should be sought and evaluated at
regular intervals.
MRI is now seen as the reference standard (140,141) for
assessment of RV volume and systolic function. It can be
helpful in assessing the severity of pulmonary regurgitation
and in evaluating important associated pathology, especially
involving the pulmonary arteries and the ascending aorta.
Left-sided heart disease can also be evaluated. Recently, CT
scanning has become available (142–144) to make similar
measurements of RV volume and systolic function and is
potentially helpful in patients who cannot have an MRI.
10.3. Recommendations for Diagnostic and
Interventional Catheterization for Adults With
Tetralogy of Fallot
CLASS I
1. Catheterization of adults with tetralogy of Fallot should be
performed in regional centers with expertise in ACHD. (Level of
Evidence: C)
2. Coronary artery delineation should be performed before any inter-
vention for the RVOT. (Level of Evidence: C)
3. Interventional catheterization in an ACHD center is indicated
for patients with previously repaired tetralogy of Fallot with the
following indications:
a. To eliminate residual native or palliative systemic–
pulmonary artery shunts. (Level of Evidence: B)
b. To manage coronary artery disease. (Level of Evidence: B)
CLASS IIa
1. Interventional catheterization in an ACHD center is reasonable
in patients with repaired tetralogy of Fallot to eliminate a
residual ASD or VSD with a left-to-right shunt greater than
1.5:1 if it is in an appropriate anatomic location. (Level of
Evidence: C)
CLASS IIb
1. In adults with repaired tetralogy of Fallot, catheterization may
be considered to better define potentially treatable causes of
otherwise unexplained LV or RV dysfunction, fluid retention,
chest pain, or cyanosis. In these circumstances, transcatheter
interventions may include:
a. Elimination of residual shunts or aortopulmonary collateral
vessels. (Level of Evidence: C)
b. Dilation (with or without stent implantation) of RVOT ob-
struction. (Level of Evidence: B)
c. Elimination of additional muscular or patch-margin VSD.
(Level of Evidence: C)
d. Elimination of residual ASD. (Level of Evidence: B)
Interventional catheterization in previously repaired tetral-
ogy of Fallot should be planned carefully with the medical
and surgical team in an ACHD center. Although there is
experience in the use of catheter devices to close residual
shunts, experience with the use of percutaneous stent-valve
implants in the RV outflow for patients with pulmonary
regurgitation and right-sided heart failure is recent, and
efficacy/safety remains undefined, but this technique appears
promising.
For the unusual case of a patient with tetralogy of Fallot
who has undergone palliation with a surgical shunt, catheter-
ization should be performed to assess the potential for repair.
The presence or absence of additional muscular VSDs may be
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determined, as well as the course and anatomy of the
epicardial coronary arteries. The pulmonary architecture and
vascular pressure and resistance should be delineated, be-
cause pulmonary artery distortion and PAH are frequent
sequelae of palliative surgical shunts. Potential catheter
interventions include the elimination of collateral vessels or
systemic–pulmonary artery shunts, dilation/stent implantation
of obstructed pulmonary arteries, and, more recently, the
possibility of percutaneous pulmonary valve implantation.
Heart catheterization is not used routinely in the assessment
of patients who have undergone repair, except when surgery
or other therapy is being considered or for evaluation of the
pulmonary and coronary arteries.
10.3.1. Branch Pulmonary Artery Angioplasty
Balloon angioplasty of a branch pulmonary artery may be
considered when the RV pressure is greater than 50% of the
systemic level or at lower pressure when there is RV
dysfunction. Balloon pulmonary artery angioplasty may also
be considered when there is unbalanced pulmonary blood
flow greater than 75%, 25%, or otherwise unexplained
dyspnea with severe vascular stenosis (145,146). Pulmonary
artery balloon angioplasty may be an effective way to reduce
obstruction to pulmonary blood flow, thereby increasing
pulmonary vascular capacitance and decreasing PVR (147).
A transcatheter approach to the management of residual
muscular or patch-margin VSDs (indications for which typ-
ically include a Qp/Qs greater than 1.5 to 2.0, or less in the
setting of PAH, left atrial hypertension, or LV failure)
remains an effective alternative to reoperative surgical clo-
sure (148,149).
10.4. Recommendations for Surgery for
Adults With Previous Repair of Tetralogy
of Fallot
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations in adults with previous repair of tetralogy of Fallot.
(Level of Evidence: C)
2. Pulmonary valve replacement is indicated for severe pulmonary
regurgitation and symptoms or decreased exercise tolerance.
(Level of Evidence: B)
3. Coronary artery anatomy, specifically the possibility of an
anomalous anterior descending coronary artery across the
RVOT, should be ascertained before operative intervention.
(Level of Evidence: C)
CLASS IIa
1. Pulmonary valve replacement is reasonable in adults with
previous tetralogy of Fallot, severe pulmonary regurgitation,
and any of the following:
a. Moderate to severe RV dysfunction. (Level of Evidence: B)
b. Moderate to severe RV enlargement. (Level of Evidence: B)
c. Development of symptomatic or sustained atrial and/or ven-
tricular arrhythmias. (Level of Evidence: C)
d. Moderate to severe TR. (Level of Evidence: C)
2. Collaboration between ACHD surgeons and ACHD interven-
tional cardiologists, which may include preoperative stenting,
intraoperative stenting, or intraoperative patch angioplasty, is
reasonable to determine the most feasible treatment for pul-
monary artery stenosis. (Level of Evidence: C)
3. Surgery is reasonable in adults with prior repair of tetralogy of
Fallot and residual RVOT obstruction (valvular or subvalvular)
and any of the following indications:
a. Residual RVOT obstruction (valvular or subvalvular) with
peak instantaneous echocardiography gradient greater
than 50 mm Hg. (Level of Evidence: C)
b. Residual RVOT obstruction (valvular or subvalvular) with
RV/LV pressure ratio greater than 0.7. (Level of Evidence: C)
c. Residual RVOT obstruction (valvular or subvalvular) with
progressive and/or severe dilatation of the right ventricle with
dysfunction. (Level of Evidence: C)
d. Residual VSD with a left-to-right shunt greater than 1.5:1.
(Level of Evidence: B)
e. Severe AR with associated symptoms or more than mild LV
dysfunction. (Level of Evidence: C)
f. A combination of multiple residual lesions (eg, VSD and
RVOT obstruction) leading to RV enlargement or reduced RV
function. (Level of Evidence: C)
Late survival after tetralogy repair is excellent; 35-year
survival is approximately 85%. The need for reintervention,
usually for pulmonary valve insertion, increases after the
second decade of life. Surgical intervention is indicated for
symptomatic patients with severe pulmonary regurgitation or
asymptomatic patients with severe PS or pulmonary regurgi-
tation in association with signs of progressive or severe RV
enlargement or dysfunction. Patients with RV–to–pulmonary
artery conduit repairs often require further intervention for
conduit stenosis or regurgitation. Any intervention that in-
volves the RVOT requires careful preoperative assessment of
the coronary anatomy to avoid interruption of an important
coronary vessel. Some patients experience increasing AR,
which requires surgical intervention.
10.5. Key Issues to Evaluate and Follow-Up
10.5.1. Recommendations for Arrhythmias:
Pacemaker/Electrophysiology Testing
CLASS I
1. Annual surveillance with history, ECG, assessment of RV
function, and periodic exercise testing is recommended for
patients with pacemakers/automatic implantable cardioverter
defibrillators. (Level of Evidence: C)
CLASS IIa
1. Periodic Holter monitoring can be beneficial as part of routine
follow-up. The frequency should be individualized depending on
the hemodynamics and clinical suspicion of arrhythmia. (Level
of Evidence: C)
CLASS IIb
1. Electrophysiology testing in an ACHD center may be reason-
able to define suspected arrhythmias in adults with tetralogy of
Fallot. (Level of Evidence: C)
Despite overall excellent hemodynamic outcomes after
surgery for tetralogy of Fallot, there remains a concerning
incidence of unexpected sudden death during long-term
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follow-up. Ventricular tachycardia appears to be the mecha-
nism for most of these events, although rapidly conducted
intra-atrial reentrant tachycardia (IART; atrial flutter) or AV
block may be responsible in some cases. The incidence of
sudden death for the adult tetralogy population can be
estimated from several large series to be on the order of 2.5%
per decade of follow-up (150–154).
Worrisome symptoms (ie, palpitations, dizziness, or an
episode of syncope) should obviously heighten the index of
suspicion for serious arrhythmias in tetralogy patients and
trigger a prompt evaluation, including hemodynamic cathe-
terization and electrophysiology study. Repairable hemody-
namic issues may also be identified by echocardiography or
cardiac catheterization that could possibly shift therapy to-
ward a surgical approach, such as closure of a residual septal
defect or relief of valve regurgitation, combined with intra-
operative ventricular tachycardia mapping and ablation. Se-
rious symptoms in adult patients with tetralogy of Fallot (ie,
documented sustained ventricular tachycardia or cardiac ar-
rest) are now managed with implantable cardioverter defibril-
lators at almost all centers.
11. Dextro-Transposition of the
Great Arteries
TGA implies that each great artery arises from the wrong
ventricle. TGA is AV concordance with ventriculoarterial
discordance. As such, d-TGA implies that the aorta arises
rightward and anterior to the pulmonary artery and arises
from the systemic right ventricle.
Patients with d-TGA by definition have abnormal origins
of the aorta and pulmonary artery. Anomalies of the coronary
ostia are also common, and clear delineation is required.
Additional congenital cardiac lesions include VSD, which
occurs in up to 45% of cases, LVOT obstruction in approx-
imately 25% of cases, and coarctation of the aorta in
approximately 5%.
11.1. Recommendation for Evaluation of the
Operated Patient With Dextro-Transposition
of the Great Arteries
CLASS I
1. Patients with repaired d-TGA should have annual follow-up with
a cardiologist who has expertise in the management of ACHD
patients. (Level of Evidence: C)
Most adults born with d-TGA will have had 1 or more
operations in childhood. All patients should have regular
follow-up with a cardiologist who has expertise in ACHD.
The frequency may be determined by the degree of residual
hemodynamic abnormalities, and these become more com-
mon, along with the occurrence of arrhythmias, with advanc-
ing age.
All operated d-TGA patients should be seen at least
annually by a specialist in an ACHD regional center, with
attention given to rhythm disorders, as well as ventricular and
valvular function. Stress testing, including cardiopulmonary
stress testing, should be applied selectively. If specialized
testing is performed, it is best done at a regional center. If
significant abnormalities are uncovered by these examina-
tions, or if the patient is symptomatic, more frequent
follow-up visits are indicated.
11.1.1. Clinical Features and Evaluation of
Dextro-Transposition of the Great Arteries
After Atrial Baffle Procedure
Because the ASO only gained acceptance in the 1980s, many
adults with d-TGA will have had a Mustard or Senning
procedure. These procedures involve an atrial baffle that
redirects the systemic venous blood to the mitral valve and
left ventricle, which remains committed to the pulmonary
artery. The pulmonary venous blood is redirected to the
tricuspid valve and right ventricle, which remains committed
to the aorta.
The atrial baffle (Mustard or Senning) procedure for
d-TGA has characteristic long-term problems. The most
common early structural complications include baffle ob-
struction, which most commonly affects the superior limb
rather than the inferior vena cava. Facial suffusion and
“superior vena cava syndrome” may result. Inferior vena cava
obstruction may cause hepatic congestion or even cirrhosis.
Baffle leaks occur in up to 25% of patients. Most are small
but many pose a risk of paradoxical embolus, particularly in
the setting of atrial arrythmias and an endocardial pacemaker.
Pulmonary venous obstruction may also occur but less
common. Subpulmonary stenosis and PS may occur, in part
related to the abnormal geometry of the left ventricle, which
becomes distorted and compressed by the enlarged systemic
right ventricle. Long-term, the most important complication
after atrial baffle is failure of the systemic right ventricle and
systemic TR. These complications have a major impact on
morbidity and mortality. Important but less common compli-
cations include PAH, residual VSD, dynamic subpulmonic
stenosis, and a host of conduction and arrhythmia distur-
bances with the potential for implantation of permanent
pacemakers or sudden death (23,155–157).
11.1.2. Imaging for Dextro-Transposition of the
Great Arteries After Atrial Baffle Procedure
CLASS I
1. In patients with d-TGA repaired by atrial baffle procedure,
comprehensive echocardiographic imaging should be per-
formed in a regional ACHD center to evaluate the anatomy and
hemodynamics. (Level of Evidence: B)
2. Additional imaging with TEE, CT, or MRI, as appropriate, should
be performed in a regional ACHD center to evaluate the great
arteries and veins, as well as ventricular function, in patients
with prior atrial baffle repair of d-TGA. (Level of Evidence: B)
CLASS IIa
1. Echocardiography contrast injection with agitated saline can
be useful to evaluate baffle anatomy and shunting in patients
with previously repaired d-TGA after atrial baffle. (Level of Evi-
dence: B)
2. TEE can be effective for more detailed baffle evaluation for
patients with d-TGA. (Level of Evidence: B)
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Evaluation for intra-atrial baffle anatomy and shunting or
obstruction may warrant echocardiography contrast injection.
Assessment of systemic RV function is challenging by
echocardiography. In addition to routine evaluation of ven-
tricular size and function, measurement of the dP/dt of the
AV regurgitant jet, Doppler tissue indices of annular motion,
and the myocardial performance index may provide further
insight (155–160). Tissue Doppler evaluation of myocardial
acceleration during isovolumic contraction has been validated
as a sensitive, noninvasive method to assess RV contractility
(161,162). The myocardial performance index has the advan-
tage of representing indices of both systolic and diastolic
function without geometric constraints and has shown a
relationship to brain natriuretic peptide levels in ACHD
patients (163). The coronary anatomy may be difficult to
evaluate by echocardiography in the adult patient.
TEE is used to provide complementary information, in-
cluding imaging of atrial anatomy, the presence of baffle leak
or obstruction, and intracardiac thrombus. Radiological imaging
with MRI or CT can be used to further assess atrial baffle
patency, systemic ventricular function, and coronary anatomy.
MRI or magnetic resonance angiography is usually superior for
evaluation of the extracardiac great arteries and veins.
11.1.3. Cardiac Catheterization
Cardiac catheterization is used to assess hemodynamics,
baffle leak, superior vena cava or inferior vena cava pathway
obstruction, pulmonary venous pathway obstruction, myocar-
dial ischemia, unexplained systemic RV dysfunction, signif-
icant LV dysfunction (subpulmonary [LVOT] obstruction), or
PAH, with potential for vasodilator testing. Cardiac catheter-
ization in patients after atrial baffle also provides the oppor-
tunity for intervention. For adults after palliative atrial baffle
repair for d-TGA, VSD, and pulmonary vascular disease,
catheterization may be indicated to assess the potential for
pulmonary artery vasomodulator therapy.
11.2. Clinical Features and Evaluation of
Dextro-Transposition of the Great Arteries
After Arterial Switch Operation
Long-term concerns after the ASO include coronary insuffi-
ciency, myocardial ischemia, ventricular dysfunction and
arrhythmias, and issues regarding stenosis at the great arterial
anastomotic sites, as well as development of aortic or pulmo-
nary regurgitation. Significant neoaortic root dilatation and
neoaortic valve regurgitation may develop over time, in part
related to older age at the time of ASO or to an associated
VSD with previous pulmonary artery banding (164).
11.2.1. Recommendations for Imaging for
Dextro-Transposition of the Great Arteries
After Arterial Switch Operation
CLASS I
1. Comprehensive echocardiographic imaging to evaluate the
anatomy and hemodynamics in patients with d-TGA and prior
ASO repair should be performed at least every 2 years at a
center with expertise in ACHD. (Level of Evidence: C)
2. After prior ASO repair for d-TGA, all adults should have at least 1
evaluation of coronary artery patency. Coronary angiography
should be performed if this cannot be established noninvasively.
(Level of Evidence: C)
CLASS IIa
1. Periodic MRI or CT can be considered appropriate to evaluate
the anatomy and hemodynamics in more detail. (Level of Evi-
dence: C)
Echocardiography after ASO may demonstrate minimal
findings or 1 or more of the recognized complications after
ASO, which include the following: 1) stenosis at the arterial
anastomotic sites, most commonly PS (165); 2) aortic root
dilatation; and 3) neoaortic valve regurgitation (native pul-
monary valve) (166). Coronary complications cannot be
assessed adequately by echocardiography, but stress echocar-
diography may facilitate detection of ischemia. CT angiog-
raphy has been used recently. Patients with intramural or
single coronary arteries have increased mortality compared
with those with the typical coronary pattern (167).
11.2.2. Recommendation for Cardiac Catheterization
After Arterial Switch Operation
CLASS IIa
1. Coronary angiography is reasonable in all adults with d-TGA
after ASO to rule out significant coronary artery obstruction.
(Level of Evidence: C)
Coronary ischemia is a recognized late complication after
ASO, with concern about ischemia or infarction reported in
up to 8% of patients after ASO. These complications are due
to reimplantation of the coronary arteries during surgery
(165). Noninvasive testing for coronary ischemia may not be
sufficiently sensitive, and coronary arteriography has been
recommended 5, 10, and 15 years after ASO to detect
significant late coronary artery stenosis. Aortic root angiog-
raphy is recommended to detect ostial coronary artery
disease.
Hemodynamic cardiac catheterization is used to assess
pulmonary and aortic anastomosis obstruction when incom-
pletely evaluated by other imaging modalities. Cardiac cath-
eterization in patients after ASO also provides the opportu-
nity for intervention.
11.3. Clinical Features and Evaluation of
Dextro-Transposition of the Great Arteries
After Rastelli Operation
The Rastelli operation for a combination of d-TGA, PS, and
VSD has recognized complications that include RVOT or
pulmonary conduit obstruction, superimposed RV failure,
and TR. LVOT obstruction may also occur from the intra-
ventricular baffle, arrhythmias from atriotomy and/or ventric-
ulotomy incisions, residual VSD, myocardial hypertrophy,
chamber enlargement, aortic root dilatation, and aortic valve
regurgitation. The 3 most common late causes of postopera-
tive death are sudden cardiac death, heart failure, and
reoperation.
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11.4. Recommendations for Diagnostic
Catheterization for Adults With Repaired
Dextro-Transposition of the Great Arteries
CLASS I
1. Diagnostic catheterization of the adult with d-TGA should be
performed in centers with expertise in the catheterization and
management of ACHD patients. (Level of Evidence: C)
CLASS IIa
1. For adults with d-TGA after atrial baffle procedure (Mustard or
Senning), diagnostic catheterization can be beneficial to assist
in the following:
a. Hemodynamic assessment. (Level of Evidence: C)
b. Assessment of baffle leak. (Level of Evidence: B)
c. Assessment of superior vena cava or inferior vena cava
pathway obstruction. (Level of Evidence: B)
d. Assessment of pulmonary venous pathway obstruction.
(Level of Evidence: B)
e. Suspected myocardial ischemia or unexplained systemic
RV dysfunction. (Level of Evidence: B)
f. Significant LV outflow obstruction at any level (LV pressure
greater than 50% of systemic levels, or less in the setting of RV
dysfunction). (Level of Evidence: B)
g. Assessment of PAH, with potential for vasodilator testing.
(Level of Evidence: C)
2. For adults with d-TGA, VSD, and PS, after Rastelli-type repair,
diagnostic catheterization can be beneficial to assist in the
following:
a. Coronary artery delineation before any intervention for RVOT
obstruction. (Level of Evidence: C)
b. Assessment of residual VSD. (Level of Evidence: C)
c. Assessment of PAH, with potential for vasodilator testing.
(Level of Evidence: C)
d. Assessment of subaortic obstruction across the left ventricle–
to–aorta tunnel. (Level of Evidence: C)
11.5. Recommendations for Interventional
Catheterization for Adults With
Dextro-Transposition of the Great Arteries
CLASS IIa
1. Interventional catheterization of the adult with d-TGA can be
performed in centers with expertise in the catheterization and
management of ACHD patients. (Level of Evidence: C)
2. For adults with d-TGA after atrial baffle procedure (Mustard or
Senning), interventional catheterization can be beneficial to
assist in the following:
a. Occlusion of baffle leak. (Level of Evidence: B)
b. Dilation or stenting of superior vena cava or inferior vena
cava pathway obstruction. (Level of Evidence: B)
c. Dilation or stenting of pulmonary venous pathway obstruc-
tion. (Level of Evidence: B)
3. For adults with d-TGA after ASO, interventional catheterization
can be beneficial to assist in dilation or stenting of supraval-
vular and branch pulmonary artery stenosis. (Level of Evidence: B)
4. For adults with d-TGA, VSD, and PS, after Rastelli-type repair,
interventional catheterization can be beneficial to assist in the
following:
a. Dilation with or without stent implantation of conduit obstruc-
tion (RV pressure greater than 50% of systemic levels, or
peak-to-peak gradient greater than 30 mmHg; these indica-
tions may be lessened in the setting of RV dysfunction). (Level
of Evidence: C)
b. Device closure of residual VSD. (Level of Evidence: C)
11.6. Recommendations for Surgical
Interventions
11.6.1. After Atrial Baffle Procedure (Mustard, Senning)
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations in patients with d-TGA and the following indications:
a. Moderate to severe systemic (morphological tricuspid) AV
valve regurgitation without significant ventricular dysfunc-l
tion (168). (Level of Evidence: B)
b. Baffle leak with left-to-right shunt greater than 1.5:1,
right-to-left shunt with arterial desaturation at rest or with
exercise, symptoms, and progressive ventricular enlarge-
ment that is not amenable to device intervention. (Level of
Evidence: B)
c. Superior vena cava or inferior vena cava obstruction not
amenable to percutaneous treatment. (Level of Evidence: B)
d. Pulmonary venous pathway obstruction not amenable to per-
cutaneous intervention. (Level of Evidence: B)
e. Symptomatic severe subpulmonary stenosis. (Level of Evi-
dence: B)
11.6.2. After Arterial Switch Operation
CLASS I
1. It is recommended that surgery be performed in patients after
the ASO with the following indications:
a. RVOT obstruction peak-to-peak gradient greater than
50 mm Hg or right ventricle/left ventricle pressure ratio
greater than 0.7, not amenable or responsive to percutane-
ous treatment; lesser degrees of obstruction if pregnancy is
planned, greater degrees of exercise are desired, or con-
comitant severe pulmonary regurgitation is present. (Level
of Evidence: C)
b. Coronary artery abnormality with myocardial ischemia not
amenable to percutaneous intervention. (Level of Evidence: C)
c. Severe neoaortic valve regurgitation. (Level of Evidence: C)
d. Severe neoaortic root dilatation (greater than 55 mm) after
ASO (169). (This recommendation is based on data for other
forms of degenerative aortic root aneurysms.) (Level of
Evidence: C)
11.6.3. After Rastelli Procedure
CLASS I
1. Reoperation for conduit and/or valve replacement after Ras-
telli repair of d-TGA is recommended in patients with the
following indications:
a. Conduit obstruction peak-to-peak gradient greater than
50 mm Hg. (Level of Evidence: C)
b. RV/LV pressure ratio greater than 0.7. (Level of Evidence: C)
c. Lesser degrees of conduit obstruction if pregnancy is being
planned or greater degrees of exercise are desired. (Level of
Evidence: C)
d. Subaortic (baffle) obstruction (mean gradient greater than
50 mm Hg). (Level of Evidence: C)
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e. Lesser degrees of subaortic baffle obstruction if LV hyper-
trophy is present, pregnancy is being planned, or greater
degrees of exercise are desired. (Level of Evidence: C)
f. Presence of concomitant severe AR. (Level of Evidence: C)
2. Reoperation for conduit regurgitation after Rastelli repair of d-TGA
is recommended in patients with severe conduit regurgitation and
the following indications:
a. Symptoms or declining exercise tolerance. (Level of Evi-
dence: C)
b. Severely depressed RV function. (Level of Evidence: C)
c. Severe RV enlargement. (Level of Evidence: C)
d. Development/progression of atrial or ventricular arrhyth-
mias. (Level of Evidence: C)
e. More than moderate TR. (Level of Evidence: C)
3. Collaboration between surgeons and interventional cardiolo-
gists, which may include preoperative stenting, intraoperative
stenting, or intraoperative patch angioplasty with or without
conduit replacements, is recommended to determine the most
feasible treatment for pulmonary artery stenosis. (Level of
Evidence: C)
4. Surgical closure of residual VSD in adults after Rastelli repair of
d-TGA is recommended with the following indicators:
a. Qp/Qs greater than 1.5:1. (Level of Evidence: B)
b. Systolic pulmonary artery pressure greater than 50 mm Hg.
(Level of Evidence: B)
c. Increasing LV size from volume overload. (Level of Evi-
dence: C)
d. Decreasing RV function from pressure overload. (Level of
Evidence: C)
e. RVOT obstruction (peak instantaneous gradient greater
than 50 mm Hg). (Level of Evidence: B)
f. Pulmonary artery pressure less than two thirds of systemic
pressure, or PVR less than two thirds of systemic vascular
resistance, with a net left-to-right shunt of 1.5:1, or a
decrease in pulmonary artery pressure with pulmonary vaso-
dilators (oxygen, nitric oxide, or prostaglandins). (Level of
Evidence: B)
5. Surgery is recommended after Rastelli repair of d-TGA in adults
with branch pulmonary artery stenosis not amenable to percu-
taneous treatment. (Level of Evidence: C)
6. In the presence of a residual intracardiac shunt or significant sys-
temic venous obstruction, permanent pacing, if indicated, should be
performed with epicardial leads (168). (Level of Evidence: B)
CLASS IIa
1. A concomitant Maze procedure can be effective for the treat-
ment of intermittent or chronic atrial tachyarrhythmias in
adults with d-TGA requiring reoperation for any reason. (Level
of Evidence: C)
11.6.4. Reoperation After Atrial Baffle Procedure
Reoperation after atrial baffle procedure in adults is recom-
mended for patients with a baffle leak that is not amenable to
device intervention, demonstrates a left-to-right shunt greater
than 1.5:1 or a right-to-left shunt with arterial desaturation at
rest or with exercise, symptoms, or progressive ventricular
enlargement. Although late conversion to an ASO has been
attempted in some centers, it has not proved successful and is
not generally considered a reasonable option for the manage-
ment of systemic ventricular failure in patients with TGA.
Patients with severe symptomatic superior or inferior vena
cava obstruction or pulmonary venous pathway obstruction
not amenable to percutaneous treatment should be referred
for operative intervention. Patients with severe symptomatic
subpulmonary stenosis should also be considered for opera-
tive intervention.
Severe symptomatic systemic AV (morphological tricus-
pid) valve regurgitation may prompt surgical referral when
the problem relates to intrinsic tricuspid valve disease and is
not secondary to systemic ventricular dysfunction. This is a
rare occurrence, because most TR after atrial baffle procedure
is secondary to systemic ventricular dysfunction. Alternative
techniques include tricuspid valve replacement, pulmonary
artery band placement, and transplantation.
11.6.5. Reoperation After Arterial Switch Operation
Reoperation after ASO should be considered for adults with
the following: severe RVOT obstruction peak-to-peak gradi-
ent greater than 50 mm Hg or RV/LV pressure ratio greater
than 0.7, not amenable or responsive to percutaneous treat-
ment, or lesser degrees of obstruction that are dynamic if
pregnancy is planned or greater degrees of exercise are
desired. Pulmonary valve replacement or repair should be
considered when severe pulmonary regurgitation is present
and there is significant RV dilatation or RV dysfunction.
Coronary ostial stenosis late after the ASO may be repaired
by coronary bypass grafting or ostial arterioplasty techniques.
Patients who have developed neoaortic root dilation without
severe AR may be treated with valve-sparing root-
replacement techniques when the aortic root diameter is
greater than 55 mm.
11.6.6. Other Reoperation Options
A concomitant Maze procedure can be effective for the
treatment of intermittent or chronic atrial tachyarrhythmias in
adults with d-TGA who are undergoing reoperation. This
option for arrhythmia management should be considered
preoperatively.
Cardiac transplantation may be required in failing systemic
ventricular circulations; given that there are frequently anom-
alous venous or arterial connections, cardiac malpositioning,
or both, technical anastomotic issues are common (170). In
addition, many patients have had multiple surgeries and have
more adhesions, which makes postoperative bleeding more of
a concern, with the need for more blood transfusions and
consequently more antigenic exposure, which leads to accel-
erated rejection.
11.7. Recommendations for Electrophysiology
Testing/Pacing Issues in Dextro-Transposition
of the Great Arteries
CLASS I
1. Clinicians should be mindful of the risk of sudden arrhythmic
death among adults after atrial baffle repair of d-TGA. These
events usually relate to ventricular tachycardia but may be
caused in some cases by rapidly conducted IART or progressive
AV block. (Level of Evidence: B)
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2. Consultation with an electrophysiologist who is experienced
with CHD is recommended to assist with treatment decisions.
(Level of Evidence: B)
3. Pacemaker implantation is recommended for patients with
d-TGA with either symptomatic sinus bradycardia or sick sinus
syndrome. (Level of Evidence: B)
CLASS IIa
1. Routine surveillance with history, ECG, assessment of RV
function, and periodic Holter monitoring can be beneficial as
part of routine follow-up. (Level of Evidence: B)
The most significant arrhythmia issue facing adults with
d-TGA is the high incidence of tachy-brady syndrome that
occurs in those who have undergone the Mustard or Senning
operations (171). There is little doubt that these arrhythmias
relate directly to the extensive suture lines created during
atrial baffling. Some degree of sinus node dysfunction will be
observed in more than half of the Mustard and Senning
populations by the time they reach adulthood, probably due to
surgical trauma in the vicinity of the sinus node or its arterial
supply during creation of the superior vena cava limb of the
atrial baffle (171). In addition, up to 30% of these patients
will develop episodic IART or atrial flutter, which typically
involves a macroreentry circuit around the atrial border of the
tricuspid valve that is supported by the narrow conduction
corridor between the inferior vena cava limb of the baffle and
the valve ring (172). Patients can become highly symptomatic
from either tachycardia or bradycardia, including the possi-
bility of sudden death due to an episode of rapidly conducted
IART (173). In patients who have advanced dysfunction of
their systemic right ventricle, ventricular arrhythmias may
also develop.
11.8. Key Issues to Evaluate and Follow-Up
11.8.1. Recommendations for Endocarditis Prophylaxis
CLASS IIa
1. Antibiotic prophylaxis before dental procedures that involve
manipulation of gingival tissue or the periapical region of teeth
or perforation of the oral mucosa is reasonable in those with
the following indications:
a. Prosthetic cardiac valve. (Level of Evidence: B)
b. Previous IE. (Level of Evidence: B)
c. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: B)
d. Completely repaired CHD with prosthetic materials,
whether placed by surgery or by catheter intervention,
during the first 6 months after the procedure. (Level of
Evidence: B)
e. Repaired CHD with residual defects at the site or adjacent
to the site of a prosthetic patch or prosthetic device that
inhibit endothelialization. (Level of Evidence: B)
2. It is reasonable to consider antibiotic prophylaxis against IE
before vaginal delivery at the time of membrane rupture in
select patients with the highest risk of adverse outcomes. This
includes patients with the following indications:
a. Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair. (Level of Evidence: C)
b. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: C)
CLASS III
1. Prophylaxis against IE is not recommended for nondental
procedures (such as esophagogastroduodenoscopy or colonos-
copy) in the absence of active infection. (Level of Evidence: C)
11.8.2. Recommendation for Reproduction
CLASS I
1. Before women with d-TGA contemplate pregnancy, a compre-
hensive clinical, functional, and echocardiographic evaluation
should be performed at a center with expertise in ACHD. (Level
of Evidence: C)
Comprehensive evaluation is recommended before preg-
nancy in all patients with d-TGA and prior repair. For patients
after atrial baffle, major prepregnancy concerns include
ventricular function assessment, systemic AV regurgitation,
and atrial arrhythmias. There is a small but recognized risk of
cardiovascular complications during pregnancy after the
atrial baffle procedure. The physiological stresses of preg-
nancy, although clinically well tolerated late after a Mustard
procedure, carry an increased risk of RV dysfunction that
may be irreversible (174).
After a Rastelli operation, pregnancy should be well
tolerated, assuming the absence of LV or RV obstruction and
preservation of ventricular function. Isolated reports are
available on the outcome of pregnancy after ASO. In the
absence of important cardiovascular residua, pregnancy is
well tolerated. A comprehensive anatomic and functional
assessment, including assessment of coronary artery anato-
my, is recommended before a patient proceeds with
pregnancy.
12. Congenitally Corrected Transposition
of the Great Arteries
Congenitally corrected TGA (CCTGA) is a complex congen-
ital anomaly with a wide spectrum of morphological features
and clinical profiles. The term “corrected” refers to the
physiologically normal direction of blood flow caused by this
“double discordance,” which makes the term “corrected”
misleading (175). The term “l-transposition” is synonymous
with CCTGA and indicates that the morphological RV is to
the left of the morphological LV. In addition, the aorta is
usually anterior to and to the left of the pulmonary artery.
12.1. Associated Lesions
Only 1% of cases are uncomplicated, that is, they do not have
associated anomalies. Frequently associated structural anom-
alies include the following:
● VSD occurs in 70% of patients and is usually perimembranous.
● PS occurs in 40% of patients and is often subvalvular.
● Some abnormality of the systemic AV valve occurs in 90%
of patients. Most commonly, this is an Ebstein-like mal-
formation in which the valve is displaced inferiorly toward
the cardiac apex (176).
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The AV node and His bundle are often in an unusual
position, and an accessory AV node is present in many
patients (177). Conduction abnormalities are also common,
with spontaneous complete heart block occurring at a rate of
approximately 2% per year, and these are related to the
abnormal position of the AV node (177–179).
12.2. Presentation in Adulthood: Unoperated
Some patients were diagnosed in childhood but did not
require operation. In some adults, the diagnosis is made for
the first time because of a heart murmur or incidentally when
an ECG, chest x-ray, or echocardiogram is performed for
other reasons (180). The diagnosis is often missed in
cardiology practice because of the failure to recognize the
abnormal position of the ventricles and the associated AV
valves (181).
12.3. Recommendations for Evaluation and
Follow-Up of Patients With Congenitally
Corrected Transposition of the Great Arteries
CLASS I
1. All patients with CCTGA should have a regular follow-up with a
cardiologist who has expertise in ACHD. (Level of Evidence: C)
2. Echocardiography-Doppler study and/or MRI should be per-
formed yearly or at least every other year by staff trained in
imaging complex CHD. (Level of Evidence: C)
3. The following diagnostic evaluations are recommended for
patients with CCTGA:
a. ECG. (Level of Evidence: C)
b. Chest x-ray. (Level of Evidence: C)
c. Echocardiography-Doppler study. (Level of Evidence: C)
d. MRI. (Level of Evidence: C)
e. Exercise testing. (Level of Evidence: C)
The frequency of follow-up visits may be determined by
the presence or absence of associated lesions but is often
annual. More frequent visits may be necessary for those with
ventricular dysfunction and systemic AV valve regurgitation,
regardless of whether they are symptomatic. Clinical exami-
nation, ECG, chest x-ray, and cardiopulmonary exercise
testing will usually be performed. If progression of heart
block is suspected by history or ECG, ambulatory ECG
monitoring for 24 hours should be considered. Patients who
have implantation of an endocardial pacemaker warrant more
frequent observation, because “septal shift” may cause dete-
rioration in systemic ventricle (SV) dysfunction.
12.4. Interventional Therapy
12.4.1. Recommendations for Catheter Interventions
CLASS IIa
1. For patients with unrepaired CCTGA, cardiac catheterization
can be effective to assess the following:
a. Hemodynamic status in the setting of arrhythmia. (Level of
Evidence: C)
b. Unexplained SV dysfunction, to define the degree of sys-
temic AV valve regurgitation, degree of intracardiac shunt-
ing, and coronary artery anatomy. (Level of Evidence: C)
c. Unexplained volume retention or cyanosis, especially when
noninvasive assessment of pulmonary outflow obstruction
is limited. (Level of Evidence: C)
Combined with noninvasive imaging techniques, diagnos-
tic and interventional cardiopulmonary catheterization play
important roles in the management of many adults with
CCTGA, both in the unoperated native state and after surgical
repair with VSD patch or Rastelli-type LV–pulmonary artery
connections.
12.4.2. Recommendations for Surgical Intervention
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations for patients with CCTGA for the following
indications:
a. Unrepaired CCTGA and severe AV valve regurgitation. (Level
of Evidence: B)
b. Anatomic repair with atrial and arterial level switch/Ras-
telli repair in cases in which the left ventricle is functioning
at systemic pressures. (Level of Evidence: B)
c. Simple VSD closure when the VSD is not favorable for
LV-to-aorta baffling or is restrictive. (Level of Evidence: B)
d. LV–to–pulmonary artery conduit in rare cases with LV dys-
function and severe LV outflow obstruction. (Level of Evi-
dence: B)
e. Evidence of moderate or progressive systemic AV valve
regurgitation. (Level of Evidence: B)
f. Conduit obstruction with systemic or nearly systemic RV
pressures and/or RV dysfunction after anatomic repair.
(Level of Evidence: B)
g. Conduit obstruction and systemic or suprasystemic LV
pressures in a patient with nonanatomic correction. (Level
of Evidence: B)
h. Moderate or severe AR/neo-AR and onset of ventricular
dysfunction or progressive ventricular dilatation. (Level of
Evidence: B)
Indications for surgery in patients who have undergone
previous operations include repair or replacement of the
systemic AV valve when a nonanatomic repair has been done
previously, conduit replacement in patients who had a
Rastelli-type anatomic repair and resection of LV outflow
obstruction in the same group. Aortic valve and mitral valve
repair/replacement are occasionally required in patients who
have undergone anatomic repair. AR is seen more commonly
in patients who underwent pulmonary arterial banding before
ASO as part of staged anatomic repair.
12.5. Recommendations for Postoperative
Care
CLASS I
1. Patients with prior repair of CCTGA should have regular
follow-up with a cardiologist with expertise in ACHD. (Level of
Evidence: C)
2. Echocardiography-Doppler study and/or MRI should be per-
formed yearly or at least every other year by staff trained in
imaging complex CHD. (Level of Evidence: C)
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Regular follow-up (usually annually) is necessary (182),
with particular emphasis on the following:
● Function of the SV
● Maintenance of sinus rhythm when possible
● Function of the systemic AV valve or systemic AV valve
prosthesis if present
● Function of the pulmonary conduit or prosthesis
● Residual septal defects
● Development or progression of AR
● Degree of PAH, if any
12.5.1. Recommendations for Endocarditis
Prophylaxis
CLASS IIa
1. Antibiotic prophylaxis before dental procedures that involve
manipulation of gingival tissue or the periapical region of teeth
or perforation of the oral mucosa is reasonable in those with
the following indications:
a. Prosthetic cardiac valve. (Level of Evidence: B)
b. Previous IE. (Level of Evidence: B)
c. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: B)
d. Completely repaired CHD with prosthetic materials,
whether placed by surgery or by catheter intervention,
during the first 6 months after the procedure. (Level of
Evidence: B)
e. Repaired CHD with residual defects at the site or adjacent
to the site of a prosthetic patch or prosthetic device that
inhibit endothelialization. (Level of Evidence: B)
2. It is reasonable to consider antibiotic prophylaxis against IE
before vaginal delivery at the time of membrane rupture in
select patients with the highest risk of adverse outcomes. This
includes patients with the following indications:
a. Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair. (Level of Evidence: C)
b. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: C)
CLASS III
1. Prophylaxis against IE is not recommended for nondental
procedures (such as esophagogastroduodenoscopy or colonos-
copy) in the absence of active infection. (Level of Evidence: C)
12.5.2. Recommendation for Reproduction
CLASS I
1. All women with CCTGA (whether repaired or not) should seek
counseling from a cardiologist with expertise in ACHD before
proceeding with a pregnancy. (Level of Evidence: C)
The volume load of pregnancy may pose too great a burden
for a compromised SV, particularly with associated systemic
AV valve regurgitation. A careful and comprehensive clinical
evaluation should be performed when pregnancy is contem-
plated. This should include a careful history, clinical exami-
nation, ECG, chest x-ray, and an assessment of the hemody-
namics, presence or absence of valvular lesions, and ejection
fraction. This should be evaluated with echocardiography
and/or MRI study. An exercise test is helpful in determining
the functional capacity of patients, and in general, it is
unlikely pregnancy will be well tolerated if the functional
aerobic capacity is less than 75% of predicted.
13. Ebstein’s Anomaly
13.1. Initial Adult Presentation
Patients with mild Ebstein’s anomaly may be asymptomatic
with no functional limitation. Survival to the ninth decade has
been reported (183). Electrophysiological rather than hemo-
dynamic symptoms are more common in patients over the age
of 10 years at presentation. Patients with Ebstein’s anomaly
who reach late adolescence and adulthood often have an
excellent outcome (184).
13.2. Clinical Features and Evaluation of the
Unoperated Patient
The disorder has the following features in common:
● Adherence of the tricuspid valve leaflets to the underlying
myocardium (failure of delamination)
● Apical displacement of the septal and posterior leaflets of
the tricuspid valve below the AV junction in the right
ventricle
● Atrialization and dilation of the inflow of the right ventricle
to varying degrees
● Redundancy, tethering, and fenestrations of the anterior
tricuspid valve leaflet
● Varying degrees of TR
● Enlargement of the right atrium
● Varying degrees of cyanosis
Associated lesions include the following:
● More than 50% of patients have a shunt at the atrial level
with either a patent foramen ovale or secundum ASD,
which results in varying degrees of cyanosis
● One or more accessory conduction pathways, increasing
the risk of atrial tachycardias (approximately 25%)
● VSD
● Varying degrees of anatomic and physiological RVOT
obstruction
● Occasionally, other anomalies such as mitral valve
prolapse
● Abnormalities of LV morphology and function
13.3. Recommendation for Evaluation of
Patients With Ebstein’s Anomaly
CLASS I
1. All patients with Ebstein’s anomaly should have periodic eval-
uation in a center with expertise in ACHD. (Level of Evidence: C)
All patients with Ebstein’s anomaly should have regular
follow-up in a center for congenital cardiology. Unoperated
patients need serial monitoring for features that suggest that
surgical intervention is required or medical therapy is indi-
cated. An assessment of functional limitation should also be
performed.
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13.4. Recommendations for Diagnostic Tests
CLASS I
1. ECG, chest x-ray, and echocardiography-Doppler are recom-
mended for the diagnostic evaluation of Ebstein’s anomaly in
adult patients. (Level of Evidence: C)
CLASS IIa
1. Pulse oximetry at rest and/or during exercise can be useful in
the diagnostic evaluation of Ebstein’s anomaly in adult pa-
tients. (Level of Evidence: C)
2. An electrophysiological study can be useful in the diagnostic
evaluation of Ebstein’s anomaly in adult patients if a supraven-
tricular arrhythmia is documented or suspected (subsequent
radiofrequency catheter ablation should be considered if clini-
cally feasible). (Level of Evidence: C)
3. The following additional diagnostic tests can be useful for the
comprehensive evaluation of Ebstein’s anomaly in adult
patients:
a. Doppler TEE examination if the anatomic information is not
provided by transthoracic imaging. (Level of Evidence: B)
b. Holter monitoring. (Level of Evidence: B)
c. Electrophysiological study for history or ECG evidence of
accessory pathway(s). (Level of Evidence: B)
d. Coronary angiography, when surgical repair is planned, if
there is a suspicion of coronary artery disease, and in men
35 years or older, premenopausal women 35 years or older
who have coronary risk factors, and postmenopausal
women. (Level of Evidence: B)
The ECG is valuable in the diagnosis of Ebstein’s anomaly.
Preexcitation may be present, usually via a right bypass tract.
Multiple bypass tracts may also occur. The P waves are often
very tall and peaked (so-called Himalayan P waves). A QR
pattern is often seen in lead V1 and may extend to V4. The
QRS duration is usually prolonged, with a right bundle-
branch pattern, but is often “splintered,” followed by inverted
T waves.
The chest x-ray may be nearly normal in mild cases and in
more severe cases shows severe enlargement. Right atrial
enlargement is prominent, with a “globular” cardiac contour
and clear lung fields. The great arteries are usually small, and
the aortic root is inconspicuous or absent.
The diagnosis of Ebstein’s anomaly is most commonly
confirmed by TTE Doppler evaluation by a skilled echocar-
diographer, preferably with expertise in CHD. Echocardiog-
raphy is the diagnostic test of choice and should document the
severity of the degree of right-sided cardiac enlargement, RV
dysfunction, and TR. TTE supplemented with intraoperative
TEE usually provides sufficient data to permit operative inter-
vention without the need to obtain additional preoperative
diagnostic structural information in patients with Ebstein’s
anomaly (185–187). The diagnostic workup may require a TEE
to assess the presence of an ASD or to delineate intracardiac
anatomy in patients with suboptimal TTE images.
Hemodynamic cardiac catheterization is rarely required in
patients with Ebstein’s anomaly before surgical intervention
is considered. In select high-risk patients, hemodynamic
assessment by cardiac catheterization may be helpful for risk
stratification. Coronary angiography should be performed
before surgical intervention if there is a concern about
coronary artery disease.
13.5. Management Strategies
13.5.1. Recommendation for Medical Therapy
CLASS I
1. Anticoagulation with warfarin is recommended for patients
with Ebstein’s anomaly with a history of paradoxical embolus
or atrial fibrillation. (Level of Evidence: C)
The large right atrium predisposes to thrombus formation,
particularly in association with atrial fibrillation. The poten-
tial for right-to-left shunting at the atrial level raises the risk
of paradoxical embolus.
13.6. Recommendation for Catheter
Interventions for Adults With Ebstein’s
Anomaly
CLASS I
1. Adults with Ebstein’s anomaly should have catheterization
performed at centers with expertise in catheterization and
management of such patients. (Level of Evidence: C)
Catheterization is not usually required for the evaluation
and management of Ebstein’s anomaly; therefore, it should
only be performed at regional centers for very specific
indications, after thorough noninvasive evaluation.
13.6.1. Recommendation for Electrophysiology
Testing/Pacing Issues in Ebstein’s Anomaly
CLASS IIa
1. Catheter ablation can be beneficial for treatment of recurrent
supraventricular tachycardia in some patients with Ebstein’s
anomaly. (Level of Evidence: B)
Supraventricular tachycardia related to accessory pathways
is a frequent accompaniment of Ebstein’s anomaly (188).
Catheter ablation has become the most attractive treatment
for this condition, although the procedure can be quite
challenging. Overall, success rates are lower and recurrence
rates are higher than those reported for ablation in a structur-
ally normal heart (189,190), in part because multiple acces-
sory pathways are present in nearly 50% of these patients
(191). Any patient suspected of having an accessory pathway
should undergo electrophysiology study before surgical re-
pair, so that the pathway(s) may be localized and catheter
ablation attempted. If catheter ablation is unsuccessful or
deemed inappropriate for any reason, surgical interruption
can be performed in the operating room. For any patients with
history of atrial flutter, a right atrial Maze procedure can be
incorporated into the surgery, and for those with atrial
fibrillation, a biatrial Maze can be performed.
13.6.2. Recommendations for Surgical Interventions
CLASS I
1. Surgeons with training and expertise in CHD should perform
tricuspid valve repair or replacement with concomitant closure
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of an ASD, when present, for patients with Ebstein’s anomaly
with the following indications:
a. Symptoms or deteriorating exercise capacity. (Level of
Evidence: B)
b. Cyanosis (oxygen saturation less than 90%). (Level of
Evidence: B)
c. Paradoxical embolism. (Level of Evidence: B)
d. Progressive cardiomegaly on chest x-ray. (Level of Evi-
dence: B)
e. Progressive RV dilation or reduction of RV systolic function.
(Level of Evidence: B)
2. Surgeons with training and expertise in CHD should perform
concomitant arrhythmia surgery in patients with Ebstein’s
anomaly and the following indications:
a. Appearance/progression of atrial and/or ventricular ar-
rhythmias not amenable to percutaneous treatment. (Level
of Evidence: B)
b. Ventricular preexcitation not successfully treated in the
electrophysiology laboratory. (Level of Evidence: B)
3. Surgical rerepair or replacement of the tricuspid valve is
recommended in adults with Ebstein’s anomaly with the
following indications:
a. Symptoms, deteriorating exercise capacity, or New York
Heart Association functional class III or IV. (Level of Evi-
dence: B)
b. Severe TR after repair with progressive RV dilation, reduc-
tion of RV systolic function, or appearance/progression of
atrial and/or ventricular arrhythmias. (Level of Evidence: B)
c. Bioprosthetic tricuspid valve dysfunction with significant
mixed regurgitation and stenosis. (Level of Evidence: B)
d. Predominant bioprosthetic valve stenosis (mean gradient
greater than 12 to 15 mm Hg). (Level of Evidence: B)
e. Operation can be considered earlier with lesser degrees of
bioprosthetic stenosis with symptoms or decreased exer-
cise tolerance. (Level of Evidence: B)
The primary operation generally consists of closure of any
interatrial communications; antiarrhythmia procedures such
as surgical division of accessory conduction pathways, cryo-
ablation of AV node reentry tachycardia, or Maze procedure;
and tricuspid valve surgery. The tricuspid valve is repaired
when feasible, and tricuspid valve replacement is performed
with a mechanical or heterograft bioprosthesis when repair is
not feasible or the repair result is not satisfactory. A right
reduction atrioplasty is often performed.
Reoperation usually requires tricuspid valve replacement
or rereplacement (tissue or mechanical). Rerepair of the
tricuspid valve is rarely successful. Other procedures are
performed as with the primary operation. A concomitant
Maze procedure may be performed for intermittent or chronic
atrial fibrillation/flutter.
13.7. Problems and Pitfalls
The problems and pitfalls associated with the management of
adults with Ebstein’s anomaly are as follows:
● Patients with Ebstein’s anomaly may be referred for
percutaneous or surgical ASD closure; however, the pres-
ence of Ebstein’s anomaly may alter the recommendation
for intervention.
● Percutaneous ablation of an accessory pathway should be
performed with caution in patients with Ebstein’s anomaly
and an interatrial communication with right-to-left shunt
because of the risk of paradoxical embolus.
● The presence of multiple accessory pathways should raise
the suspicion for Ebstein’s anomaly.
● Patients with Ebstein’s anomaly and marked cardiomegaly
may complain of few symptoms despite marked limitation.
Exercise testing will demonstrate functional limitation and
should be included as part of the regular assessment of
these patients. Exercise testing should include monitoring
of oxygen saturation, because exercise-induced cyanosis
may occur.
● Patients with newly diagnosed Ebstein’s anomaly may be
told they have concomitant PAH, particularly when cyano-
sis and right-sided heart enlargement are present. This is
usually a misdiagnosis, because PAH is very rare among
Ebstein patients.
● Other tricuspid valve disorders may be misdiagnosed as
Ebstein’s anomaly (refer to Section 13.4, Recommenda-
tions for Diagnostic Tests).
13.8. Recommendation for Reproduction
CLASS I
1. Women with Ebstein’s anomaly should undertake prepreg-
nancy counseling with a physician with expertise in ACHD.
(Level of Evidence: C)
Most women with Ebstein’s anomaly can have a successful
pregnancy with proper care, but there is an increased risk of
low birth weight and fetal loss if significant cyanosis is
present. The risk of CHD in the offspring (in the absence of
a family history) is approximately 6% (192).
13.9. Recommendation for
Endocarditis Prophylaxis
CLASS IIa
1. Antibiotic prophylaxis before dental procedures that involve
manipulation of gingival tissue or the periapical region of the
teeth or perforation of the oral mucosa is reasonable in
cyanotic patients with Ebstein’s anomaly and postoperative
patients with a prosthetic cardiac valve. (Level of Evidence: C)
Antibiotic prophylaxis is usually unnecessary in the acya-
notic, unoperated patient (refer to Section 1.6, Recommenda-
tions for Infective Endocarditis, for additional information).
14. Tricuspid Atresia/Single Ventricle
This section focuses on conditions that are not amenable to
biventricular repair and will include the various types of
so-called univentricular hearts, such as tricuspid atresia,
mitral atresia, double-inlet left ventricle, single ventricle,
hypoplastic right ventricle or left ventricle, and heterotaxia
syndromes.
14.1. Clinical Course (Unoperated and
Palliated)
Patients usually fall into 2 general categories. The first
category includes those patients with no anatomic restrictions
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to pulmonary blood flow with early postnatal development of
a large left-to-right shunt and symptoms of congestive heart
failure. The second major clinical presentation is severe
cyanosis due to obstruction to pulmonary flow, frequently
caused by valvular/subvalvular PS or atresia.
A small number of patients will present with mild cyanosis
and no congestive heart failure. These patients have sufficient
PS to limit pulmonary flow to levels that do not cause heart
failure symptoms but is adequate to prevent severe hypox-
emia. The vast majority of adults with these conditions will
have undergone previous palliation with some type of
systemic–to–pulmonary artery shunt, cavopulmonary connec-
tion (bidirectional Glenn), or 1 of the modifications of the
Fontan operation (193,194).
14.2. Recommendation for Catheterization
Before Fontan Procedure
CLASS I
1. In the evaluation of hemodynamics to assess the potential for
definitive palliation of unoperated or shunt-palliated adults with
univentricular hearts, catheterization is indicated to:
a. Assess the nature of pulmonary artery obstruction, with
potential to restore maximal continuous, effective, unim-
peded systemic venous flow to the maximal number of
pulmonary artery segments. (Level of Evidence: C)
b. Assess and eliminate systemic–to–pulmonary vein collater-
als. (Level of Evidence: C)
c. Assess and eliminate systemic–to–pulmonary artery con-
nections. (Level of Evidence: C)
d. For adults with systemic–to–pulmonary shunts, the poten-
tial for perioperative transcatheter shunt exclusion should
be examined. (Level of Evidence: C)
Data to be obtained include intracardiac, pulmonary artery,
and aortic pressures; oxygen saturations; and estimations of
pulmonary and systemic blood flow and resistances. Imaging
data would include angiograms of systemic venous anatomy,
great vessel anatomy (specifically, anatomy of the pulmonary
arteries and estimations of ventricular volume), hypertrophy,
and ejection fraction. Coronary angiography is needed for
older patients and those with questionable ischemia or coro-
nary anomalies. Assessment of venous and arteriopulmonary
collaterals is also important, because these may be amenable
to coil occlusion.
14.3. Recommendation for Surgical Options
for Patients With Single Ventricle
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations for single-ventricle anatomy or physiology. (Level of
Evidence: C)
Surgical options for the treatment of adults with tricuspid
atresia/single ventricle are outlined below.
Systemic–to–pulmonary artery shunt:
● Often from the ascending aorta to the main or right pulmonary
artery; rarely performed as an isolated procedure, and only if
a cavopulmonary connection is contraindicated.
Bidirectional Glenn (bidirectional cavopulmonary anasto-
mosis [BDCPA]):
● Most commonly performed in infancy or early childhood
as a staged procedure toward the Fontan completion; this
provides a stable source of pulmonary blood flow without
volume loading the SV; it generally should not be the sole
source of pulmonary blood flow (except as the stage II
procedure for hypoplastic left-sided heart syndrome).
BDCPA plus additional pulmonary blood flow:
● The most reliable source of additional pulmonary blood
flow is via the native RVOT with native PS or with a pul-
monary artery band. A concomitant systemic–to–pulmonary
artery shunt may be added if an increase in systemic
oxygenation is required, but this is at the expense of an
increase in volume load on the SV and often elevated
superior vena cava pressure.
Single-ventricle repair:
● When the rudimentary pulmonary ventricle is less than
30% of its normal volume, a Fontan-type of operation is
performed. The operation has gone through many modifi-
cations; each allows systemic venous return to enter the
pulmonary circulation directly.
Modified Fontan Procedures:
● Extracardiac conduit–BDCPA plus conduit from inferior
vena cava to right pulmonary artery/main pulmonary artery
● Intra-atrial conduit–BDCPA plus intra-atrial conduit from
inferior vena cava to right pulmonary artery/main pulmo-
nary artery; preferred when the ventricular mass would lie
on top of an extracardiac conduit, eg, isolated dextrocardia
or isolated levocardia with situs inversus
● Intracardiac lateral tunnel plus BDCPA
● Intracardiac lateral tunnel
● Atriopulmonary connection (rarely used in the current era)
● Fenestration between systemic venous pathway and left
atrium
1.5-Ventricle Repair:
A term used to describe a procedure for cyanotic CHD
performed when the pulmonary ventricle is insufficiently
developed to accept the entire systemic venous return. A
BDCPA is constructed to direct superior vena cava blood
directly into the pulmonary arteries while the inferior caval
blood is directed to the lungs via the small pulmonary
ventricle.
2-Ventricle Repair:
A term used to describe a procedure for cyanotic CHD with
a common ventricle or adequately sized pulmonary ventricles
and SVs that communicate via a VSD. The pulmonary and
systemic circulations are surgically septated by placement of
an interventricular patch (for common ventricle) or VSD
patch (for separate pulmonary and SV cavities).
Transplantation:
Heart and/or heart/lung transplantation are reserved for
severe SV failure with or without PAH when there is no
conventional surgical option.
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14.4. Recommendation for Evaluation and
Follow-Up After Fontan Procedure
CLASS I
1. Lifelong follow-up is recommended for patients after a Fontan-
type operation; this should include a yearly evaluation by a
cardiologist with expertise in the care of ACHD patients. (Level
of Evidence: C)
All patients should have follow-up with a cardiologist who
has expertise in ACHD. The frequency, although typically
annual, may be determined by the extent and degree of
residual abnormalities. Long-term problems include atrial
arrhythmias and right atrial thrombus, especially common in
direct atrium–to–pulmonary artery connections, ventricular
dysfunction and edema, need for reoperation, hepatic conges-
tion and dysfunction, and protein-losing enteropathy.
14.5. Recommendation for Imaging
CLASS I
1. All patients with prior Fontan-type repair should have periodic
echocardiographic and/or magnetic resonance examinations
performed by staff with expertise in ACHD. (Level of Evidence: C)
Echocardiography is the cornerstone of the postoperative
evaluation. Spontaneous contrast is often seen in the Fontan
circuit and represents slow flow in the pathway. It is impor-
tant to image the Fontan pathway in its entirety, and TEE is
often necessary to accomplish this. In addition, TEE is
needed to rule out right atrial thrombus. The presence or
absence of a Fontan fenestration should be sought, and if
present, the gradient across the fenestration should be
measured.
14.6. Recommendation for Diagnostic and
Interventional Catheterization for Adults
After Fontan Procedure
CLASS I
1. Catheterization of adults with a Fontan-type repair of single-
ventricle physiology should be performed in regional centers
with expertise in ACHD. (Level of Evidence: C)
For adults after Fontan palliation, cardiac catheterization,
often assisted by contrast echocardiography, is indicated to
investigate and potentially treat unexplained volume reten-
tion, fatigue or exercise limitation, atrial arrhythmia, or
cyanosis and hemoptysis. To further investigate oxygen-
unresponsive hypoxemia in the adult Fontan survivor, cath-
eterization is directed at assessing and potentially relieving
(when applicable) the following: persistent Fontan fenestra-
tion; systemic–to–pulmonary venous collaterals; pulmonary
arteriovenous malformations; and the cause of volume reten-
tion, increasing Fontan pathway pressure and resistance, and
thereby worsening right-to-left shunting.
Evaluation of postoperative Fontan patients with worsen-
ing cyanosis (oxygen saturation usually 90% or less at rest
and decreasing with exercise):
In addition to pressure and resistance data, an angiographic
search for atrial right-to-left shunts and shunts from inferior
cava, superior cava, and innominate vein to the left atrium
should be performed, as well as a search for pulmonary
arteriovenous malformations. Interventional closure of resid-
ual shunts by coils or ASD devices is often possible.
14.7. Recommendations for Management
Strategies for the Patient With Prior
Fontan Repair
CLASS I
1. Management of patients with prior Fontan repair should be
coordinated with a regional ACHD center. Local cardiologists,
internists, and family care physicians should develop ongoing
relationships with such a center with continuous availability of
specialists. (Level of Evidence: C)
2. At least yearly follow-up is recommended for patients after
Fontan repair. (Level of Evidence: C)
3. Arrhythmia management is frequently an issue, and consulta-
tion with an electrophysiologist is recommended as a vital part
of care. (Level of Evidence: C)
4. New-onset atrial tachyarrhythmia should prompt a comprehen-
sive noninvasive imaging evaluation to identify associated
atrial/baffle thrombus, anatomic abnormalities of the Fontan
pathway, or ventricular dysfunction. (Level of Evidence: C)
Patients with single-ventricle physiology should be consid-
ered to have a chronic disease that requires active manage-
ment to prevent secondary disability and preserve the func-
tion of the single ventricle for the maximum possible time.
This requires close follow-up and coordination between all
providers. Ventricular dysfunction, congestive heart failure,
symptomatic arrhythmias, thromboembolism, and edema are
all possible findings on long-term follow-up and require
management directed by an ACHD center as defined in these
guidelines.
14.7.1. Recommendations for Medical Therapy
CLASS I
1. Warfarin should be given for patients who have a documented
atrial shunt, atrial thrombus, atrial arrhythmias, or a thrombo-
embolic event. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to treat SV dysfunction with ACE inhibitors and
diuretics. (Level of Evidence: C)
Anticoagulants should be given to all patients with atrial
arrhythmias even if atrial thrombus has not been documented.
Warfarin should also be given to those with a residual ASD,
especially those with dual atrial pulmonary connections,
spontaneous right atrial contrast on echocardiography, and an
ejection fraction less than 40%.
Ventricular dysfunction, congestive heart failure, symp-
tomatic arrhythmias, thromboembolism, and edema are all
possible findings on long-term follow-up and require man-
agement directed by an ACHD center as defined in these
guidelines. Many patients require afterload reduction with
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ACE inhibitors. Many adult survivors also require diuretic
therapy.
14.8. Recommendations for Surgery for
Adults With Prior Fontan Repair
CLASS I
1. Surgeons with training and expertise in CHD should perform
operations on patients with prior Fontan repair for single-
ventricle physiology. (Level of Evidence: C)
2. Reoperation after Fontan is indicated for the following:
a. Unintended residual ASD that results in right-to-left shunt
with symptoms and/or cyanosis not amenable to transcathe-
ter closure. (Level of Evidence: C)
b. Hemodynamically significant residual systemic artery–to–
pulmonary artery shunt, residual surgical shunt, or residual
ventricle–to–pulmonary artery connection not amenable to
transcatheter closure. (Level of Evidence: C)
c. Moderate to severe systemic AV valve regurgitation. (Level
of Evidence: C)
d. Significant (greater than 30 mm Hg peak-to-peak) subaortic
obstruction. (Level of Evidence: C)
e. Fontan pathway obstruction. (Level of Evidence: C)
f. Development of venous collateral channels or pulmonary
arteriovenous malformation not amenable to transcatheter
management. (Level of Evidence: C)
g. Pulmonary venous obstruction. (Level of Evidence: C)
h. Rhythm abnormalities, such as complete AV block or sick
sinus syndrome, that require epicardial pacemaker inser-
tion. (Level of Evidence: C)
i. Creation or closure of a fenestration not amenable to trans-
catheter intervention. (Level of Evidence: C)
CLASS IIa
1. Reoperation for Fontan conversion (ie, revision of an atriopul-
monary connection to an intracardiac lateral tunnel, intra-atrial
conduit, or extracardiac conduit) can be useful for recurrent
atrial fibrillation or flutter without hemodynamically significant
anatomic abnormalities. A concomitant Maze procedure should
also be performed. (Level of Evidence: C)
CLASS IIb
1. Heart transplantation may be beneficial for severe SV dysfunc-
tion or protein-losing enteropathy. (Level of Evidence: C)
Reoperation includes valve repair or replacement for sys-
temic AV valve regurgitation, resection of subaortic obstruc-
tion, closure of an unintended residual shunt, revision of
Fontan pathway obstruction, or Fontan conversion for atrial
tachyarrhythmias with or without anatomic abnormalities
(195). Venous collateral channels or arteriovenous malforma-
tions in the right lung in the presence of a classic Glenn shunt
may be ameliorated by conversion to a modified Fontan
procedure. This enables hepatic venous blood to perfuse the
right-sided pulmonary vascular bed (195). Arteriovenous
malformations often regress, provided they are not large and
have not been long-standing. Clinically significant persistent
venous collateral channels or systemic aortopulmonary col-
laterals are usually treated with transcatheter occlusion.
Atrial tachycardias can be treated by catheter ablation
versus Fontan conversion with Maze procedure (196). Com-
plete AV block or sick sinus syndrome commonly requires
permanent pacing, usually epicardial.
Protein-losing enteropathy not amenable to medical or
catheter therapy may be treated by creation of an atrial septal
fenestration or Fontan conversion. The Fontan revision car-
ries an operative mortality rate of 5% to 25% in reported
series (197,198). If protein-losing enteropathy is due to
Fontan pathway obstruction, successful revision of the Fontan
communication may be curative. Protein-losing enteropathy
often requires heart transplantation (197). although the
protein-losing enteropathy does not always resolve. Severe
SV dysfunction often requires heart transplantation (199).
14.9. Key Issues to Evaluate and Follow-Up
14.9.1. Recommendations for Electrophysiology
Testing/Pacing Issues in Single-Ventricle Physiology
and After Fontan Procedure
CLASS I
1. Arrhythmia management is frequently an issue in patients after
the Fontan procedure, and consultation with an electrophysiolo-
gist with expertise in CHD is recommended as a vital part of care.
(Level of Evidence: C)
2. New-onset atrial tachyarrhythmias should prompt a compre-
hensive noninvasive imaging evaluation to identify associated
atrial/baffle thrombus, anatomic abnormalities of the Fontan
pathway, or ventricular dysfunction. (Level of Evidence: C)
3. Electrophysiological studies in adults with Fontan physiology
should be performed at centers with expertise in the manage-
ment of such patients. (Level of Evidence: C)
4. Clinicians must be mindful of the high risk for symptomatic
IART in adult patients who have undergone the Fontan opera-
tion. This arrhythmia can cause serious hemodynamic compro-
mise and contribute to atrial thrombus formation. Treatment is
often difficult, and consultation with an electrophysiologist
who is experienced with CHD is recommended whenever
recurrent IART is detected. (Level of Evidence: C)
The most significant rhythm issue facing adults who have
undergone the Fontan operation is recurrent IART. This
arrhythmia is a major source of morbidity in the post-Fontan
population, especially for patients who have undergone an
atriopulmonary connection and subsequently developed ad-
vanced degrees of dilation, thickening, and scarring of their
right atrial chamber (200). Beyond the surgical technique,
other risk factors for development of IART include concom-
itant sinus node dysfunction and older age at time of Fontan
operation (57). Tachycardia episodes can result in significant
hemodynamic compromise and, if long in duration, clot
formation within the dilated right artery.
14.9.2. Recommendations for Endocarditis
Prophylaxis
CLASS IIa
1. Antibiotic prophylaxis before dental procedures that involve manipu-
lation of gingival tissue or the periapical region of teeth or perforation
of the oral mucosa is reasonable in those patients with the following
indications:
a. Prosthetic cardiac valve. (Level of Evidence: B)
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b. Previous IE. (Level of Evidence: B)
c. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: B)
d. Completely repaired CHD with prosthetic materials,
whether placed by surgery or catheter intervention, during
the first 6 months after the procedure. (Level of Evidence: B)
e. Repaired CHD with residual defects at the site or adjacent
to the site of a prosthetic patch or prosthetic device that
inhibit endothelialization. (Level of Evidence: B)
2. It is reasonable to consider antibiotic prophylaxis against IE
before vaginal delivery at the time of membrane rupture in
select patients with the highest risk of adverse outcomes. This
includes patients with the following indications:
a. Prosthetic cardiac valve or prosthetic material used for
cardiac valve repair. (Level of Evidence: C)
b. Unrepaired and palliated cyanotic CHD, including surgically
constructed palliative shunts and conduits. (Level of Evi-
dence: C)
CLASS III
1. Prophylaxis against IE is not recommended for nondental
procedures (such as esophagogastroduodenoscopy or colonos-
copy) in the absence of active infection. (Level of Evidence: C)
14.9.3. Recommendations for Reproduction
CLASS I
1. All women with a Fontan operation should have a comprehen-
sive evaluation by a physician with expertise in ACHD before
proceeding with a pregnancy. (Level of Evidence: C)
CLASS III
1. Pregnancy should not be planned without consultation and
evaluation at a comprehensive ACHD center with experience
and expertise in maternal and prenatal management of com-
plex CHD. (Level of Evidence: C)
Successful pregnancy has been reported in postoperative
Fontan patients, but atrial arrhythmias, ventricular dysfunc-
tion, edema, and ascites have been reported as maternal
complications (201,202). In addition, there is an increased
risk for spontaneous abortion and premature birth. For those
patients undergoing warfarin anticoagulation, this poses the
additional risk of fetal exposure in the first trimester and
resulting fetal embryopathy. In each case, management must
be individualized.
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